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Chapter 1 
General Introduction 
Chapter I 
The hematopoietic system is comprised of many different cell types that fulfill 
important physiological functions throughout embryonic and adult stages of mouse 
development. As the mature blood cells have a limited life-span, the pool of blood cells 
needs constant replenishing. At the basis of the hematopoietic system reside the 
hematopoietic stem cells (HSCs). HSCs are characterized by the ability to self-renew and to 
produce all the different mature hematopoietic cell types120' 143' 178. These HSCs differentiate 
to the common lymphoid and myeloid progenitors (CLP and CMP) which in tum give rise 
to more lineage restricted precursor cells that then differentiate into mature hematopoietic 
cells (Figure 1 ). Mature hematopoietic cells can be subdivided into the lymphoid 
compartment, comprising T and B lymphocytes which form the adaptive immune (defense) 
system, and the myeloid compartment which is comprised of the oxygen transporting 
erythrocytes (red blood cells), blood clot-mediating platelets, immune response-mediating 
neutrophils, eosinophils and basophils and the macrophages, of which the main function is 
to remove dead and foreign cells. Although the mature blood cells fulfill the physiological 
functions of the hematopoietic system, the hematopoietic stem cells are essential within the 
adult hematopoietic hierarchy since these cells are responsible for the life long production 
of the different mature hematopoietic cells. 
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Figure 1. Schematic overview of the hematopoietic hierarchy in the adult mouse 
Hematopoietic stem cells (HSC) are at the basis of the hematopoietic hierarchy and produce the 
pluripotent progenitors that give rise to committed progenitors which in turn differentiate into the 
lineage restricted mature blood cells. HPC= hematopoietic progenitor cell; CLP= common lymphoid 
progenitor and CMP= common myeloid progenitor. Adapted from Gilbert 72 
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Characteristics of mouse hematopoietic stem cells 
How to identify hematopoietic stem cells 
General Introduction 
In the adult mouse, hematopoietic stem cells (HSCs) are localized in the bone 
marrow where they receive signals from the micro-environment to either retain their stem 
cell characteristics or to proceed along the differentiation pathway of the hematopoietic 
hierarchy. HSCs are a rare cell type in the adult bone marrow with as few as 1 to 10 HSCs 
in 100.000 cells20'79•80 . To measure HSC activity, the in vivo long-term repopulation assay 
(LTR assay) is still the gold standard143' 161 . In this assay marked donor cells are injected 
into an irradiated adult recipient and reconstitution of the hematopoietic system is analyzed 
several months post-transplantation. Limiting dilution and competitive long-term 
repopulation experiments can be used to determine in a more quantitative and qualitative 
manner the repopulation ability of HSCs within a certain cell population80. Besides the 
repopulation assay other methods are being used to identify HSCs and progenitor cells. A 
well known in vivo method is the CFU-S assay (colony forming unit of the spleen). Upon 
transplantation ofHSCs/ progenitor cells, a fraction of these cells will migrate to the spleen 
and form macroscopic colonies consisting of progenitor cells and differentiated blood cells. 
The number of colonies correlates with the number of HSC/ progenitor cells that were 
originally transp1anted120•58 . Also, since HSC/ progenitor cells form hematopoietic colonies 
when placed in the appropriate microenvironment, several in vitro methods have been 
developed. Best known methods are the colony forming unit (CFU) assays in which 
HSCs/HPCs are cultured in a semi-solid medium with hematopoietic growth factors and the 
long term culture-initiating cell (LTC-IC) assay, where HSCs/HPCs are grown together 
with supportive stromal cells (reviewed in references 58, 227). 
Together, these methods allow identification of the most immature cells of the 
hematopoietic system. The major advantage of the in vitro methods to identify HSCs and 
progenitor cells is that the environment can be controlled and manipulated. The in vivo LTR 
assay has as major advantage that true HSC activity can be determined within the 
physiological micro-environment. In both cases stem cell activity is measured indirectly 
through the presence of HSC-derived differentiated cells. Impairment either in homing 
capacity, proliferation or differentiation of HSCs will all result in a lack of HSC-derived 
mature blood cells and will be interpreted as a lack of stem cell activity, without 
discrimination between the different defects. The use of in vitro techniques to identify 
HSCs and progenitor cells circumvents the migration aspect of HSC homing to the correct 
microenvironment as is required for the in vivo techniques. However, the distinction 
between a defect in proliferation or differentiation is less easily made, particularly if the 
blockage occurs early in the hematopoietic hierarchy. 
Markers to identify hematopoietic (stem) cells 
With the methods described above the presence of HSCs and progenitor cells 
within a cell population can be determined, but the cellular characteristics remain 
unresolved. In 1891 Romanovsky discovered that upon exposure of cells to specific dyes 
several hematopoietic cell types can be distinguished based on the staining characteristics 
and the morphology of the cells104. The use of antibodies recognizing proteins expressed on 
the cell surface of hematopoietic cells allows further discrimination of hematopoietic cells, 
as the different cell types within the hematopoietic system have a characteristic cell-surface 
protein expression pattern. The subsequent technical development to separate cells stained 
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with antibodies coupled to a fluorescent dye by F ACS (fluorescence activated cell sorting) 
has lead to more insight into the physiological properties of different cell types. This 
method has been proven very valuable for studying HSCs as they can be enriched from the 
bone marrow. Several protein markers for HSCs have been identified over the last years 
and an overview of some markers is provided in Table 1. It should be noted that despite the 
availability of multiple markers, it has proven difficult to obtain a pure population of HSCs, 
since most markers are expressed by more than one cell type. Therefore, usually a 
combination of markers (i.e. c-kit/CD34+) is used to obtain highly enriched populations of 
HSCs by FACS sorting196•212•213 . In addition to the markers recognizing HSCs, cell 
populations can also be divided into progenitor cell and mature differentiated cell fractions. 
A mixture of antibodies (i.e. CD4/8, B220, Grl, Ter119) recognizing mature hematopoietic 
cells is used for selection of differentiated hematopoietic cells. The lineage marker negative 
cell (Lin·) fraction contains the progenitor cells, while the differentiated cells reside in the 
lineage marker positive (Lin+) fraction. 
Another method to separate HSCs (and stem cells from other tissues) by FACS is 
based on the physiological characteristic that stem cells express multidrug resistance 
channel (MDRl). MDRl allows high efflux of certain dyes such as Hoechst 33342 and 
Rhodaminel23 from stem cells17•26• This method circumvents the use of membrane markers 
that are not exclusively expressed by HSCs and allows a high degree of HSC (side 
population or SP cells) enrichment17•74·119• However, not all HSCs are found within the side 
population fraction and thus rare HSCs can be lost. 
In general, the most commonly used HSC enrichment protocol involves the 
depletion of mature lineage marker positive cells in combination with a positive selection 
for HSC markers. Some of the characteristics of the most frequently used HSC markers are 
described here. CD34, a member of the sialomucin family of glycoproteins, is expressed on 
hematopoietic stem and progenitor cells, vascular endothelium and embryonic 
fibroblasts205•249 and is frequently used as a hematopoietic stem cell marker. During mouse 
development CD34 has proven to be a good marker for HSCs196, but in the adult mouse 
CD34 expression seems not to correlate very well with HSC activity. In the adult mouse 
bone marrow most HSC activity is found in the CD34- fraction. Moreover CD34 expression 
on bone marrow HSCs was shown to be reversible, as CD34- cells upon culture could give 
rise to CD34+ HSCs which loose CD34 expression upon transplantation136•198•214. The 
function of CD34 is not completely understood, but CD34 might play a role in mediating 
adhesion of leukocytes and hematopoietic progenitor to the vascular endothelium via the 
binding to selectins205•229 . 
Sea-l (Stem cell antigen-1) is also often used as a marker for HSCs in both the 
embryo as well as the adult mouse40212•225 • Sea-l is a cell-surface glycoprotein encoded by 
the Ly6A/E gene and is expressed in HSCs, HPCs, T-and B-lymphoid and myeloid cells. 
Additionally, Sea-l expression is found in the vascular endothelium and in the cortical 
tubules of the kidney (130,131,149 and references therein). The function of Sea-l is poorly 
understood, but it was suggested that Sea-l might play a role in cell signaling in 
lymphocytes, via Src family kinases (95 and references therein). Transgenic mice have 
been generated expressing the lacZ or GFP marker gene under the control of either the 
Ly6E or the Ly6A gene regulatory elements130' 149• Analysis of these mice revealed that 
marker expression was found 'in tissues that were previously shown to express Sea-l. In 
transgenic mice with the GFP marker under the control of the Ly6A gene regulatory 
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elements all HSC activity was found in the GFP+ cell population in the bone marrow and in 
fetal hematopoietic sites40 . Analysis of Sea-l (Ly6A) deficient mice by Ito et al. showed that 
mice lacking functional Sea-l have mild thrombocytopenia, decreased numbers of colony 
forming cells and defects in the hematopoietic stem cell compartment as determined by 
competitive repopulation assays95 . Besides the repopulation disadvantage, HSCs of Sea-l-/-
mice did not engraft secondary recipients. This suggests that Sea-l might fulfill a role either 
in the generation, maintenance or self-renewal ofHSCs in the mouse. 
Table 1. Overview of hematopoietic (stem) cell markers. 
Marker /CD number Cell types expressing the marker Remarks Reference 
AA4.1 - HPCs in fetal liver and adult BM transmembrane IS5 
- vascular endothelium protein 
- lung and heart in adult 
a 11 b integrin/ - HPCs in YS and AGM cell adhesion 147.152 
CD41 - megakaryocytes 
-platelets 
CD34 -HSCs/HPCs glycoprotein 54,136,198,214, 
- vascular endothelium 249 
- embryonic fibroblasts 
CD45 - hematopoietic cells tyrosine 116.190 
phosphatase 
c-kit/ CD117 -HSCs/HPCs receptor tyrosine 5,23 
-mast cells kinase 
-testis 
- melanocytes 
- vascular endothelium 
Flk-1 - HSCs in the embryo and adult receptor tyrosine 34.202.245.246 
- vascular endothelium kinase 
Mac-1 (a.MB2 integrin)/ - HSCs in AGM and fetal liver cell adhesion 116,196 
CDllb - macro phages, B and T -cells 
PECAM/CD31 -HSCs/HPCs glycoprotein 54.97.116.190 
- T and B cells, myeloid cells cell adhesion 
-platelets 
- vascular endothelium 
- several adult tissues 
Sea-l -HSCs/HPCs glycoprotein 130.131,149 
- T and B cells, myeloid cells 
- vascular endothelium 
Tie-2 and Tek -HSCs receptor tyrosine 54.78.86 
- vascular endothelium kinase 
Another frequently used HSC marker is the tyrosine kinase receptor c-kit which 
binds to the ligand SCF (stem cell factor). Within the bone marrow approximately 5-10% of 
the cells express c-kit and HSC activity is confined to the c-kit expressing cells89 . Also in 
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the midgestation AGM and liver HSC activity is confined to the c-kit expressing cells196• 
Moreover, expression of c-kit overlaps with other HSC markers, including Sea-l and 
CD3489•196. Mice deficient for the receptor c-kit or its ligand SCF display severe anemia and 
defects in the HSC compartment5•23•67 . The function and expression of c-kit and SCF will be 
discussed in more detail in the section regulators ofHSCs. 
Interestingly, the expression of certain HSC (and progenitors) markers is 
dependent of the developmental stage and site of hematopoiesis. For example, the markers 
CD41 and Mac-1/CD 11 b are expressed on HSCs/HPCs only during embryonic stages and 
not in the adult bone marrow147' 152.1 96 . This temporal expression could reflect a specific 
developmental function for these proteins. Since both these markers belong to a family of 
cell adhesion receptors, the expression of CD41 and Mac-1 on HSCs in the embryo might 
fulfill a role in migration of HSCs in the embryo. For this reason, a closer investigation of 
known HSC markers with an unknown function could reveal novel insights into the 
physiology and properties ofHSCs. 
Hematopoiesis and HSCs in the mouse embryo. 
· localization of HSCs and hematopoietic cells in the mouse embryo 
Similar to other organs during mouse development, the hematopoietic system is 
shaped and remodeled in a dynamic temporal and spatial manner until the end of gestation. 
In the adult mouse HSCs are located in the bone marrow, however during development 
HSCs are located from Ell onwards in the fetal liver, where their number increases 
dramaticalll0•114' 161 • Around birth HSCs migrate from the fetal liver to bone marrow where 
they will remain throughout the adult stages of life. Hence, during development the fetal 
liver is an important hematopoietic organ, although it is not the only hematopoietic organ 
during development (Figure 2A). The yolk sac is the site where the first hematopoietic cells 
in the mouse embryo arise around E7.5. These primitive, nucleated erythrocytes are formed 
in so-called blood islands in close association with the developing yolk sac vasculature 
(Figure 2B; reviewed in reference 181). 
The first primitive hematopoietic cells arise in the extra-embryonic yolk sac, but 
more complex hematopoiesis occurs in the intra-embryonic fetal liver during later stages of 
development. The question arises whether the adult hematopoietic system and more 
importantly whether HSCs are generated in the extra-embryonic or the intra-embryonic 
sites during development. Around 1970 Metcalf and Moore showed that the E8 yolk sac, 
but not the embryo proper, has the ability to produce hematopoietic colonies both in vitro as 
well as in vivo. Additionally, injection of Ell yolk sac cells into lethally irradiated 
recipients resulted in hematopoietic reconstitution by the donor cells 30 days post-
transplantation. Based on these results it was concluded that the extra-embryonic yolk sac 
and not the embryo proper produces hematopoietic stem cells that migrate to the fetal liver 
during later stages of mouse development156. 
In 197 5 the hypothesis on the yolk sac origin of the adult hematopoieitic system 
during development was challenged by the studies of Dieterlen-Lievre and Turpen in the 
avian and amphibian model systems respectively. Grafting experiments with chick-quail 
chimeric embryos showed that the adult hematopoietic system is derived from an intra-
embryonic source and that there is no contribution by the yolk sac47 . Experiments with 
amphibians revealed that an intra-embryonic source contributes to a major extent to the 
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adult hematopoietic system. Also a minor contribution by the yolk sac to the adult 
hematopoietic system was observed106·224• In agreement with the non-mammalian vertebrate 
models, careful mapping studies and L TR-assay studies in the mouse embryo showed that 
the first adult-repopulating HSCs become detectable within the embryo proper in a region 
. 147 161 
referred to as AGM (aorta-gonad-mesonephros) from El0.5 onwards (Figure 2C) -· . 
From Ell onwards HSC activity becomes detectable in the circulation, the yolk sac and the 
fetal liver114•142•161 • Moreover, when El 0 yolk sac and AGM tissues were cultured in an 
organ culture system and analyzed by LTR-assays it was shown that the AGM, but not the 
yolk sac, autonomously generates HSCs142. The use of this organ culture system excludes 
the possibility that HSCs from the yolk sac seed the AGM region via the circulation and 
therefore these data demonstrate that the AGM is the first site in the embryo where HSCs 
are autonomously generated. A closer examination of the AGM revealed that these adult-
repopulating HSCs arise in aorta subregion42. At the same time HSCs can also be found in 
the vitelline and umbilical arteries42 . These blood vessels are derived from intra-embryonic 
tissue and connect the embryo proper with the yolk sac and the placenta. 
Recent studies in several species, including human and Xenopus also revealed the 
existence of an intra-embryonic source of multi potent hematopoietic (stem) cells21935• Fate-
mapping studies showed that in Xenopus the yolk sac equivalent (ventral blood islands) and 
the AGM equivalent (dorsal lateral plate) arise from different cells (blastomeres). The 
separate origins of these tissues and the finding that definitive blood is produced from an 
intra-embryonic source in the Xenopus embryo, correlates with the findings that HSCs are 
derived from an intra-embryonic source. Nevertheless the debate on the origin of HSCs in 
the mouse embryo is still ongoing and recent studies have again challenged the idea that 
HSCs originate from an intra-embryonic source247 • Injection of E9 yolk sac or para-aortic 
splanchnopleura (P-Sp )" cells into the liver of HSC-ablated neonatal recipients resulted in 
repopulation of the hematopoietic system for a prolonged period of time. These 
experiments suggest that the yolk sac does contain neonatal LTR-HSCs, but that these cells 
upon injection into adult recipients fail to repopulate the hematopoietic system. It was 
proposed that E9 yolk sac HSCs have not gone through the necessary maturation processes 
(i.e. expression of the correct cell adhesion receptors) in order to engraft the bone marrow 
of adult recipients, and are therefore not detected in LTR-assays in adult recipients. To date, 
it remains unclear whether these neonatal L TR-HSCs are autonomously generated in the 
yolk sac, AGM or in both tissues. However, these studies do indicate that besides adult 
LTR-HSCs, neonatal LTR-HSCs exist. While both possess the similar physiological 
properties of long-term reconstitution of the hematopoietic system, they differ greatly in 
their properties of homing and/or engraftment. 
• The para-aortic splanchnopleura (P-Sp) is the precursor tissue of the AGM region 
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Figure 2. Schematic overview of hematopoietic tissues during mouse midgestation development. 
(A) Schematic overview of a midgestation mouse embryo. The yolk sac is the first hematopoietic site 
in the embryo and primitive erythrocytes can be detected in the yolk sac from E7.5 onwards. The 
AGM region and the vitelline and umbilical (v+u) vessels are the first sites were adult repopulating 
hematopoietic stem cell activity can be detected and the fetal liver is the main hematopoietic organ 
fi·om E12 onwards until the end of gestation (adapted _from Dzierzak et a!. 58). (B) Schematic 
representation of a blood island of the yolk sac with primitive erythrocytes surrounded by the 
vascular endothelium of the yolk sac vessels (adapted from Dzierza~7). (C) Schematic representation 
of the AGM region with the dorsal aorta in the middle surrounded by the primordial gonads and 
mesonephros (adapted from De Bruijn et al. 42) 
The fact that prior to the emergence of detectable HSC activity in the embryo 
differentiated hematopoietic cells and hematopoietic precursor cells can be found both in 
the embryo and the yolk sac38,4l,l72.Jso raises another puzzling issue. One explanation could 
be that the hematopoietic hierarchy as known in the adult, in which HSCs give rise to 
mature blood cells, does not exist in the embryo. This model would be consistent with the 
idea that the hematopoietic system, as other organs, is generated and shaped during 
development and reflects the needs of the embryo during the different stages of 
development. A known example of organ remodeling in the embryo is the development of 
the kidney. The embryonic kidney during midgestation exists of the mesonephros which 
degenerates, after which the adult kidney is independently generated from the metanephros. 
Another theoretical possibility could be that HSCs from the earliest stages of development 
are producing all different hematopoietic progenitors, consistent with the adult 
hematopoietic hierarchy, but that the currently available assays fail to detect this HSC 
activity at early embryonic stages. Thus, due to the in utero development of mammals and 
the inability to perform embryo-grafting experiments, the exact relationship between the 
different hematopoietic cells, precursors and HSCs found in the mammalian embryo 
remains unresolved to date. 
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Lineage relationship between hematopoietic and vascular endothelial cells 
The hematopoietic system is thought to be derived from the mesodermal lineage 
during development. Indeed, the close relationship between the development of the 
hematopoietic system and the blood vessel endothelial cells raised the idea that HSCs and 
endothelial cells are derived from a common mesodermal precursor, the so-called 
hemangioblast. The first supporting evidence for this theory comes from the observation 
was that primitive hematopoietic cells develop in close association with the vascular 
endothelium195 . In the yolk sac, primitive erythrocytes are formed within the developing 
blood vessels in blood islands and similarly in the intra-embryonic AGM region HSCs arise 
close to or within the endothelium of the dorsal aorta40A2·181 . Clusters at the ventral aspect 
of the dorsal aorta have been detected in embryos of several species, ranging from fish to 
human70•100•168·218 . These clusters are believed to contain HSCs based on the expression of 
hematopoietic (stem) cell markers, such as CD45 and c-kie68.I69•218 • Moreover, HSCs were 
shown to express a number of markers, such as CD34, Flk-1, Tie-2, PECAM-1 and Tek that 
are also expressed by vascular endothelial cells78·87•115.I68•249• Recently, a study with 
transgenic mice expressing GFP under the control of the promoter of the HSC marker 
Sea-l showed that HSCs are GFP+ and that GFP expression was restricted to the 
endothelium of the dorsal aorta in the AGM40. Altogether these studies show that HSCs not 
only share the expression of several markers with endothelial cells but that HSCs localize 
during a defined window of developmental time to the endothelium of the dorsal aorta. 
The idea of a common precursor is further strengthened by the results of several 
gene targeting studies in mice. Generation of mice deficient for the Flk-1 tyrosine kinase 
receptor or the transcription factors Lmo2 and SCL/tall results in an embryonic lethal 
phenotype with defects in both the vascular endothelium as well as in the hematopoietic 
cell compartment12.I93•201•202233•241 . Flk-1 expression has been observed in both the 
endothelial cells and the intravascular clusters of the aorta in the P-Sp/ AGM region and 
studies with chimeric mice revealed that Flk-1 deficient ES cells do not contribute to the 
vascular endothelium or the primitive and definitive hematopoietic cell compartmenf01 •202 . 
In addition, studies by Choi et al.34 showed that the cultures of ES cells to 
embryoid bodies gave rise to a transitional cell type (the blast-colony forming cell) that can 
differentiate to both endothelial and hematopoietic cell lineages. The embryoid body 
culture technique has previously been shown to mimic the development of yolk sac 
hematopoiesis and might therefore reflect the in vivo developmental process 107•211 •237 . 
Altogether these data strongly suggest a common origin for the endothelial and 
hematopoietic cell lineages in the embryo and the studies from Choi et al. do provide 
evidence that in vitro a common precursor for endothelial and hematopoietic cells does 
exist. Nevertheless, formal proof that indeed one precursor cell gives rise to both 
endothelial and hematopoietic cells within the embryo is still lacking. 
Regulators of hematopoiesis 
For both the generation as well as the maintenance of the hematopoietic system the 
continuous input of signals from the environment needs to be translated into a cellular 
response. In the adult hematopoietic system a constant production of mature blood cells is 
required to refill the pool of mature blood. During development the production of 
erythrocytes is required to ensure oxygen supply to the developing embryo. 
15 
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HSC proliferation, differentiation and survival. 
The regulation of the cellular processes of HSCs requires tight control, as either 
excessive proliferation or cell death (apoptosis) will result in too many or too few 
hematopoietic cells. Similarly, tight control over the differentiation and self-renewal of 
HSCs is essential to maintain the appropriate balance of hematopoietic progenitors and 
mature blood cells and to protect the HSC pool for life long hematopoiesis. Several studies 
examined these properties ofHSCs in the adult bone marrow and the results ofthese studies 
imply that HSCs in the adult are mainly quiescent, and enter cell cycle at a low 
frequencyu3• In contrast, during development the number of HSCs within the embryo 
increases dramaticalll0.1 14, suggesting that HSCs are not quiescent, but highly 
proliferative. Alternatively, the increases in HSC number during development might be due 
to the differentiation of HSCs from hemangioblasts or from hemogenic endothelial cells. 
Nevertheless, this difference in regulation of HSC numbers most likely involves different 
signals in the embryo as compared to the adult or similar signals triggering a different 
response depending on the micro-environment. To more specifically describe the regulators 
of hematopoiesis the following sections will focus on apoptosis, developmental patterning 
factors, growth factors and transcription factors. As the number of hematopoietic regulators 
is still rapidly expanding, the following sections will highlight only the most important 
regulators related to the studies presented in this thesis. 
HSC survival and apoptosis 
Inherent to cell differentiation and proliferation is the decision for cells to life or 
die. In tissue remodeling during development and in tissue homeostasis throughout life 
programmed cell death/apoptosis is an essential and highly conserved mechanism which is 
counteracted by anti-apoptotic signals to ensure cell survivaL The key players of apoptotic 
processes are conserved between several species and homologous proteins between 
mammals and the worm C.elegans have been identified6u 44. The executioners of apoptosis 
belong to a family of cysteine proteases, named caspases, and are responsible for the 
degradation of the cellular organelles, the nucleus and the fragmentation of the DNA, which 
are the hallmarks of apoptosis36•84. Caspases are produced as pro-enzymes and their activity 
is under regulation of several adapter proteins which in tum are under regulation of 
members of the Bcl-2 protein famill. The Bcl-2 protein family consists of three 
subfamilies, the anti-apoptotic Bcl-2 subfamily and the pro-apoptotic Bax and BH3-only 
subfamilies3. One of the proposed mechanisms by which Bcl-2 family members may 
regulate apoptosis is through cytochrome c release from the mitochondria. Based on several 
biochemical and cellular findings it has been proposed that pro-and anti-apoptotic proteins 
counteract each other's function via protein-protein interactions (reviewed in 3,22). 
To date it is unclear what role apoptosis exactly plays under normal physiological 
circumstances in the bone marrow HSC population. However, it is clear that under stressful 
conditions, such as exposure to irradiation, a large amount of HSCs will enter the apoptotic 
pathway. Overexpression of anti-apoptotic genes, for example Bcl-2, within the HSC 
compartment will result in increased viability, which is most likely due to diminished HSC 
apoptosis52·53•171• However, also in steady state conditions apoptosis might play a role in 
maintenance and regulation of HSCs numbers. Several studies have shown that 
overexpression of the anti-apoptotic Bcl-2 gene within the HSC compartment results in a 
higher frequency of HSCs as determined by L TR -activity and an increased number of c-kit+ 
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cells in the bone marrow as determined by FACS analysis52' 177• A remaining question is 
what signals are involved in triggering apoptosis in HSCs during normal physiology. 
The regulation of the cellular processes of HSCs, such as proliferation and 
apoptosis, is certainly influenced by the micro-environmental cues. Both in the embryo and 
the adult, HSCs are surrounded by stromal cells, which will provide regulatory signals for 
the HSCs. To date, several regulatory signals have been identified, including 
morphogenetic/patterning factors and hematopoietic growth factors, but the interplay 
between these signals remains unclear. Despite numerous attempts to culture HSCs ex vivo 
in the presence of known hematopoietic growth factors, it is still not possible to maintain 
HSC activity over a prolonged period of time. However, promising new studies by de Haan 
et al. revealed that addition of fibroblast growth factor-1 (FGF-1) to bone marrow cells 
induces expansion of HSCs ex vivo43 . Nevertheless, it remains unclear whether the 
expansion of HSCs in these cultures is induced by FGF -1 alone or whether FGF -1 acts in 
concert with other growth factors produced by accessory cells in these cultures. The finding 
that Fgfr 1-1- ES cells are impaired in their ability to form hematopoietic cells does suggest 
that FGFs play a role in hematopoietic development62• To mimic more closely the in vivo 
situation, HSCs are often cultured in the presence of accessory or stromal cells. In contrast 
to the cultures with hematopoietic growth factors, the presence of stromal cells allows 
maintenance and, in some cases, expansion of HSC activity ex vivo166•175 , indicating that 
stromal cells provide essential signals for HSC survival and proliferation. Several 
explanations for the role of support by stromal cells on hematopoietic (stem) cells have 
been suggested, including direct cell-cell cpntact that provides signals for survival, 
proliferation or differentiation. Additionally, secretion of growth or inductive signals by 
stromal cells could regulate hematopoietic cell behavior. Most likely it is a combination of 
both cell-cell contacts and a multitude of secreted factors that provide the necessary signals 
for the hematopoietic cell survival and proliferation. 
Developmental signaling pathways, Patterning Factors and Hematopoiesis 
During development several morphogenetic signals are required for the correct 
spatial and temporal formation of tissues and organs. Members of the transforming growth 
factor ~ (TGFI3), Wnt and Hedgehog families were reported to play such roles during 
development (reviewed in 29,90,135,141,239). Morphogenetic or patterning factors are 
often expressed in a gradient along which several cell types are exposed to different 
amounts of the morpho gen. Both the concentration as well as the duration of the exposure 
of cells to a morphogen determines the impact of the signaL Morhogenetic/patterning 
factors can therefore have different effects on different cell types depending on their 
position with respect to the source of the morphogen. Morphogens often act as priming 
signals that allow cells to become responsive to other instructive signals69'77 . As the 
development ofHSCs within the embryo also occurs in both a specific temporal and spatial 
manner, several studies have addressed the role of instructive signaling pathways in the 
induction ofHSCs. 
Hedgehog proteins and hematopoiesis 
The hedgehog proteins Sonic and Indian hedgehog (SHH and IHH), were shown · 
to have instructive properties during early mouse hematopoietic development with regard to 
the induction of hematopoietic and vascular cell fate 18'56• Moreover, expression ofiHH was 
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detected in the yolk sac and shown to be an important regulator of yolk sac blood island 
formation and vascular remodeling in the embryo proper1L28. Also in the adult, SHH plays a 
role in inducing proliferation of human hematopoietic progenitors cells18. The ligand SHH, 
the receptors patched and smoothened and the transcription factors Gli-1, 2 and 3 are 
expressed in primitive hematopoietic cells and blood vessel endothelial cells18. 
Interestingly, several of these studies implicated a role for Bone morphogenetic protein -4 
(BMP-4) as mediator of these effects, as BMP-4 expression was upregulated by hedgehog 
proteins. Moreover, the BMP inhibitor, noggin, could block the proliferation of 
hematopoietic progenitor cells induced by SHH18•56• In the mouse embryo, BMP-4, a 
member of the TGFI3 family, had been already suggested to play a role in mesoderm 
formation and more specifically in the development of both hematopoietic and vascular 
systems238. Altogether, these data suggest that hedgehog proteins, possibly via BMP-4 
regulation, might indeed play a role in the induction or regulation ofHSCs. 
TGFI3 family members and hematopoiesis 
Several studies have implicated BMP-4 as an important regulator of hematopoiesis 
in the embryo. Loss of function studies in the mouse revealed that Bmp-4 deficient embryos 
die early in development (between E6.5-9.5) due to impaired mesoderm formation238• 
However, careful examination of these embryos also revealed a reduced numbers of red 
blood cells in the yolk sac and the embryo proper238 . In vitro studies with mouse embryonic 
stem cells showed that BMP-4 could increase the amount of hematopoietic cells formed in 
these cultures103 . In addition, BMP-2, 4 and 7 were shown to allow maintenance or to 
induce the proliferation of mouse bone marrow HPCs19• Interestingly, BMP-4 expression 
has been observed at the ventral aspect of the dorsal aorta in the human AGM region 
underlying intra-aortic hematopoietic clusters believed to harbor the HSCs134• These data 
suggest a role for BMP-4 in the formation of these hematopoietic clusters or the generation 
ofHSCs in the embryo and support the idea that BMP-4 might be a true regulator ofHSCs 
during development. 
Besides BMPs, other members of the TGFI3 family have been implicated to play a 
role in hematopoiesis. TGFI3l can inhibit the proliferation of endothelial and hematopoietic 
(progenitor) cells25'207 . Studies addressing the role of TGFI3 during development showed 
that 50% of the homozygous TgffJI null embryos die around El0.5 due to defects in the 
hematopoietic and vascular systems46. Embryos that do not express the TGFI3 type 1 
receptor die between El 0.5-11.5 with defects in the vascular system, but no obvious defects 
in yolk sac hematopoiesis117. Interestingly, Endoglin, an accessory receptor for TGFI330•135, 
was shown to be a marker for bone marrow HSCs in the mouse, again indicative for a role 
ofTGFI3 in HSC regulation31 . 
Wnt signaling and hematopoiesis 
Wnt genes encode secreted glycoproteins that act as ligands in a highly conserved 
developmental signaling pathway. A large number of homologous genes have been 
identified in several species ranging from Drosophila to human. The key player in the 
canonical Wnt signaling pathway is the protein 13-catenin. Upon binding of Wnt to the 
Frizzled (Fz) receptor degradation of 13-catenin is inhibited, resulting in accumulation and 
translocation of 13-catenin to the nucleus, where it interacts with transcription factors of the 
TCFILEF family and induces activation of target genes (reviewed in 29,150,239). Besides 
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this canonical Wnt signaling pathway, P-catenin independent signaling has also been 
reported92' 183 . Several members of the Wnt family were shown to affect hematopoiesis in 
several species. In the mouse, Wnt5a and lOb as well as several Wnt receptors are 
expressed in the yolk sac and fetal liver. Both Wnt5A and lOb stimulate expansion of fetal 
liver progenitor cells6. Also in humans, Wnt2b, 5a and lOb increase the number of 
progenitor cells in vitro226 . A more recent study revealed that Wnt5A does not affect the 
proliferation rate of human HSCs in vitro, but does enhance in vivo engraftment of these 
cells163 . Loss of function studies in mice show that Wnt5A is required for the 
morphogenesis of the limb and other structures. Wnt5A deficient mice die shortly after 
birth. However, the fact that no obvious defects were detected in the hematopoietic 
system244 suggests either that Wnt5A does not play an essential role in the regulation of 
hematopoiesis during mouse development or more likely that there is functional 
redundancy with other Wnt family members. Based on the expression ofWnt proteins, Wnt 
receptors and signaling components in hematopoietic tissues, including the yolk sac, fetal 
liver and adult BM, together with the effects of Wnt proteins on hematopoietic progenitor 
cells in vitro, it is likely that Wnt proteins are involved in HSC regulation. Their exact role 
in HSC regulation in vivo needs clarification in further studies. 
Taken together, these studies underline the importance of instructive signals by 
Hegdehog, TGFP and Wnt family members in the induction and regulation of the 
hematopoietic system during development. Interestingly, several of these studies indicate 
that these instructive signals often act on both the development of the vascular and 
hematopoietic system, consistent with the findings that the vascular system and the 
hematopoietic system develop in close association. Besides the effects of single patterning 
factors on hematopoietic (stem) cells, these patterning factors might act in concert to 
regulate hematopoietic development as several studies have shown cross-talk between these 
different patterning factors and their signaling components. 
Growth factors and cytokines and hematopoiesis 
Stem cell factor (SCF) and the c-kit receptor 
The natural occurring white spotting (W) mutation in mice was first recognized in 
1908 and most homozygous mutant mice die perinatally due to severe anemia. Surviving 
mice are sterile and have coat pigmentation defects167. The finding that mutations at the 
Steel (Sl) locus resulted in a similar phenotype, suggested a relationship between these two 
loci. Further investigations revealed that the W locus encodes for a receptor tyrosine kinase, 
named c-kit and that the Sl locus encodes the receptor ligand, named stem cell factor 
(SCF)b s,67,23. 
Expression of c-kit was detected in the hematopoietic system, the brain 
(hippocampus and cerebellum), the developing digestive tract, vascular and breast 
endothelial cells, renal tubules, melanocytes in the skin and in the gonads5'67 . Within the 
hematopoietic system c-kit expression was found in several mature cell types, HSCs and 
progenitor cells196'23 . During the differentiation of progenitor cells along the several 
hematopoietic lineages c-kit expression is down-regulated and studies with blocking 
antibodies indicate that c-kit is required for myelopoiesis, but not for lymphopoiesis5. 
b SCF is also known as Kit Ligand (K.L), mast cell growth factor (MGF) or steel factor. 
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The ligand for the c-kit receptor is an 18.5 kD protein named SCF and alternative 
splicing results in either a soluble or membrane bound protein isoform. SCF expression is 
observed in BM stromal cells, fibroblasts, endothelial cells, keratinocytes, gut epithelial 
cells, the thymus, embryonic brain and spinal cord and at low levels in the circulationc 5•23 • 
Within the hematopoietic system SCF acts at multiple levels within the hematopoietic 
hierarchy and regulates several processes, including proliferation, cell survival, 
differentiation and functional activation. Moreover, SCF synergizes with several cytokines, 
including IL-1/3/6 to induce expansion of (human} BM progenitor cells227•523 . This 
expansion was suggested to be caused by induction of cell cycle progression23 . 
Besides its role in proliferation and cell survival, SCF is an important regulator of 
cell adhesion, migration and mobilization of hematopoietic cells. Injection of SCF in mice 
results in mobilization of HSCs from the BM to the peripheral blood5. Interestingly, it was 
shown recently that cytokine induced matrix metalloproteinase 9 (MMP-9) activation 
mediates the release of soluble kit ligand in the BM resulting in the cell cycle entry and 
mobilization ofHSCs to the peripheral blood82. Additionally, SCF is a chemo-attractant for 
mast cells and progenitor cells and in vitro studies showed that SCF increases the avidity of 
the (31 integrins VLA-4 and VLA-5 of CD34+ BM cells, resulting in increased adhesion to 
fibronectin5• Besides the effect of SCF on the expression/regulation of adhesion receptors, 
the membrane bound isoform of SCF is believed to increase adhesion of hematopoietic 
cells via the interaction with the c-kit receptor. 
Interleukin 1 and its role as a hematopoietic regulator 
Interleukin 1 (IL-l) is part of the large family of cytokines, which are low 
molecular weight proteins that control the development of hematopoietic cells and regulate 
immune responses. The cytokine family includes the interleukins, colony-stimulating 
factors and tumor necrosis factors 83 . Cytokines can function as chemo-attractants, growth 
and/or differentiation factors. In 1984 the first two interleukin genes, IL-l a and IL-l (3, were 
cloned and since their discovery a vast number of studies have addressed the role of IL-l in 
normal physiology and during pathogenesis. IL-l plays a central role within the innate 
immune system and as a mediator of inflammation processes. Besides its involvement in 
innate immunity and inflammation, IL-l has also implicated as a regulator of adult mouse 
and human bone marrow hematopoietic stem and progenitor cells. Functional studies show 
that IL-l has a radio-protective effect on HSCs and progenitor cells164•176•250 and might also 
be involved in HSC and progenitor cell adhesion and migration64•157. Furthermore, IL-l can 
upregulate the expression of several cytokines, including IL-1/3/6, GM-CSF and SCF and 
their receptors, as well as molecules involved in hematopoietic cell adhesion and 
migration49. 
IL-l in combination with other hematopoietic growth factors can induce expansion 
of hematopoietic progenitor and myeloid precursor cells24'63•81 • In contrast, other studies 
showed that IL-l itself had no proliferative effect and that IL-l in combination with other 
cytokines induced differentiation instead of expansion of hematopoietic progenitor cells or 
even resulted in complete abrogation ofHSC activity98248 . As these studies were performed 
with different populations of bone marrow cells, different amounts and combinations of 
c in normal human serum at approximately 3 ng/ml 
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(hematopoietic) growth factors, it is difficult to compare these results. Nevertheless, the fact 
that in some studies IL-l has a positive effect on the proliferation of hematopoietic stem/ 
progenitor cells, together with the reported expression of IL-l and the IL-l receptor in 
hematopoietic stem/ progenitors cells96.1 32·139, suggests that (under certain circumstances) 
IL-l is a positive regulator of adult HSCs and hematopoietic progenitor cells. 
By gene targeting, mice deficient for several components of the IL-l signaling 
cascade have been generated, including the Il-l rl, Il-l a and Il-l~' and the intracellular 
signaling mediators Myd88 and Irak-42.73.85·215 . Mice defective for IL-l signaling 
components display impaired IL-l signaling and impaired immune responses, including 
lymphocyte activation and fever induction. Apart from these defects, the mice develop 
normally and are relatively healthy. Most likely, due to functional redundancy with IL-18, 
Toll, RANK and other related molecules, many effects of IL-l signaling deficiency are 
maskedsutz.zo4. 
Regulation and expression of IL-l and the IL-l receptors 
Within the IL-l receptor and ligand system there are multiple levels of regulation. 
The ligands IL-l a and ~ are regulated at both the transcriptional and translational leveL 
Several studies have reported that increased Il-l mRNA expression did not result in 
increased protein expression49. Hence, the second level of regulation is post-translational as 
both IL-l a and IL-113 are produced as precursor proteins of 31 kD. Proteolytic cleavage of 
the precursor proteins is mediated by ICE (interleukin converting enzyme; also known as 
caspase 1) and results in mature 17kD IL-l proteins. Although no obvious difference in the 
biological activity between IL-Ia and 13 has been observed in several studies, a striking 
difference between these isoforms is the finding that in humans IL-l a is normally not 
secreted, while IL-113 is usually secreted and can be detected in the circulation. Moreover, it 
was shown that IL-l a bound to the IL-l RI can be found in the nucleus where it might act as 
a transcription regulator39.154. Besides the biologically active IL-l a and 13 isoforms, an IL-l 
antagonizing protein, named IL-lRa, exists which can bind to the IL-l receptor, thereby 
preventing IL-l binding and signaling. Although the amino acid similarity between IL-l a, 
IL-l~ and IL-lRa only ranges from 18-22%, the three dimensional protein structure is 
highly similar 48. The main source of IL-l is monocytic cells, which produce and secrete 
IL-l upon a large variety of stimuli, including microbal inducers, stress factors, cytokines 
and extracellular matrix components. Maximal IL-lfJ gene expression in monocytes 
requires the transcription factor Spi-l/PU.lu0. IL-l can also be induced by several neuronal 
factors and expression was detected in the brain49. IL-lRa is expressed by several 
hematopoietic cells, endothelial and epithelial cells and fibroblasts4.49. 
The IL-l receptor is composed of two subunits, the IL-lRl and the IL-lRAcP 
(receptor associating protein). Upon binding ofiL-1 to the IL-lRl, IL-lRAcP is recruited 
to the complex to stabilize the binding of IL-l and to mediate recruitment of signaling 
proteins and thereby activating the signaling cascade55. The third IL-l receptor, named IL-
lRII has a very short 29 amino acid intracellular tail and lacks a signal propagating 
domain 55. Biochemical studies showed that the IL-l RII lacks signaling properties and 
therefore acts as a decoy receptor37·55 .140·206. Binding ofiL-1 to the decoy IL-lRII therefore 
fulfills a function in regulating the amount of biologically active IL-l. Besides the 
inhibiting properties of the IL-l RII and transcriptional regulation, the IL-l RI and RII can 
be proteolytically cleaved resulting in soluble receptors with the ability to bind and 
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sequester IL-1 55•179•210• The IL-lRl is 80k:D and is expressed on endothelial cells, smooth 
muscle cells, epithelial cells, hepatocytes, fibroblasts, keratinocytes and several 
hematopoietic cell types. The number of IL-l receptors expressed on the cell surface of 
primary cells is generally low (usually less than 200 receptors per cell). The expression 
pattern ofiL-lRAcP is similar to that ofiL-lRl and highest expression levels are found in 
the brain49·55 . The IL-lRII is 60k:D and its expression is more restricted than the IL-lRl 
55
·
206
. IL-lRII is highly expressed in myeloid and lymphoid cells and at lower levels in 
keratinocytes and liver cells140. IL-lRII binds with a very high affinity to IL-l~ and with 
much lower affinity IL-la49•140• 
Interleukin-1 signaling 
The IL-l receptor belongs to the IL-l/ Toll-like receptor superfamily which 
consists of a large number of receptors which all contain an intracellular TIR (Toll-IL-l 
Receptor) domain. Within the TIR domain 3 conserved regions have been identified which 
are highly conserved from Drosophila to mammals and region 2 and 3 have been suggested 
to play a crucial role in signal transduction55•209• As reviewed, several signaling cascades 
are activated by IL-lR stimulation, including the Ras-Raf-p42/44 MAPK pathway, p38 
MAPK signaling and phospholipase A2 (PLA2) signaling. The best characterized signaling 
pathways activated by IL-l are the Jun kinase (JNK) pathway and the NFKB signaling 
cascade49•50•55•204. IRAK kinases (especially IRAK-4) were shown to be a crucial 
components ofiL-1 signaling101•215 • Interestingly, IRAK-1 was reported to translocate to the 
nucleus upon IL-l stimulation, similar as reported for the IL-lR itself 21 •39• The NFKB 
signaling cascade which is activated by IL-l, is highly conserved within the innate immune 
system as shown in Figure 3. Within the IL-l receptor signaling cascade the kinase TAKl 
and the regulatory TAKl binding proteins (TABs) play an important role in the activation 
of JNK and NFKB. 
TGF-~ activated kinase 1 (TAKl) and TAK1-binding (TAB) proteins 
Transforming growth factor ~ activated kinase 1 (T AKl) was originally identified 
in a screening for proteins involved in TGF-~ signaling243 . In the adult mouse TAKl is 
expressed ubiquitously, with highest expression levels in thymus and brain243• Analysis of 
TAKl protein expression during mouse development revealed that at El0.5 the highest 
TAKl expression is in the spinal cord and the brain. From E12.5 onwards high levels of 
TAKl expression were observed in the gut epithelium and the meta-and mesonephros 
(kidney anlagen). Also in the testis, lung and pancreas TAKl expression was detected at 
El4.599 • The human TAKI gene is located on chromosome 6ql6.1-3 and contains 17 exons 
and mouse Takl is located on chromosome 4. Through alternative splicing of exon 12 and 
16, four different splice isoforms are generated, resulting in four proteins that differ in their 
C-terminus. It is unclear what the function of these different isoforms is, although it was 
suggested that interaction of TAKl with TAKl binding proteins might be altered as this 
interaction is mediated via the C-terminus ofTAK1 111 . 
Soon after the identification of TAKl, the identification of two TAKl binding 
proteins, TAKl binding protein! and 2 (TABl and 2d) was reported208• Human TABI is 
d TAKl binding proteins are also referred to as map3k7ip (map3k7 interacting proteins). 
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Figure 3. Signaling cascade of the Drosophila Toll and mammalian IL-l receptor. 
Signaling via the Toll/IL-l receptor is a highly conserved pathway between Drosophila and mammals. 
In Drosophila the ligand pro-Spiitzle needs to be proteolytically processed prior to binding to the Toll 
receptor, which upon binding Spiitzle recruits the adapter Tube and the kinase Pelle. Upon 
phosphorylation and activation of Pelle, downstream signaling is propagated via to date unknown 
kinases towards Cactus which in tum gets phosphorylated and targeted for degradation Upon Cactus 
degradation the transcription factor Dif is released and will trans locate to the nucleus and activate 
target genes, In mammals pro-IL-l is proteolytically processed prior to binding to the IL-l receptor. 
Upon IL-l interaction with the IL-lRJ, the accessory receptor IL-lRAcP is recruited and allows 
interaction of the adapter protein MyD88 and the kinase IRAK with the receptor. Via the adapter 
proteins TRAF6, TABl and possibly TAB2 and the kinase TAKl the signal is propagated to the kinase 
JNK which activates gene activation via the transcription factor c-jun. The signaling cascade also 
relays a signal to the IKE kinase complex, which will phosphorylate IKE and target it for degradation 
The transcription factor NFKE is released and allowed to trans/ocate to the nucleus in order to 
activate target genes. Upon binding of IL-l to the IL-lRJI no signal is propagated as the IL-lRJI lacks 
an intracellular TIR domain which is required for recruitment of signaling proteins. The IL-lRJI 
therefore is regarded as a decoy receptor. (Adapted from Silverman 204). 
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located on chromosme 22q13 and contains 13 exons, mouse Tabl is localized on 
chromosome 15. It was shown that TABl is ubiquitously expressed and constitutively 
associated with TAKI. As overexpression ofTABl resulted in enhanced TAKl kinase 
activity, it was proposed that TABl is a positive regulator of TAKl. Later it was shown 
that a conserved C-terminal a-helix motif in TABl is involved in the binding and activation 
of TAK1 178• Further analysis by Ge et al. revealed that TABl is involved in the 
autophosphorylation of TAK1 71 • Apart from Northern blotting and RT-PCR RNA 
expression analysis, the expression pattern of Tab] in the adult and during embryonic 
stages has to date not been further determined. However, Tabl deficient mice die around 
the end of gestation due to abnormal lung and cardiovascular development, suggesting an 
important role for TABl in heart and lung development111 . Interestingly, TAKl was 
implicated as an mediator of BMP signaling required for cardiomyocyte differentiation158 
and TAKl overexpression in transgenic mice induced heart failure255 . 
Both TAKl and TABl are highly conserved and homologous proteins have been 
identified in human, mouse, Xenopus, Drosophila and C.elegans. The TAKl and TABl 
homologues in C.elegans (MOM-4 and TAP-1) antagonize Wnt signaling during 
development145'220. Also in mammalian cells and during Xenopus development a similar 
antagonizing effect of TAKl, via NEMO like kinase (NLK) was shown to dowmegulate 
Wnt induced ~-catenin/ TCF transcriptional activation92-94• Drosophila dTAKl plays an 
important role in innate immunity via regulation of NFKB228 • Moreover, during Xenopus 
development TAKl and TABl are implicated in BMP-4 signaling in the central nervous 
system203•242• BMP-4 plays a role in the repression of neural fate of Xenopus ectoderm 
cells75 • In these studies overexpression of TAKl, resulting in higher levels of activated 
TAKl which mimics BMP-4 signaling, enhanced ventral mesoderm formation at the 
expense of neural differentiation203•242 . Interestingly, overexpression of TAKl induced 
extensive apoptosis and therefore these studies were performed together with 
overexpression of the anti-apoptotic Bcl-2 protein203•242 . 
Besides its role in BMP and Wnt signaling, TAKl plays a role in several other 
signaling pathways including the IL-l, IL-18, LPS . and RANK signaling 
pathways91 •155•216•217•230 . However, besides the relatively well characterized TABl protein 
two other TAB proteins have been identified, named TAB2 and TAB3. In contrast to TABl 
of which its role in T AKl regulation has been clarified, the role of T AB3 and to a lesser 
extent TAB2 in TAKl regulation remains unclear. TAB2 was originally reported as a 
adapter protein required for interaction of TAKl and TRAF6 in IL-lR signaling216 . 
Moreover, biochemical protein analysis revealed that upon IL-l stimulation both T AKl and 
TAB2 translocate from the plasma membrane to the cytosolic fraction, consistent with the 
idea that these proteins would first have to interact with the IL-l receptor in order to 
transduce signals to other proteins in the cytosol102'216'217 . Recently, immunofluoresence 
studies by Beak et al. showed that T AB2 is localized in the nucleus of neuronal cells and 
translocated to the cytoplasm upon IL-l stimulation7. They proposed that TAB2 in the 
nucleus fulfilled a role as repressor of NFKB-mediated gene activation7. Further evidence 
that TAB2 might not play a crucial role as an adapter protein in IL-lR signaling, was 
provided by Tab2 gene disruption experiments197• Tab2 deficient mice die around El2.5 
due to fetal liver degeneration by apoptosis. However, upon IL-l stimulation Tab2-deficient 
cells respond similarly to wildtype cells in the induction of IL-l target genes, JNK and 
NFKB activation, suggesting that TAB2 might not be involved in IL-lR proximal signal 
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transduction events197. Therefore, the exact role of TAB2 in IL-l signaling remains 
controversial and to be further elucidated. The last identified TAB protein, TAB3 is 
implicated in BMP signaling in Xenopus. Based on its high homology to TAB2, it was 
proposed to function as an adapter protein linking TAK1 to the BMP receptor162. 
Transcriptional regulation, Transcription factors and hematopoiesis 
Transcription factors play an important role in converting (extracellular) signals 
into gene expression changes that will result subsequently in the alteration of cellular 
behavior or properties. As transcription factors fulfill such an important role in mediating 
changes in cellular behavior and regulating cell fate changes, they have been subject of 
intense investigation over the years. By means of gene targeting studies several 
transcription factors, including Runx-le, SCL/tal-1, and GATA-2, have been shown to 
play an important role in the emergence and/or regulation of HSCs during mouse 
development189•192,1 93•222·223•232 . Besides the transcription factors that are required for the 
most immature hematopoietic cells, several other transcription factors were shown to play a 
role in more mature cells within the hematopoietic system. For example, GATA-1 is 
required for erythroid differentiation187, Pax5 for B-cell differentiation170 and Ikaros for 
lymphoid cell development 221•231 • An overview of several important transcription factors 
that act within the hematopoietic system is provided in Table 2. 
Interestingly, several transcription factors that have been implicated to fulfill a 
crucial role in mammalian hematopoiesis have also been implicated in Drosophila 
hematopoiesis. The conserved transcription factor of the Rel family, NFKB plays an 
important role in innate immunity in both mammals and Drosophila204• Within the 
Drosophila hematopoietic system there are three main cell types. Hemocytes are precursor 
cells that can differentiate into plasmatocytes or crystal cells. The plasmatocytes resemble 
monocyte/macrophage like cells and the crystal cells are involved in wound healing and 
encapsulating foreign invaders68 . The transcription factor Serpent (GATA homolog) is 
important for maintenance and proliferation of hemocyte precursors and the transcription 
factor lozenge (Runx-1 homolog) is important for crystal cell differentiation68•118. 
Within the hematopoietic hierarchy there is a tight regulation of transcription 
factors that fulfill crucial roles during the differentiation process into mature hematopoietic 
cells. For several transcription factors it has been shown that down or up-regulation at 
specific points in the hematopoietic hierarchy is crucial for correct differentiation. For 
example, for the transcription factor GATA-1 it was shown that both lack of gene 
expression as well as increased gene expression resulted in inhibition of erythrocyte 
differentiation, indicating that tight regulation of GAT A-1 is prerequisite for normal 
erythrocyte production186•187•236 . Also for the transcription factor Runx-1 it was shown that 
normal Runx-1 function was required for myeloid differentiation and that Runx-1 regulates 
the gene expression of several myeloid genes, including the transcription factor Pu.l 
129
•
173
•
174
• Besides the expression of these transcription factors required for HSC function, it 
has been proposed that HSCs (and other stem cells) express at low level a large number of 
genes and transcription factors that fulfill crucial roles at later stages in the hematopoietic 
hierarchy. Differentiation of multi-potent cells into a specific mature cell lineage would be 
e AML-1 has recently be renamed Runx -1 and is also known as PEBP2aB, CBF a2. 
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accompanied with downregulation of genes required for other mature cell lineages88. 
Within the hematopoietic hierarchy an important commitment step has been proposed to 
reside at the choice between lymphoid or myeloid differentiation via the common lymphoid 
progenitor (CLP) and common myeloid progenitor (CMP). The two progenitor cell types 
either express lymphoid specific genes or myeloid specific genes 153 • How these different 
choices are regulated and how the downregulation of lineage specific genes is regulated is 
still under investigation. 
Table 2. TranscriJ:!tion factors imJ:!licated in hematOJ:!Oietic (stem) cell regulation 
Transcription Class Expression Phenotype gene targeting studies Reference 
factor in mice 
GATA-1 zinc finger - erythrocytes 
- embryonic lethal 186,187,235 
-mast cells 
- erythroid differentiation defects 
- megakaryocytes 
- sertoli cells 
GATA-2 zincfmger -HSCs/HPCs 
- embryonic lethal E1 0-11 151,184,222, 
- early erythroid cells 
- definitive hematopoiesis defects 223 
-mast cells 
- blood cell differentiation defects 
- megakaryocytes 
- brain, kidney, heart 
GATA-3 zinc finger - fetal liver/ thymus 
-embryonic lethal Ell.S-12.5 32.133.182 
- E 10-11 dorsal aorta 
- fetal liver hematopoiesis defects 
- nervous system 
- CNS development defects 
-kidney 
Ikaros zinc fmger -HSCs/HPCs 
- HSC/ HPC defects 108,165,221. 
- lymphoid cells 
- B and T lymphoid defects 
231 
-brain 
c-myb Leucine -HPCs 
-embryonic lethal El5 160,208 
zipper - colonic mucosa 
- erythroid defects 
- fetal and adult brain 
- less CFU-GM progenitors 
NFKB (ReWp65) RHD - ubiquitous -embryonic lethal El5-16 14.44 
- fetal liver apoptosis 
NFKB(RelB) RHD - lymphoid tissues - multi-organ inflammation 27.234 
- impaired T cell responses 
NFKB (c-rel) RHD - hematopoietic organs - impaired immune responses 113 
- T and B cells 
NFKB1/p50 RHD - ubiquitous - B cell defects 44.200 
PU.l ETS - B-cells - embryonic lethal E 17-18 65,66,128,138, 
- myeloid cells 
- myeloid and lymphoid defects 
199 
- erythroblasts 
- HSC homing defects 
Rbtn2/Lmo2 LIM - hematopoietic clusters 
- embryonic lethal E9-l 0 133.233.241 
-vascular endothelium 
- erythroid development defects 
- fetal liver/ thymus 
- YS hematopoiesis defects 
- embryonic brain 
- definitive hematopoiesis defects 
Runx-11 AML-11 bHLH -HSCs/HPCs - embryonic lethal El2.5 168,174.232 
Cbfa2 - vascular endothelium 
- defmitive hematopoiesis defects 
- nervous system 
- hemorrhaging CNS 
SCLI tal-l bHLH 
- HSCs/HPCs -embryonic lethal E9.5 12,59,105,189 
- erythroid cells - YS hematopoiesis defects 
- megakaryocytes - YS vascular defects 
-mast cells - definitive hematopoiesis defects 
- brain, heart 
- vascular endothelium 
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Runx-1/ AML-1 
The RUNX-1 gene is one of the most frequently mutated genes in human leukemia 
and was originally identified as a target of the t(8,12) chromosomal translocation that 
occurs in acute myeloid leukemias129. After the original identification, several other 
chromosomal translocations of the RUNX-1 gene have been reported, resulting in 
inappropriate Runx-1 expression or disturbed Runx-1 protein function129. Runx-1 belongs 
to the family of conserved runt homology domain transcription factors. Runx-1 is a helix-
loop-helix transcription factor and forms the DNA binding subunit of a heterodimeric CBF 
(core binding factor) transcription factor, consisting ofRunx-1 and CBFJ3. Besides Runx-1, 
two homologous transcription factors have been identified, named Runx-2 and Runx-3 
which also dimerize with CBFJ3. The CBFJ3 subunit enhances DNA binding and is involved 
in transcriptional regulation of the Runx subunit129. Runx-1 binds to the DNA sequence 
TGT/cGGT and regulates several hematopoietic genes including Gm-csf and M-csf 
receptor, Il-3, Myeloperoxidase, Pu.l, c-Myb, Vav and Flk-2 129•173• 
Mice expressing the lacZ marker gene under control of the Runx-1 gene regulatory 
sequences revealed that Runx-1 expression can be detected between E8 and ElO in 
primitive erythrocytes in the yolk sac and from E8.5 onwards the endothelial cells of the 
vitelline artery and dorsal aorta. From El0.5 onwards Runx-1 expression is detected in the 
liver and in some parts ofthe nervous system168• In the absence ofRunx-1 no intra-aortic 
clusters are found in the dorsal aorta, strongly indicating that Runx-1 is involved in the 
generation ofHSCs during embryogenesis168• Further transplantation studies with Runx-1+ 
and Runx-1- sorted cells from Ell-El2 AGM or fetal liver showed that all LTR-HSC 
activity is in the Runx+ population169. 
Gene targeting studies in mice in causing disruption of the Runx-1 gene revealed 
that Runx-1 deficient embryos die around E12.5 of gestation due to the absence of fetal 
liver hematopoiesis232J 74 • Primitive yolk sac hematopoiesis is not affected in Runx-1 
deficient embryos. In addition, Cbfj3 deficient mice have a similar phenotype as Runx-1-/-
mice confirming that both subunits of the CBF transcription factor play an important role in 
hematopoiesis in vivo232• Furthermore, Runx-1-1- ES cells failed to generate myeloid or 
definitive erythrocyte cells, indicating that Runx-1 indeed plays a crucial role in definitive 
hematopoiesis174•232. Besides the hematopoietic defect, also necrosis and hemorrhaging in 
the central nervous system was detected in Runx-1-1- embryos. Interestingly, when E 11 
AGM tissue was cultured in an organ culture system, LTR-HSC activity was lost in 
Runx-1+1- AGMs, but not in wild type AGMs, suggesting there is a defect in the AGM 
microenvironment that normally supports LTR-HSCs232. Altogether, these studies indicate 
an important role for Runx-1 in emergence and regulation of HSCs during development. 
Most interesting is that lack of Runx-1 expression results in a severe defect in definitive 
hematopoiesis. 
SCL/tal-1 
The SCL gene (also known as tal-l) encodes a helix-loop-helix transcription factor 
that binds to the E-box motif CANNTG 15• SCL was originally identified in a case of acute 
T -cell leukemia with a stem cell phenotype. Since its identification, aberrant expression of 
the SCL gene was found in a large number of cases of T -cell leukemia 15• Besides its 
involvement in leukemia, the SCL/tal-1 gene was found to play an essential role in 
hematopoiesis. In the mouse embryo SCL protein expression was detected in the 
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developing blood islands of the yolk sac in both endothelial as well as hematopoietic cells 
at E8.5. From E9.5 onwards SCL expression can be found in the developing liver and 
between El0.5 and El4.5 SCL expression further increases, correlating with the increasing 
hematopoietic activity in the fetal liver105 . In the human, SCL is expressed in 
megakaryocytes, erythroblasts, basophilic granulocytes and CD34+ progenitor cells in the 
peripheral blood and BM, but not in circulating T -cells or B-cells. The expression of SCL 
parallels that of GATA-1 and both genes are downregulated upon differentiation into mature 
blood cells159• 
Sci deficient embryos die around E9.5 due to the absence ofYS hematopoiesis and 
abnormalities of vitelline vessels. More detailed analysis revealed that in Sci deficient 
embryos transcripts for Qata-1, Pu.1 and embryonic Globin j3H1 were absent193 . Further 
studies with Sel-l- ES cells in chimeric mice and in embryoid body cultures revealed that 
Sel-l- ES cells were unable to contribute to the hematopoietic system or to form 
hematopoietic colonies189•192. This suggests an early block in hematopoietic development, 
either at the level of specification of the hematopoietic stem cell or at the level of the 
hematopoietic progenitor cell. Despite its important role during development, SCL 
expression in the adult mouse might not be crucial for HSC function. Recent studies in 
which the Sci gene was disrupted in adult mice, revealed that bone marrow HSCs lacking a 
functional Sci gene could upon transplantation repopulate the hematopoietic system and 
give rise to several hematopoietic celllineages148. 
GATA transcription factors 
GAT A factors are zinc finger transcription factors that bind to the DNA consensus 
sequence (TIA)GATA(A/G). The GATA members 1, 2 and 3 are regarded as the· 
hematopoietic GATA transcription factors and GATA members 4, 5 and 6 as non-
hematopoietic family members. GATA-1 is essential for erythrocyte differentiation and 
GATA-3 forT-cell development and hematopoietic precursor regulation. Gene targeting 
studies for Gata-1 and 3 revealed that lack of gene expression result in an embryonic lethal 
phenotype. Gata-2 was shown to be an important regulator in HSCs by gene targeting 
studies32J 33•182•186J 87•235• GATA-2 is highly expressed in immature hematopoietic cells and 
GATA-2 expression is down-regulated upon differentiation into most mature hematopoietic 
cells184. Outside the hematopoietic system GATA-2 expression can be detected in the 
central nervous system, endothelial cells, liver and kidney (151 and references therein). 
Gata-2 deficient mice have an embryonic lethal phenotype and die between El 0.5-11.5 of 
gestation due to severe anemia. More detailed investigations revealed that Gata-2 deficient 
mice have reduced numbers of primitive erythrocytes, but that the definitive hematopoiesis 
was severely disrupted. Studies with Gata-2 deficient chimeric mice revealed that 
Gata-2 -1- ES cells do not contribute to fetal liver hematopoiesis or to hematopoiesis in 
adult mice. Within a Rag -1- background the Gata-2 -1- ES cells contributed to a small 
extent to the lymphoid system. Based on these findings is was concluded that GATA-2 
expression is required for all hematopoietic lineages222 . 
Interestingly, similar to the dosage effects of Gata-1, Gata-2 overexpression has 
detrimental effects on hematopoietic progenitor cells. Overexpression of Gata-2 in the adult 
bone marrow hematopoietic stem cell compartment (i.e. Sea+ /Lin· BM cells) resulted in a 
lower frequency of CFU-S and impaired hematopoietic recovery upon transplantation. 
However, Gata-2 overexpression does not result in increased apoptosis 184• Thus, GATA-2 
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is an important factor involved in the regulation and possibly emergence, of HSCs during 
development and also for adult hematopoiesis. The observation that GATA-2 expression 
can be detected from E9 onwards in the P-Sp/AGM region, the region where the first adult-
repopulating HSCs can be detected, strongly suggests that GATA-2 is a regulator ofHSCs 
from the earliest stages onwards. 
Rel!NFKB 
Nuclear Factor kappaB (NFKB) was first identified as a DNA binding factor 
regulating the expression of K light chains in mouse B lymphocytes10. Numerous studies 
have shown that members of the NFKB family play an important role in differentiation, 
apoptosis and proliferation regulation in several hematopoietic cell lineages10•44•204. 
Although the role of NFKB transcription factors has been extensively studied within the 
(innate) immune system204, their role in the regulation of HSCs and progenitor cells is less 
well understood. Members of the Rel/NFKB family are conserved dimeric transcription 
factors which share a 300 amino acid Rel homology domain (RHD) and can bind to the 
consensus DNA sequence (KB motif) GGG(A/G)NN(T/C)(T/C)CC10'44• In mammals there 
are 5 known NFKB members, namely ReWp65, RelB, c-rel, NFKBl (p105/50) and NFKB2 
(pl00/p52)44• RelA, RelB and c-rel have strong transactivation domains and are generated 
as mature proteins. In contrast, the family members p50 and p52 are generated from the 
p 105 and p 100 proteins and lack strong activation domains. Therefore, these two members 
are presumed to function as modulators or inhibitors ofNFKB-mediated gene regulation. In 
order to exert their function, NFKB proteins have to homo or heterodimerize and several 
combinations are possible, although the p65/p50 heterodimer is the most common one10•44. 
As mentioned in the section on IL-l signaling, NFKB is, in non-stimulating 
conditions, located in the cytoplasm bound to IKB inhibitor proteins. Upon stimulation, IKB 
is phosphorylated by IKB kinases (IKK) and targeted for degradation, thereby releasing 
NFKB and exposing its ·nuclear localization signal. NFKB is subsequently able to 
translocate to the nucleus and activate target genes 10.44204. For both the IKB and the IKB 
kinase proteins several homologous proteins have been described, with different affinities 
for their substrates and different modes ofregulation122' 123' 137.146 . A large number ofNFKB 
target genes have been identified and these include cytokines, chemokines, adhesion 
molecules and acute phase proteins and several regulators of apoptosis 9·71.121 •240 . Besides 
IL-l, several other signals can induce NFKB signaling, among which are TNFa, LPS, 
cellular stress inducing factors and others. Apart from the inducible signals to activate 
NFKB, also constitutive NFKB gene regulation has been observed. The selectivity ofNFKB 
signaling and gene regulation appears to be regulated through the specific interaction of the 
NFKB subunits with each other and their target gene promoters, as well as through several 
levels of regulation within the signaling cascade. 
NFKB members play an important role within the innate immune system, in 
Drosophila as well as in mammals44'204. Through gene targeting studies in mice their 
essential role in the immune system was revealed. RelB deficient mice lack dendritic cells 
and have impaired immune responses as well as multi-organ inflammation27•234• Mice 
lacking c-Rel expression display impaired T and B cell function113 and mice deficient in 
NjKbl or NjKb2 have B cell defects 8'200 . None of these mutant mice are embryonic lethal, 
which is in contrast to RelA deficient mice which die due to fetal liver apoptosis around . 
E15-16 of gestation14. Moreover, Ikky and IkkfJ deficient mice die also due to fetal liver 
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apoptosis, although slightly earlier during development at El2-13 123,1 94. Together these 
studies indicate an important role for NFKB signaling during fetal liver development, as 
mice deficient for either the NFKB regulator Ikk or for the NFKB family member RelA 
display fetal liver defects. Functional redundancy between the different NFKB transcription 
factors, but not between the regulatory IKK proteins might account for the discrepancy 
between the time of death of the RelA deficient embryos (El5-16) and the Ikk deficient 
embryos (El2-13). Furthermore, it was shown that TNFa played a crucial role in the 
induction of fetal liver apoptosis in RelA deficient mice13• 
The HSC genetic program: approaches for novel gene discovery. 
Within the hematopoietic system, HSCs are the most immature cells with the 
ability of extensive self-renewal. The characteristic of self-renewal is an interesting 
biological property, as most cell types within the adult have limited self-renewal capacity. 
However, besides HSCs, other types of stem cells with extensive self-renewal capacity 
have been identified, including neural and mesenchymal stem cells. Most likely, in these 
stem cells a specific set of genes responsible for self-renewal is expressed, while in other 
cell types with limited self-renewal properties, these genes are not or differently expressed. 
Another interesting feature of HSCs is that their descendants differentiate towards lineage-
restricted precursors which in tum differentiate towards the mature hematopoietic cells. 
During this differentiation process the intermediate precursors and mature cells have 
specific gene expression patterns meeting the requirements of the different functions these 
cells have to perform. The expression of genes at a transcriptional level correlates with the 
presence and/or amount of mRNA within a cell. Therefore, comparing the mRNA content 
between two or more cell populations, cell types or tissues can reveal the difference in gene 
expression between these cell populations. Moreover, these comparisons can yield more 
insight into which genes play an important role in certain cell types, such as stem cells, or 
are involved in processes such as differentiation. 
Several studies have applied different techniques to detect the expression of genes 
within specific populations of cells within the hematopoietic system. These studies 
compared the gene expression pattern of HSCs and the lineage restricted precursors to gain 
insight into the regulatory processes along the first steps of the differentiation pathway of 
the hematopoietic hierarchy188. More recently, two studies compared different populations 
of stem cells to gain insight into the shared characteristics of these cells as compared to 
differentiated cells96.1 91 • Together these studies have provided important insights into the 
regulation and gene expression pattern of HSCs. As with all studies addressing gene 
expression differences between two (or more) populations of cells, the purity of the starting 
population of cells is an important factor in determining the success of the final results. 
HSCs are a rare population of cells within the bone marrow and also within the embryo. 
Therefore, to obtain material for these studies, HSCs need to be enriched. The quality and 
amount of HSCs depends on the enrichment protocol and the purity of the enrichment by 
F ACS sorting. In the cases that the starting population of cells contains a small percentage 
of HSCs, specific I-ISC gene expression information might be masked by the gene 
expression pattern of other cell types within the population. Despite these difficulties, 
several studies successfully employed these gene expression screenings to unravel parts of 
the gene expression pattern in HSCs and thereby gain insight into their physiological 
properties. 
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One of the first methods developed to monitor changes in gene expression was 
Differential Display RT-PCR (DD RT-PCR)125 and a schematic overview of this technique 
is shown in Figure 4. Since the original description of the technique in 1992 by Liang and 
Pardee125 several improvements to the technique have been introduced158. Especially the 
use of longer, more specific primers has improved the reproducibility of the 
technique76' 124' 126 . In addition, methods to screen the large number of DD RT-PCR clones 
have been introduced 109. The disadvantage of the DD RT-PCR technique is the large 
number of false positive clones that are generated and that for a representative overview of 
differentially expressed genes a large number of primers should be used124' 126. Most false 
positive clones are introduced during the excision of the differentially expressed PCR 
fragments from the polyacrylamide gel. The excised band usually contains, besides the 
PCR fragment of interest, additional PCR fragments that are not differentially expressed. 
These latter PCR fragments are the major source of false positive clones and therefore 
additional screening methods (i.e. virtual Northern blotting and eDNA dot blot expression 
analysis) have been developed to eliminate these clones. Another drawback that has been 
suggested is that DD RT -PCR is biased towards identification of highly expressed 
mRNAs16• The major advantage is that DD RT-PCR requires small amounts of starting 
material (1 ).lg total RNA is sufficient for a small screening with 8 primers) and that 
manipulation of the starting material is minimal, thereby reducing the changes of artifacts. 
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Figure 4. Overview of the 
Differential Display RT-PCR 
technique. 
RNA from two or more populations 
of cells or tissues is isolated and 
eDNA is generated. The 
radioactive RT-PCR with arbitrary 
primers is performed under low 
stringent PCR conditions for 2-3 
cycles to allow the primers to bind 
to non-perfect matched target 
eDNA. Subsequently high stringent 
PCR conditions are applied for 30-
40 cycles. The RT-PCR mixture is 
separated on a polyacrylamide gel 
and exposed to a film. Differential 
bands can be excised from the gel, 
purified and cloned for further 
analysis. 
In addition to DD RT-PCR, other methods were developed to identify 
differentially expressed genes. The suppression subtractive hybridization (SSH) and 
representational difference analysis (RDA) methods are based on similar principles and 
have in common that first the common mRNAs between the two starting mRNA population 
are removed and that only the differentially expressed mRNAs are amplified. These 
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methods have been suggested to be more sensitive to identify low expressed mRNAs 45' 127. 
The major disadvantages of these techniques are that a large amount of starting material is 
required which is manipulated in a large extent (i.e. restriction enzyme digestion and 
adapter ligation). In addition, changes in expression levels are not easily identified, as 
common mRNAs are eliminated during the procedure. The major advantages of these 
techniques are the low number of false positive clones and the high reproducibility. Besides 
DD RT-PCR and the subtractive screening methods other methods have been developed 
over the years that are mostly based on the principles ofDD RT-PCR and SSH. 
The state of the art methods to identify differentially expressed genes are the 
macro and micro-arrays. These arrays (either a filter or a glass slide) contain a large number 
of small spots of eDNA (or oligonucleotides) ranging from several hundreds of spots up to 
several thousand of spots. Hybridization of radioactive or fluorescent labeled eDNA 
populations allows the analysis of a large number of genes that are differentially expressed 
between two or more populations of cells. The major advantages of this technique are that 
in one experiment the expression of a large number of genes can be monitored and the high 
sensitivity of the technique. However, due to the high sensitivity of this technique, small 
differences in the isolation and manipulation of the starting material will result in false 
positive differentially expressed genes. Nonetheless, the micro-array technology allows 
gene expression profiling of a large number of genes and has proven to be major step 
forward into the identification of differentially expressed genes. 
Scope of this thesis 
In this introduction an overview of the current knowledge of HSC development 
and regulation is provided. Despite the large number of studies on HSCs in the adult, little 
is known concerning the genetic program for HSC emergence in the mouse embryo. Since 
HSC function is ultimately based on the genetic program, the aim of this study was to 
identify (novel) genes involved in hematopoiesis and in particular involved in the 
emergence/ regulation of hematopoietic stem cells in the mouse AGM region between ElO 
and Ell of development. 
Chapter 2 describes the results of the search for novel genes in the mouse AGM 
region between ElO and Ell by Differential Display RT-PCR. We found several 
differentially regulated genes of which some were not previously linked to hematopoiesis 
and three genes were novel mouse homologues of known human genes. Two of these 
genes, namely mTm9sj2 and mTab2 were further investigated. Chapter 3 describes the 
expression pattern of TAB2 and related genes. As TAB2 was implicated in IL-l signaling 
we investigated the role the role of IL-l on midgestation hematopoiesis, which is described 
in Chapter 4. In Chapter 5 we describe our investigations regarding the role of apoptosis 
and the Bcl-2 protein on hematopoiesis. In the last chapter, the general discussion, we 
attempt to integrate the findings of these signaling molecules and their possible role in 
regulating HSCs and hematopoiesis during the earliest stages of development. 
32 
General introduction 
References 
1. Abkowitz, J. L. et al. 2000. In vivo kinetics of murine hemopoietic stem cells. Blood96:3399-3405. 
2. Adachi, 0. et al. 1998. Targeted disruption of the MyD88 gene results in loss of IL-l- and IL-lS-
mediated function. Immunity. 9:143-150. 
3. Adams, J. M. eta!. 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326. 
4. Arend, W. 2002. The balance between IL-l and IL-lRa in disease. Cytokine Growth Factor Rev 
13:323-340. 
5. Ashman, L. K 1999. The biology of stem cell factor and its receptor c-kit. Int.J Biochem Cell Biol 
31:1037-1051. 
6. Austin, T. W. eta!. 1997. A role for the Wnt gene family in hematopoiesis: expansion ofmultilineage 
progenitor cells. Blood 89:3624-3635. 
7. Baek, S. H. et al. 2002. Exchange ofN-CoR corepressor and Tip60 coactivator complexes links gene 
expression by NF-KB and 13-Amyloid precursor protein. Cell110:55-67. 
8. Baeuerle, P. A. eta!. 1996. NF-kappaB: ten years after. Cell87:13-20. 
9. Barkett, M. et al. 1999. Control of apoptosis by Rel!NF-KB transcription factors. Oncogene 18:6910-
6924. 
10. Barnes, P. J. 1997. Nuclear factor-KB.lnt.J.Biochem.Cell Biol. 29:867-870. 
11. Baron, M. 2001. Induction of embryonic hematopoietic and endothelial stem/progenitor cells by 
hedgehog-mediated signals. Differentiation 68:175-185. 
12. Barton, L. M. et a!. 1999. The stem cell leukaemia (SCL) gene: a critical regulator of haemopoietic 
and vascular development.Jnt.J Biochem Cell Biol31:1193-1207. 
13. Beg, A. A. et al. 1996. An essential role for NF-KB in preventing TNF-a.-induced cell death. Science 
274:782-784. 
14. Beg, A. A. et al. 1995. Embryonic lethality and liver degeneration in mice lacking the Re!A component 
ofNF-KB. Nature 376:167-170. o 
15. Begley, C. G. et al. 1999. The SCL gene: from case report to critical hematopoietic regulator. Blood 
93:2760-2770. 
16. Bertioli, D. J. et al. 1995. An analysis of diffemtial display shows a strong bias towards high copy 
number rnRNAs. Nucl.Acids Res. 23:4520-4523. 
17. Bertolini, F. eta!. 1997. Multilineage long-term engraftment potential of drug-resistant hematopoietic 
progenitors. Blood 90:3027-3036. 
18. Bhardwaj, G. eta!. 2001. Sonic hedgehog induces the proliferation of primitive human hematopoietic 
cells via BMP regulation. Nat.lmmunol. 2:172-180. 
19. Bhatia, M. et a!. 1999. Bone morphogenetic proteins regulate the developmental program of human 
hematopoietic stem cells. J.Exp.Med. 189:1139-1148. 
20. Boggs, D. R. et a!. 1982. Hematopoietic stem cells with high proliferative potential. Assay of their 
concentration in marrow by the frequency and duration of cure of W/Wv mice. J Clin.lnvest 70:242-
253. 
21. Bol, G. et al. 2000. Translocation of the inter!eukin-1 receptor-associated kinase-! (IRAK-1) into the 
nucleus. FEES Lett. 477:73-78. 
22. Bouillet, P. eta!. 2000. The role of the pro-apoptotic family member bim in physiological cell death.' 
Ann.N.Y.Acad.Sci. 926:83-89. 
23. Broudy, V. C. 1997. Stem cell factor and hematopoiesis. Blood 90:1345-1364. 
24. Brugger, W. eta!. 1993. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by 
stem cell factor, interleukin-113 (IL-113), IL-6, IL-3, interferon-ganuna, and erythropoietin. Blood 
81:2579-2584. 
25. Bruno, E. eta!. 1998. The Smad5 gene is involved in the intracellular signaling pathways that mediate 
the inhibitory effects of transforming growth factor-13 on human hematopoiesis. Blood 91: 1917-1923. 
26. Bunting, K D. et al. 2000. Enforced P-glycoprotein pump function in murine bone marrow cells 
results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood 96:902-
909. 
27. Burkly, L. et al. 1995. Expression ofrelB is required for the development of thymic medulla and 
dendritic cells. Nature 373:531-536. 
28. Byrd, N. eta!. 2002. Hedgehog is required for murine yolk sac angiogensis. Development 129:361-
372. 
29. Cadigan, K M. et al. 1997. Wnt signaling: a common theme in animal development. Genes Dev 
11:3286-3305. 
33 
Chapter I 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
41. 
42. 
43. 
44. 
45. 
46. 
47. 
48. 
49. 
50. 
51. 
52. 
53. 
54. 
55. 
56. 
57. 
58. 
59. 
60. 
34 
Cheifetz, S. et al. 1992. Endoglin is a component of the transforming growth factor-~ receptor system 
in human endothelial cells. J Bioi Chern 267:19027-19030. 
Chen, C. Z. et al. 2002. Identification of endoglin as a functional marker that defmes long-term 
repopulating hematopoietic stem cells. Proc Nat! Acad Sci US A. 99:15468-15473. 
Chen, D. et al. 2001. Enforced expression of the GATA-3 transcription factor affects cell fate 
decisions in hematopoiesis. Exp.Hematol. 29:971-980. 
Cheshier, S. H. et al. 1999. In vivo proliferation and cell cycle kinetics of long-term self-renewing 
hematopoietic stem cells. Proc.Natl.Acad.Sci. U.S.A. 96:3120-3125. 
Choi, K. et al. 1998. A common precursor for hematopoietic and endothelial cells. Development 
125:725-732. 
Ciau-Uitz, A. et al. 2000. Distinct origins of adult and embryonic blood in Xenopus. Cell102:787-
796. 
Cohen, G. M. 1997. Caspases: the executioners of apoptosis. Biochem.J. 326:1-16. 
Colotta, F. et al. 1994. The type II 'decoy' receptor: a novel regulatory pathway for interleukin L 
Immunol.Today 15:562-566. 
Cumano, A. et al. 1993. Differentiation and characterization of B-cell precursors detected in the yolk 
sac and embryo body of embryos beginning at the 10- to 12-somite stage. Proc.Natl.Acad.Sci.U.S.A 
90:6429-6433. 
Curtis, B. M. et al. 1990. IL-l and its receptor are translocated to the nucleus. J.Immunol. 144:1295-
1303. 
de Bruijn, M. F. et al. 2002. Hematopoietic stem cells localize to the endothelial cell layer in the 
midgestation mouse aorta. Immunity 16:673-683. 
de Bruijn, M. F. et al. 2000. CFU-S(ll) activity does not localize solely with the aorta in the aorta-
gonad-mesonephros region. Blood 96:2902-2904. 
de Bruijn, M. F. et al. 2000. Defmitive hematopoietic stem cells first develop within the major arterial 
regions of the mouse embryo. EMBO J 19:2465-2474. 
de Haan, G. et al. 2003. In vitro generation of long-term repopulating hematopoietic stem cells by 
fibroblast growth factor- L Dev Cell 4:241-25 L 
Denk, A. et al. 2000. NFKB transcription factors: critical regulators of hematopoiesis and neuronal 
survivaL Cytoldne Growth Factor Rev 11:303-320. 
Diatchenko, L. et al. 1996. Suppression subtractive hybridization: A method for generating 
differentially regulated or tissue-specific eDNA probes and libraries. PNAS 93:6025-6030. 
Dickson, M. C. et al. 1995. Defective haematopoiesis and vasculogenesis in transforming growth 
factor-beta 1 knock out mice. Development 121:1845-1854. 
Dieterlen-Lievre, F. 1975. On the origin of haemopoietic stem cells in the avian embryo: an 
experimental approach. J.Embryol.Exp.Morphology 33:607-619. 
Dinarello, C. A. 1994. The interleukin-1 family: 10 years of discovery. FASEB J. 8:1314-1325. 
Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood87:2095-2!47. 
Dinarello, C. A. 1997. Interleukin-1. Cytoldne Growth Factor Rev. 8:253-265. 
Dinarello, C. A. 1998. Interleukin-1~, interleukin-18, and the interleukin-1~ converting enzyme. 
Ann.N. Y.Acad.Sci. 856:1-1 L 
Domen, J. et al. 2000. The role of apoptosis in the regulation of hematopoietic stem cells: 
Overexpression ofBcl-2 increases both their number and repopulation potentiaL J Exp Med. 191:253-
264. 
Domen, J. et al. 1998. Systemic overexpression of Bcl-2 in the hematopoietic system protects 
transgenic mice from the consequences oflethal irradiation. Blood 91:2272-2282. 
Drake, C. J. et al. 2000. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood95:!67!-!679. 
Dunne, A. et al. 2003. The Interleukin-1 Receptor/ Toll-like receptor superfamily: signal transduction 
during inflammation and host defense. Sci.STKE. 
Dyer, M. A. et al. 2001. Indian hedgehog activates hematopoiesis and vasculogenesis and can 
respecif'y prospective neurectodermal cell fate in the mouse embryo. Development 128:1717-1730. 
Dzierzak, E. 2001. A developmental approach to hematopoiesis. In Steinberg, Higgs, and Nagel (ed.), 
Disorders of Hemoglobin. Cambridge University Press, New York. 
Dzierzak, E. et al. 1998. Qualitative and quantitative aspects of hematopoietic cell development in the 
mammalian embryo. Imm.Today 19:228-236. 
Elefanty, A. G. et al. 1999. SCL expression in the mouse embryo detected with a targeted lacZ 
reporter gene demonstrates its localization to hematopoietic, vascular, and neural tissues. Blood 
94:3754-3763. 
Ema, H. et al. 2000. Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. 
Blood 95:2284-2288. 
General Introduction 
61. Evan, G. et al 1998. A matter of life and cell death. Science 281:1317-1322. 
62. Faloon, P. et al 2000. Basic fibroblast growth factor positively regulates hematopoietic development. 
Development 127: 1931-1941. 
63. Fibbe, W. E. et al 1988. Proliferation of myeloid progenitor cells in human long-term bone marrow 
cultures is stimulated by interleukin-1~. Blood72:l242-l247. 
64. Fibbe, W. E. et al 1992. Sustained engraftment of mice transplanted with IL-l-primed blood-derived 
stem cells. J.Immunol. 148:417-421. 
65. Fisher, R C. et al 1999. A critical role for PU.l in homing and long-term engraftment by 
hematopoietic stem cells in the bone marrow. Blood 94:1283-1290. 
66. Fisher, R C. et al 1998. Role ofPU.l in hematopoiesis. Stem Cells 16:25-37. 
67. Fleischman, R A. 1993. From white spots to stem cells: the role of the Kit receptor in mammalian 
development. Trends Genet. 9:285-290. 
68. Fossett, N. et al 2001. Functional conservation of hematopoietic factors in Drosophila and vertebrates. 
Differentiation 69:83-90. 
69. Freeman, M. et al 2002. Regulatory principles of developmental signaling. Annu.Rev.Cell Dev.Biol. 
18:515-539. 
70. Garcia-Porrero, J. A. et al 1995. Potential intraembryonic hemogenic sites at pre-liver stages in the 
mouse. Anat Embryo! (Berl) 192:425-435. 
71. Ghosh, S. et al 2002. Missing pieces in the NF-kappaB puzzle. Cell109:S81-S96. 
72. Gilbert, S. F. 1994. Developmental Biology. Sinauer Associates Inc., Massachusetts. 
73. Glaccum, M. B. et al 1997. Phenotypic and functional characterization of mice that lack the type I 
receptor for IL-l. J.Immunol. 159:3364-3371. 
74. Goodell, M.A. et al 1996. Isolation and functional properties of murine hematopoietic stem cells that 
are replicating in vivo. J.Exp.Med. 183:1797-1806. 
75. Goswami, M. et al 2001. Regulation of MAP kinase by the BMP-4/TAKl pathway in Xenopus 
ectoderm. Dev.Biol. 236:259-270. 
76. Graf, D. et al 1997. Rational primer design greatly improves differential display PCR (DD-PCR). 
Nucl.Acids Res. 25:2239-2240. 
77. Gurdon, J. B. et al 1998. Cells' perception of position in a concentration gradient. Cell95:159-162. 
78. Hamaguchi, I. et al 1999. In vitro hematopoietic end endothelial cell development from cells 
expressing TEK receptor in murine aorta-gonad-mesonephros region. Blood 93:1549-1556. 
79. Harrison, D. E. et al 1988. Number and continuous proliferative pattern of transplanted primitive 
immunohematopoietic stem cells. Proc.Natl.Acad.Sci. U.S.A 85:822-826. 
80. Harrison, D. E. et al 1993. Primitive hemopoietic stem cells: direct assay of most productive 
populations by competitive repopulation with simple binomial, correlation and covariance calculations. 
Exp Hematol21:206-219. 
81. Heimfeld, S. et al 1991. The in vitro response of phenotypically defined mouse stem cells and 
myeloerythroid progenitors to single or multiple growth factors. Proc.Natl.Acad.Sci. U.S.A 88:9902-
9906. 
82. Reissig, B. et al 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires 
mmp-9 mediated release of kit-ligand. Cell109:625-637. 
83. Helmreich, E. J. M. 2001. The Biochemistry of cell signaling. Oxford University Press Inc., New 
York. 
84. Hengartner, M. 0. 2000. The biochemistry of apoptosis. Nature 407:770-776. 
85. Horai, R et al 1998. Production of mice deficient in genes for interleukin (IL)-la, IL-l~, IL-l a/~, 
and IL-l receptor antagonist shows that IL-l~ is crucial in turpentine-induced fever development and 
glucocorticoid secretion.J.Exp.Med. 187:1463-1475. · 
86. Hsu, H. C. et al 2000. Hematopoietic stem cells express tie-2 receptor in the murine fetal liver. Blood 
96:3757-3762. 
87. Hsu, H. C. et al 2000. Hematopoietic stem cells express tie-2 receptor in the murine fetal liver. Blood 
96:3757-3762. 
88. Hu, M. et al 1997. Multilineage gene expression precedes commitment in the hemopoietic system. 
Genes Dev 11:774-785. 
89. Ikuta, Ketal 1992. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on 
steel factor for their generation. Proc.Natl.Acad.Sci. U.S.A 89:1502-1506. 
90. Ingham, P. W. et al 2001. Hedgehog signaling in animal development: paradigms and principles. 
Genes Dev. 15:3059-3087. 
91. lrie, T. et al 2000. TAKl mediates an activation signal from toll-like receptor(s) to nuclear factor-
kappaB in lipopolysaccharide-stimulated macrophages. FEES Lett. 467:160-164. 
35 
Chapter 1 
36 
92. Ishitani, T. et al. 2003. The TAK1-NLK mitogen-activated protein kinase cascade functions in the 
Wnt5a/ Ca2+ pathway to antagonize Wnt! ~-catenin signaling. Mol Cell Biol23: 131-139. 
93. Ishitani, T. et al. 2003. Regulation of Lymphoid Enhancer Factor 11 T-Cell Factor by Mitogen-
Activated Portein Kinase-related Nemo-Like Kinase dependent phosphorylation in Wnt1~-catenin 
signaling. Mol Cell Biol23:1379-1389. 
94. Ishitani, T. et al. 1999. The TAK1-NLK-MAPK-related pathway antagonizes signalling between ~­
catenin and transcription factor TCF. Nature 399:798-802. 
95. Ito, C. Y. et al. 2003. Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood 
101:517-523. 
96. Ivanova, N. B. et al. 2002. A stem cell molecular signature. Science 298:601-604. 
97. Jackson, D. E. 2003. The unfolding tale ofPECAM-1. FEES Lett. 540:7-14. 
98. Jacobsen, S. E. et al. 1994. Distinct and direct synergistic effects ofiL-1 and IL-6 on proliferation and 
differentiation of primitive murine hematopoietic progenitor cells in vitro. Exp.Hematol. 22:1064-1069. 
99. Jadrich, J. L. et al. 2003. Expression of TAKl, a mediator of TGF-~ and BMP signaling, during 
mouse embryonic development. Gene Expression Patterns 3:131-134. 
100. Jaffredo, T. et al. 1998. Intraaortic hemopoietic cells are derived from endothelial cells during 
ontogeny. Development 125:4575-4583. 
101. Janssens, S. et al. 2003. Functional diversity and regulation of different interleukin-1 receptor-
associated kinase (IRAK) family members. Mol Cell11:293-302. 
102. Jiang, Z. et al. 2002. Interleukin-1 (IL-l) receptor-associated kinase-dependent IL-l-induced signaling 
complexes phosphorylate TAKl and TAB2 at the plasma membrane and activate TAKl in the cytosol. 
Mol. Cell Biol. 22:7158-7167. 
103. Johansson, B. M. et al. 1995. Evidence for involvement ofactivin A and bone morphogenetic protein 
4 in mammalian mesoderm and hematopoietic development. Mol. Cell Biol. 15:141-151. 
104. Junqueira, J. C., J. Carneiro, and A. Contopoulos. 1975. Basic Histology. Lange Medical 
Publishers. 
105. Kallianpur, A. R. et al. 1994. The SCL/TAL-1 gene is expressed in progenitors of both the 
hematopoietic and vascular systems during embryogenesis. Blood 83:1200-1208. 
106. Kau, C. L. et al. 1983. Dual contribution of embryonic ventral blood island and dorsal lateral plate 
mesoderm during ontogeny of hemopoietic cells in Xenopus laevis. J Immunol. 131:2262-2266. 
107. Keller, G. et al. 1993. Hematopoietic commitment during embryonic stem cell differentiation in 
culture. Mol Cell Biol13:473-486. 
108. Kelley, C. M. et al. 1998. Helios, a novel dimerization partner of Ikaros expressed in the earliest 
hematopoietic progenitors. Cwnnt Biology 8:508-515. 
109. Kester, H. A. et al. 1997. Novel progesterone target genes identified by an improved differential 
display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with 
enhancement of differentiation. J.Biol.Chem. 272:16637-16643. 
110. Kominato, Y. et al. 1995. Monocyte expression of the human prointerleukin 1~ gene (ILlB) is 
dependent on promoter sequences which bind the hematopoietic transcription factor Spi-1/PU.l. 
Mol. Cell Biol. 15:59-68. 
111. Kondo, M. et al. 1998. Molecular cloning of human TAKl and its mutational analysis in human lung 
cancer. Int.J.Cancer 75:559-563. 
112. Kong, Y. Y. et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and 
lymph-node organogenesis. Nature 397:315-323. 
113. Kontgen, F. et al. 1995. Mice lacking the e-re! proto-oncogene exhibit defects in lymphocyte 
proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 9:1965-1977. 
114. Kumaravelu, P. et al. 2002. Quantative developmental anatomy of definitive hematopoietic stem 
cells/ long-term repopulating units (HSC/ RUs): role of the aorta-gonad-mesonephros (AGM) region 
and the yolk sac in colonisation of the mouse embryonic liver. Development 129:4891-4899. 
115. Lacaud, G. et al. 2001. Regulation ofhemangioblast development. Ann.N Y.Acad.Sci. 938:96-107. 
116. Lai, L. et al. 1998. Mouse cell surface antigens: nomenclature and immunophenotyping. J Immunol 
160:3861-3868. 
117. Larsson, J. et al. 2001. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I 
receptor-deficient mice. EMBO J. 20:1663-1673. 
118. Lebestky, T. et al. Specification of Drosophila hematopoietic lineage by conserved transcription 
factors. 
119. Leemhuis, T. et al. 1996. Isolation of primitive human bone marrow hematopoietic progenitor cells 
using Hoechst 33342 and Rhodamine 123. Exp.Hematol. 24:1215-1224. 
120. Lemischka, I. R. 1992. The haemopoietic stem cell and its clonal progeny: mechanisms regulating the 
hierarchy of primitive haematopoietic cells. Cancer Surveys 15:3-18. 
General Introduction 
121. Li, J. et al. 2001. Novel NEMO!IKB kinase and NF-KB target genes at the pre-B to immature B cell 
transition. J.Biol.Chem. 276:18579-18590. 
122. Li, Q. et al. 1999. IKK.l-deficient mice exhibit abnormal development of skin and skeleton. Genes 
Dev. 13:1322-1328. 
123. Li, Q. et al. 1999. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 
284:321-325. 
124. Liang, P., L. et a!. 1994. Methods of Differential Display. In K. W. Adolph (ed.), Methods in 
Molecular Genetics. Academic Press, New York. 
125. Liang, P. et al. 1992. Differential display of eukaryotic mRNA by means of polymerase chain reaction. 
Science 257:967-971. 
126. Liang, P. et al. 1995. Recent advances in differential display. Curr.Op.Immunology 7:274-280. 
127. Lisitsyn, N. eta!. 1993. Cloning the differences between two complex genomes. Science 259:946-951. 
128. Lloberas, J. et a!. 1999. The key role of PU.I/SPI-1 in B cells, myeloid cells and macrophages. 
Immunol.Today 20:184-189. 
129. Lutterbach, B. et al. 2000. Role of the transcription factor AML-1 in acute leukemia and 
hematopoietic differentiation. Gene 245:223-235. 
130. Ma, X. et al. 2002. Expression of the Ly-6A (Sea-l) lacZ transgene in mouse haematopoietic stem 
cells and embryos. Br.J.Haematol. 116:401-408. 
131. Ma, X. et al. 2002. The Ly-6A (Sea-l) GFP Transgene is Expressed in all Adult Mouse Hematopoietic 
Stem Cells. Stem Cells 20:514-521. 
132. Majka, M. et al. 2001. Numerous growth factors, cytokines, and chemokines are secreted by human 
CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in 
an autocrine/paracrine manner. Blood 97:3075-3085. 
133. Mauaia, A. et al. 2000. Lmo2 and GATA-3 associated expression in intraembryonic hemogenic sites. 
Development 127:643-653. 
134. Marshall, C. J. et al. 2000. Polarized expression of bone morphogenetic protein-4 in the human aorta-
gonad-mesonephros region. Blood 96:1591-1593. 
135. Massague, J. et al. 2000. Controlling TGF-P signaling. Genes Dev. 14:627-644. 
136. Matsuoka, S. et al. 2001. CD34 expression on long-term repopulating hematopoietic stem cells 
changes during developmental stages. Blood 97:419-425. 
137. May, M. J. et al. 1998. Signal transduction through NF-KB. Immunol.Today 19:80-88. 
138. McKercher, S. R. et al. 1996. Targeted disruption of the PU.l gene results in multiple hematopoietic 
abnormalities. EMBO J. 15:5647-5658. 
139. McKinstry, W. J. et al. 1997. Cytokine receptor expression on hematopoietic stem and progenitor 
cells. Blood 89:65-71. 
140. McMahan, C. J. et al. 1991. A novel IL-l receptor, cloned from B cells by mammalian expression, is 
expressed in many cell types. EMBO J 10:2821-2832. 
141. McMahon, A. P. 2000. More surprises in the Hedgehog signaling pathway. Cell100:185-188. 
142. Medvinsky, A. et al. 1996. Defmitive hematopoiesis is autonomously initiated by the AGM region. 
Cell86:897-906. 
143. Medvinsky, A. L. et al. 1998. Development of the defmitive hematopoietic hierarchy in the mouse. 
Dev.Comp Immunol. 22:289-301. 
144. Meier, P. et al. 2000. Apoptosis in development. Nature 407:796-801. 
145. Meneghini, M.D. et al. 1999. MAP kinase and Wnt pathways converge to downregulate an HMG-
domain repressor in Caenorhabditis elegans. Nature 399:793-797. 
146. Michel, F. et al. 2001. Crystal structure of the ank')'rin repeat domain ofBcl-3: a unique member of the 
IkappaB protein family. EMBO J. 20:6180-6190. 
14 7. Mikkola, H. K. et al. 2003. Expression of CD41 marks the initiation of definitive hematopoiesis in the 
mouse embryo. Blood 101:508-516. 
148. Mikkola, H. K. et al. 2003. Haematopoietic stem cells retain long-term repopulating activity and 
multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 421:547-551. 
149. Miles, C. et al. 1997. Expression of the Ly-6E.l (Sea-l) transgene in adult hematopoietic stem cells 
and the developing mouse embryo. Development 124:537-547. 
150. Miller, J. R. et al. 1996. Signal transduction through P-catenin and specification of cell fate during 
embryogenesis. Genes Dev 10:2527-2539. 
151. Minegishi, N. et al. 1999. The mouse GATA-2 gene is expressed in the Para-aortic splanchnopleura 
and aorta-gonads and mesonephros region. Blood 93:4196-4207. 
152. Mitjavila-Garcia, M. T. et al. 2002. Expression of CD41 on hematopoietic progenitors derived from 
embryonic hematopoietic cells. Development 129:2003-2013. 
37 
Chapter 1 
153. 
154. 
155. 
156. 
157. 
158. 
159. 
160. 
161. 
162. 
163. 
164. 
165. 
166. 
167. 
168. 
169. 
170. 
171. 
172. 
173. 
174. 
175. 
176. 
177. 
178. 
179. 
180. 
181. 
38 
Miyamoto, T. et al. 2002. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage 
commitment. Dev.Cel/3:137-147. 
Mizel, S. B. et al. 1987. The interleukin 1 receptor. Dynamics of interleukin 1 binding and 
internalization in T cells and fibroblasts. J.Immunol. 138:2906-2912. 
Mizukami, J. et al. 2002. Receptor Activator ofNF-KB Ligand (RANKL) Activates TAK.l Mitogen-
Activated Protein Kinase Kinase Kinase through a Signaling Complex Containing RANK, TAB2, and 
TRAF6. Mol. Cell Biol. 22:992-1000. 
Moore, M.A. S. et al. 1970. Ontogeny of the haemopoietic system: yolk sac origin of vivo and in vitro 
colony forming cells in the developing mouse embryo. J.Haematology 18:279-296. 
Moser, R. et al. 1989. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial 
cells to promote transendothelial neutrophil passage. J.Clin.Invest 83:444-455. 
Mou, L. et al. 1994. Improvements to the differential display method for gene analysis. Biochem 
Biophys.Res Commun. 199:564-569. 
Mouthon, M.-A. et al. 1993. Expression of tal-l and GATA-binding proteins during human 
hematopoiesis. Blood 81:647-655. 
Mucenski, M. L. et al. 1991. A functional c-myb gene is required for normal murine fetal hepatic 
hematopoiesis. Cell65:677-689. 
Miiller, A. M. et al. 1994. Development of hematopoietic stem cell activity in the mouse embryo. 
Immunity 1:291-301. 
Munoz-Sanjuan, I. et al. 2002. Gene profiling during neural induction in Xenopus laevis: regulation 
of BMP signaling by post-transcriptional mechanisms and TAB3, a novel TAK!-binding protein. 
Development 129:5529-5540. 
Murdoch, B. et al. 2003. Wnt-5A augments repopulating capacity and primitive hematopoietic 
development of human blood stem cells in vivo. Proc Nat[ Acad Sci US A 100:3422-3427. 
Neta, R. et al. 1986. Interleukin 1 is a radioprotector. J.Immunol. 136:2483-2485. 
Nichogiannopoulou, A. eta!. 1999. Defects in hemopoietic stem cell activity in Ikaros mutant mice. 
J.Exp.Med. 190:1201-1214. 
Nishikawa, M. et al. 2001. Role of the microenvironment of the embryonic aorta-gonad-mesonephros 
region in hematopoiesis. Ann.N Y.Acad.Sci. 938:109-116. 
Nocka, K. et al. 1990. Molecular bases of dominant negative and loss of function mutations at the 
murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J. 9:1805-1813. 
North, T. et al. 1999. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. 
Development 126:2563-2575. 
North, T. E. et al. 2002. Runxl expression marks long-term repopulating hematopoietic stem cells in 
the midgestation mouse embryo. Immunity. 16:661-672. 
Nutt, S. L. et al. 1999. Commitment to the B-lymphoid lineage depends on the transcription factor 
Pax5. Nature 401:556-562. 
Ogilvy, S. et al. 1999. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects 
multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci US A. 96:14943-14948. 
Ohmura, K. et al. 2001. Immature multipotent hemopoietic progenitors lacking long-term bone 
marrow-reconstituting activity in the aorta-gonad-mesonephros region of murine day 10 fetuses. 
J.Immunol. 166:3290-3296. 
Okada, H. et al. 1998. AMLl(-/-) embryos do not express certain hematopoiesis-related gene 
transcripts including those of the PU.l gene. Oncogene 17:2287-2293. 
Okuda, T. et al. 1996. AMLl, the target of multiple chromosomal translocations in human leukemia, 
is essential for normal fetal liver hematopoiesis. Cell84:321-330. 
Oostendorp, R. A. et al. 2002. Stromal cell lines from mouse aorta-gonads-mesonephros subregions 
are potent supporters of hematopoietic stem cell activity. Blood 99:1183-1189. 
Oppenheim, J. J. et al. 1989. Interleukin-1 enhances survival oflethally irradiated mice treated with 
allogeneic bone marrow cells. Blood74:2257-2263. 
Orelio, C. et al. Bcl-2 overexpression reveals a possible role for apoptosis in midgestation aortic 
hematopoietic stem cells. submitted for publication. 
Orkin, S. 2000. Diversification ofhaematopoietic stem cells to specific lineages. Nature reviews 1:57-
64. 
Orlando, S. et al. 1997. Role of metalloproteases in the release of the IL-l type II decoy receptor. 
J.Biol.Chem. 272:31764-31769. 
Palis, J. et al. 1999. Development of erythroid and myeloid progenitors in the yolk sac and embryo 
proper of the mouse. Development 126:5073-5084. 
Palls, J. et al. 2001. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp.Hematol. 
29:927-936. 
General Introduction 
182. Pandolfi, P. P. et al. 1995. Targeted disruption of the GATA3 gene causes severe abnormalities in the 
nervous system and in fetal liver haematopoiesis. Nat. Genet. 11:40-44. 
183. Peifer, M. et al. 2000. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. 
Science 287:1606-1609. 
184. Persons, D. A. et al. 1999. Enforced expression of the GATA-2 transcription factor blocks normal 
hematopoiesis. Blood 93:488-499. 
185. Petrenko, 0. et al. 1999. The molecular characterization of the fetal stem cell marker AA4.1mmunity 
10:691-700. 
186. Pevny, L. et al. 1995. Development of hematopoietic cells lacking transcription factor GATA-1. 
Development 121:163-172. 
187. Pevny, L. et al. 1991. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the 
gene for transcription factor GAT A-I. Nature 349:257-260. 
188. Phillips, R. L. et al. 2000. The genetic program of hematopoietic stem cells. Science 288:1635-1640. 
189. Porcher, C. et al. 1996. The T cell leukemia oncoprotein SCL/ tal-l is essential for development of all 
hematopoietic lineages. Cell86:47-57. 
190. Preffer, F. I. et al. 2002. Lineage-negative side-population (SP) cells with restricted hematopoietic 
capacity circulate in normal human adult blood: immunophenotypic and functional characterization. 
Stem Cells 20:417-427. 
191. Ramalho-Santos, M. et al. 2002. "Sternness": transcriptional profiling of embryonic and adult stem 
cells. Science 298:597-600. 
192. Robb, L. et al. 1996. The sci gene product is required for the generation of all hematopoietic lineages 
in the adult mouse. EMBO J 15:4123-4129. 
193. Robb, L. et al. 1995. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the 
sci gene. Proc.Natl.Acad.Sci. U.S.A 92:7075-7079. 
194. Rudolph, D. et al. 2000. Severe liver degeneration and lack of NF-kappaB activation in 
NEMO!IKKgamma-deficient mice. Genes Dev 14:854-862. 
195. Sabin, F. R. 1920. Studies on the origin of blood-vessels and of red blood corpuscles as seen in the 
living blastoderm of chicks during the second day of incubation. Contrib.Emb1yol.Carnegie Inst. 
9:215-258. 0 
196. Sanchez, M.-J. et al. 1996. Characterization of the first definitive hematopoietic stem cells in the 
AGM and liver of the mouse embryo.Immunity 5:513-525. 
197. Sanjo, H. et al. 2003. TAB2 is essential for prevention of apoptosis in fetal liver but not for 
interleukin-1 signaling. Mol. Cell Bioi. 23:1231-1238. 
198. Sato, T. et al. 1999. Reversible expression of CD34 by murine hematopoietic stem cells. Blood 
94:2548-2554. 
199. Scott, E. W. et al. 1994. Requirement of transcription factor PU.l in the development of multiple 
hematopoietic lineages. Science 265:1573-1577. 
20t'. Sha, W. C. et al. 1995. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal 
defects in immune responses. Cell80:321-330. 
201. Shalaby, F. et al. 1997. A requirement for Flkl in primitive and definitive hematopoiesis and 
vasculogenesis. Cell89:981-990. 
202. Shalaby, F. et al. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. 
Nature 376:62-66. 
203. Shibuya, H. et al. 1998. Role ofTAKl and TAB! in BMP signaling in early Xenopus development. 
EMBO J17:1019-1028. 
204. Silverman, N. et al. 2001. NF-KB signaling pathways in mammalian and insect innate immunity. 
Genes Dev. 15:2321-2342. 
205. Simmons, P. J. et al. 200LMucin-like molecules as modulators of the survival and proliferation of 
primitive hematopoietic cells. Ann.N.Y.Acad.Sci. 938:196-206. 
206. Sims, J. E. et al. 1993. Interleukin 1 signaling occurs exclusively via the type I receptor. 
Proc.Natl.Acad.Sci.U.S.A 90:6155-6159. 
207. Sitnicka, E. et al. 1996. Transforming growth factor beta 1 directly and reversibly inhibits the initial 
cell divisions of long-term repopulating hematopoietic stem cells. Blood 88:82-88. 
208. Sitzmann, J. et al. 1995. Expression of mouse c-myb during embryonic development. Oncogene 
11:2273-2279. 
209. Slack, J. L. et al. 2000. Identification of two major sites in the type I interleukin-1 receptor 
cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways. J.Biol.Chem. 
275:4670-4678. 
210. Smith, D. E. et al. 2003. The Soluble Form ofiL-1 Receptor Accessory Protein Enhances the Ability 
of Soluble Type II IL-l Receptor to Inhibit IL-l Action. Immunity. 18:87-96. 
39 
Chapter 1 
211. 
212. 
213. 
214. 
215. 
216. 
217. 
218. 
219. 
220. 
221. 
222. 
223. 
224. 
225. 
226. 
227. 
228. 
229. 
230. 
231. 
232. 
233. 
234. 
235. 
236. 
237. 
238. 
239. 
40 
Snodgrass, H. R. et al. 1992. Embryonic stem cells and in vitro hematopoiesis. J Cell Biochem. 
49:225-230. 
Spangrude, G. J. et al. 1988. Purification and characterization of mouse hematopoietic stem cells. 
Science 241:58-62. 
Spangrude, G. J. et al. 1991. Mouse hematopoietic stem cells. Blood78:1395-1402. 
Sudo, K. et al. 2000. Age-associated characteristics of murine hematopoietic stem cells. J Exp Med. 
192:1273-1280. 
Suzuki, N. et al. 2002. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice 
lacking IRAK.-4. Nature 416:750-756. 
Takaesu, G. et al. 2000. TAB2, a novel adaptor protein, mediates activation ofTAKl MAPKKK by 
linking TAKl to TRAF6 in the IL-l signal transduction pathway. Mol Cell5:649-658. 
Takaesu, G. et al. 2001. Interleukin-1 (IL-l) receptor-associated kinase leads to activation ofT AK 1 by 
inducing TAB2 translocation in the IL-l signaling pathway. Mol. Cell Biol. 21:2475-2484. 
Tavian, M. et al. 1996. Aorta-associated CD34+ hematopoietic cells in the early human embryo. 
Blood 87:67-72. 
Tavian, M. et al. 2001. The human embryo, but not its yolk sac, generates lympho-myeloid stem cells. 
mapping multipotent hematopoietic cell fate in intraembryonic mesoderm. immunity. 15:487-495. 
Thorpe, C. J. et al. 1997. Wnt signaling polarizes an early C. elegans blastomere to distinguish 
endoderm from mesoderm. Cell90:695-705. 
Tonnelle, C. et al. 2001. Forced expression of the Ikaros 6 isoform in human placental blood CD34(+) 
cells impairs their ability to differentiate toward the B-lymphoid lineage. Blood 98:2673-2680. 
Tsai, F. Y. et al. 1994. An early haematopoietic defect in mice lacking the transcription factor GATA-
2. Nature 371:221-226. 
Tsai, F. Y. et al. 1997. Transcription factor GATA-2 is required for proliferation/survival of early 
hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. 
Blood 89:3636-3643. 
Turpen, J. B. et al. 1976. Alternate sites of lymphopoiesis in the amphibian embryo. 
Ann.lmmunol.(Paris) 127:841-848. 
Uchida, N. et al. 1992. Searching for hematopoietic stem cells: evidence that Thy-l.llo Lin- Sea-l+ 
cells are the only stem cells in C57BL/Ka-Thy-l.l bone marrow. J.Exp.Med. 175:175-184. 
Van Den Berg, D. J. et al. 1998. Role of members of the Wnt gene family in human hematopoiesis. 
Blood 92:3189-3202. 
Veiby, 0. P. et al. 1997. Growth factors and hematopoietic stem cells. Hematol Oneal Clin North Am 
11:1173-1184. 
Vidal, S. et al. 2001. Mutations in the Drosophila dTAKl gene reveal a conserved function for 
MAPKKKs in the control of rel!NF-KB-dependent innate immune responses. Genes Dev. 15:1900-
1912. 
Voermans, C. et al. 2000. Adhesion molecules involved in transendothelial migration of human 
hematopoietic progenitor cells. Stem Cells 18:435-443. 
Wald, D. et al. 2001. IRAK and TAKl are required for IL-lS-mediated signaling. Eur.J.Immunol. 
31:3747-3754. 
Wang, J. H. et al. 1996. Selective defects in the development of the fetal and adult lymphoid system in 
mice with an Ikaros null mutation. Immunity 5:537-549. 
Wang, Q. et al. 1996. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central 
nervous system and blocks definitive hematopoiesis. Proc.Natl.Acad.Sci. US.A 93:3444-3449. 
Warren, A. J. et al. 1994. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for 
erythroid development. Cell78:45-57. 
Weih, F. et al. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted 
disruption ofRelB, a member of the NF-KB/Rel family. Cell80:331-340. 
Weiss, M. J. et al. 1994. Novel insights into erythroid development revealed through in vitro 
differentiation ofGATA-1 embryonic stem cells. Genes Dev. 8:1184-1197. 
Whyatt, D. et al. 2000. An intrinsic but cell-nonautonomous defect in GATA-1-overexpressing mouse 
erythroid cells. Nature 406:519-524. 
Wiles, M. V. et al. 1991. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in 
culture. Development 111:259-267. 
Winnier, G. et al. 1995. Bone morphogenetic protein-4 is required for mesoderm formation and 
patterning in the mouse. Genes Dev 9:2105-2116. 
Wodarz, A. et al. 1998. Mechanisms ofWnt signaling in development. Annu.Rev Cell Dev Bioll4:59-
88. 
General Introduction 
240. Wulczyn, F. G. eta!. 1996. The NF-KB/Rel and IKB gene families: mediators ofimmun~ response and 
inflammation. J.Mol.Med. 74:749-769. 
241. Yamada, Y. et al. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse 
hematopoiesis. Proc.Natl.Acad.Sci. U.S.A 95:3890-3895. 
242. Yamaguchi, K. et al. 1999. XIAP, a cellular member of the inhibilor ofapoptosis protein family, links 
the receptors to TABl-TAKl in the BMP signaling pathway. EMBO J18:179-187. 
243. Yamaguchi, K. eta!. 1995. Identification of a member of the MAPKKK family as a potential mediator 
ofTGF-~ signal transduction. Science 270:2008-201 L 
244. Yamaguchi, T. P. et a!. 1999. A Wnt5a pathway underlies outgrowth of multiple structures in the 
vertebrate embryo. Development 126:1211-1223. 
245. Yamaguchi, T. P. et a!. 1993. Flk-1, an fit-related receptor tyrosine kinase is an early marker for 
endothelial cell precursors. Development 118:489-498. 
246. Yamashita, J. et a!. 2000.Flkl-positive cells derived from embryonic stem cells serve as vascular 
progenitors. Nature 408, 92-96. 
247. Yoder, M. C. eta!. 1997. Characterization of defmitive lymphohematopoietic stem cells in the day 9 
murine yolk sac. Immunity 7:335-344. 
248. Yonemura, Y. et a!. 1996. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of 
hematopoietic stem cells. Proc.Natl.Acad.Sci. U.S.A 93:4040-4044. 
249. Young, P. E. eta!. 1995. The sialomucin CD34 is expressed on hematopoietic cells and blood vessels 
during murine development. Blood 85:96-105. 
250. Zucali, J. R. eta!. 1994. Radioprotection of hematopoietic stem cells by interleukin-1. Exp.Hematol. 
22:130-135. 
41 

Chapter 2 
Identification of two novel genes developmentally regulated in the 
mouse aorta-gonad-mesonephros region 
Claudia Orelio and Elaine Dzierzak 
The information of this chapter was published as a Brief Report in Blood, 2003 
Chapter 2 
Abstract 
During mouse development the first adult-repopulating hematopoietic stem cells 
(HSC) emerge in the aorta-gonad-mesonephros (AGM) region at embryonic day 10.5 prior 
to their appearance in the yolk sac and fetal liver. Several transcription factors, growth 
factors and morphogenetic signals are known to piay a pivotal role in the onset of adult-
type hematopoiesis in the AGM region. However, there are still large gaps in our 
understanding of the developmental program taking place in the AGM region at the time of 
HSC emergence. To identify novel developmentally regulated genes that play a role in the 
emergence of HSCs in the AGM region, we performed Differential Display RT-PCR. We 
detected several differentially expressed genes in the AGM region between ElO and Ell, 
including ~catenin and two novel mouse genes highly homologous to human TM9SF2 and 
TAB2. Other components of the Wnt/~-catenin signaling pathway were also detected in the 
AGM and fetal liver, suggesting a role for Wnt signaling in AGM hematopoiesis. We 
characterized the expression pattern of the novel mouse genes, Tm9sj2 and Tab2, in the 
embryo and adult by Northern blotting and RT-PCR. ·More importantly, the specific 
expression ofmTAB2 protein in the endothelium of the Ell dorsal aorta (the site known to 
harbor HSCs) suggests a role for mTAB2 in HSC emergence and/ or regulation. These 
studies identifying novel differentially expressed genes in the midgestation AGM region 
should yield further insights into the development of this tissue and into the emergence and 
regulation ofHSCs. 
Introduction 
The stem cells that form the basis of the hematopoietic hierarchy in the adult bone 
marrow are characterized by their ability to self-renew as well as undergo extensive 
differentiation and proliferation. Hematopoietic stem cells (HSC) are functionally identified 
by their ability to reconstitute the entire blood system when injected into HSC-ablated adult 
animals (reviewed in 24,49). During mouse development, such adult-repopulating HSCs 
first appear during midgestation (embryonic day 10.5; El0.5) within the embryo proper in a 
region containing the developing vascular and urogenital tissues. This mesodermally-
derived region is referred to as the dorsal aorta-gonad-mesonephros (AGM) region 9•29•32• 
More detailed studies show that HSCs are localized within the dorsal aorta (and also the 
vitelline and umbilical arteries) 10•11 . The HSCs autonomously generated in the aorta during 
midgestation are as potent as those residing in the adult bone marrow (BM) 32. Slightly later 
at Ell, HSCs are found also within the yolk sac (YS) and the fetal liver 32. Spatial and 
temporal mapping of HSCs suggest a lineage relationship that is consistent with the general 
notion that following their generation, HSCs migrate and colonize the liver during fetal 
stages and subsequently the bone marrow where they reside throughout adult stages of 
life23'29 • Thus, since the de novo production of HSCs is thought to take place only in a 
limited time within the embryo, the AGM region is of particular interest for the study of the 
signals and genes involved in the generation, proliferation and regulation of earliest HSCs. 
An increased understanding of these signals under normal physiological circumstances will 
result in a better understanding of deregulated hematopoiesis, such as in leukemia. 
Research has focused on the influence of the microenvironment, the role of known 
morphogenetic signals, growth factor receptors and transcription factors leading to the 
induction of HSCs in a specific temporal and spatial manner within the embryo. To date, 
some of the morphogenetic signals required for the correct spatial and temporal formation 
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of most tissues and organs during development, i.e. members of the Hedgehog, TGF~ and 
Wnt families (reviewed in 60,8,17,27,28,14) are being examined for their role(s) in the 
induction of HSCs. For example, hedgehog family members IHH and SHH respectively 
induce hematopoietic/vascular cell fate during early mouse development 15 and the 
proliferation of human hematopoietic progenitors 5. In addition, BMP-4 (TGF~ family 
member) is implicated as mediator of these effects and both BMP-4 and TGF~l (another 
TGF~ family member) play a role in the development of both hematopoietic and vascular 
systems in the mouse embryo 7,1 3.48•59. The expression pattern ofBMP-4 on the ventral side 
of the dorsal aorta in the human AGM further supports a role for BMP-4 in HSC generation 
26
. Also, Wnt signaling has been shown to affect hematopoiesis. Members of the Wnt 
family induce the proliferation of mammalian hematopoietic progenitor cells1•55 and Wntll 
is required for the formation of all hematopoietic lineages in avian embryos 6• Taken 
together, these known developmental modulators appear to play important instructive roles 
during hematopoietic and vascular development. 
Other studies have addressed the role of known growth factors and transcription 
factors in the induction and regulation of HSC during development. Some pivotal growth 
factor receptors involved in these processes are c-kit and Flk-1 41 •44•45 and some pivotal 
transcription factors are Aml-1, Gata-2 and Scl/tal-1 3336•39'53• While these genes are 
required for fetal liver/adult hematopoiesis, Scl/tal-1 and Flk-1 also affect the development 
of the vasculature 39.45•64 suggesting the existence of a common precursor for both lineages, 
the hemangioblast. Such genetic evidence has supported the notion that hemangioblast-type 
cells are the direct precursors to AGM HSCs in the midgestation embryo 19• 
Despite these studies, which have addressed the role of known genes in the 
emergence and regulation of HSCs during development, there are many gaps in our 
understanding of the genetic program of HSCs and the inductive microenvironment within 
the AGM. In order to further increase our understanding of the properties and genes 
involved in the emergence and regulation ofHSCs in the AGM, we set out to identify novel 
genes that are differentially expressed in the AGM at the time of HSC induction. Several 
gene screening and cloning techniques (i.e. Differential Display (DD) RT-PCR, SAGE and 
micro-array analysis etc.) have been developed and have successfully identified panels of 
differentially expressed genes between two (or more) distinct hematopoietic cell 
populations 35•58. Using the non-biased DD RT-PCR technique, we performed screenings on 
AGM tissues derived prior to (at early EIO) and subsequent to (at Ell) the emergence of 
HSCs to identify new genes. We report here the identification several genes that are up- or 
down-regulated in the AGM at the time of HSC induction, including jJ-catenin, a member 
of the Wnt signaling pathway, and two novel mouse genes homologous to a human 
transmembrane protein TM9SF2 and human TAB2, a member of the IL-l signaling cascade. 
We provide evidence that suggests a role for jJ-catenin and other Wnt signaling components 
in the AGM. Characterization of the two novel mouse genes, Tm9sj2 and Tab2, similarly 
suggest a role for these genes in hematopoiesis. Most interestingly, the localized expression 
ofmTAB2 within the endothelium of the Ell dorsal aorta, suggests an important role for 
Tab2 in the emergence and/or regulation ofHSCs during development. 
45 
Chapter 2 
Material and Methods 
Embryo generation and cell lines 
To generate embryos, matings were set up between C57BL/6 or (CBA x C57BL/10)Fl 
males and females. The day of vaginal plug discovery is EO. Mice were killed by cervical dislocation 
and embryos were collected in PBS/ 10% FCS. AGM, aorta-mesenchyme (AM) and gonad-
mesonephros (UGR) tissues were dissected as described previously 11•32. Animals were housed 
according to institutional guidelines, with free access to water and food. Animal procedures were 
carried out in compliance with the Standards for Humane Care and Use of Laboratory Animals. Cell 
lines were cultured as described previously 5457. 
RNA isolation, eDNA synthesis and Northern blotting 
Total RNA from embryonic and adult mouse tissues was isolated with Ultraspec (Biotecx) 
and Trizol (Gibco/ Life- Technologies) respectively, according to manufacturer's instructions. RNA 
was dissolved in dH20, integrity verified on 1% agarose/TBE gels and concentration determined by 
OD260 measurement. Prior to eDNA synthesis RNA was DNAse treated with RQl RNAse free 
DNAse (Promega). 
For eDNA synthesis 1-5 ).lg of total RNA was reverse transcribed with Superscript II 
reverse transcriptase (Gibco/ Life Technologies). eDNA was diluted to the desired concentration with 
dH20. 
For Northern blots 10-25 ).lg total RNA was separated on formaldehyde gels and blotted 
with 20x SSC in an upward capillary manner to Genescreen membranes (NEN technologies). Blots 
were probed with a- 32P-dATP labeled DNA fragments that were generated with a nick translation kit 
(Amersham Pharmacia Biotech). 
Differential Display RT-PCR 
Differential Display RT-PCR was performed essentially as described 20 with some minor 
modifications. Briefly, total RNA was isolated from ElO (30-35 somite pairs) AGMs and Ell (40-50 
somite pairs) AGMs, AMs and UGRs. 1 ).lg of total RNA was reverse transcribed with Superscript II 
and purified with PCR spin columns (Qiagen) and eluted in 100 ).ll TE. DD RT-PCR was carried out 
with 2 J.ll of eDNA, 200 ng of degenerate primer, 20).lM dNTPs, 1 ).lCi a-33P-dATP (Amersham), with 
4U of AmpliTaq and provided buffer (PerkinE!mer) in a total volume of 20 J.ll. PCR cycles were as 
follows: 3 min 95°C, 2x (1 min 95°C, 5 min 37°C, 5 min 37-72°C, 5 min 72°C), 30-35x (1 min 95°C, 
2 min 55°C, 5 min 72°C), 10 min 72°C. In total 8 arbitrary primers were used with a length of 19-21 
bp and approximately 50% GC content. Primers were tested for their ability to produce a clear 
banding pattern in the DD RT-PCR procedure. Primer sequences are available upon request. 
5 ).ll of the PCR sample was mixed with an equal volume of96% formamide loading buffer, 
boiled for 2 min and was separated on a 6% acrylamide/ Urea gel. The gel was dried and exposed to 
Biomax MR Films (Kodak). Differential bands were excised and DNA was eluted in TE and 
amplified by PCR using the same degenerate primer as used for identifying the differential band. The 
PCR product was cloned into PGEM-T easy vector (Promega) and clones were screened for false 
positives as described 20• Potential differential clones were sequenced and sequences were run through 
NCBI non-redundant gene and EST databases to identifY the corresponding gene or EST. A small 
number of clones was verified for differential expression by eDNA dot blotting, RT -PCR or Northern 
blotting. 
eDNA dot blots 
RNA and eDNA from several embryonic and adult mouse tissues, as well as hematopoietic 
cell lines was prepared as described. An equivalent of 1 ).lg, 200ng and 50ng of each sample was dot 
blotted with a vacuum dot blot apparatus onto Genescreen membrane (NEN technologies). Dot blots 
were probed with 32P-dATP labeled DNA fragments excised from differential display clones that 
were generated with Klenow enzyme (Roche). Results were further processed with a Phosphorlmager 
(Molecular Dynamics) and ImageQuant software. 
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RT-PCR analysis 
RNA and eDNA from several embryonic mouse tissues was prepared as described. RT-
PCR was performed in a 50f.!l volume with 1 OOng of each primer (listed in Table 1 ), 0.2mM dNTPs, 
AmpliTag and provided buffer (PerkinElmer) together with a 40ng RNA equivalent of eDNA. RT-
PCRs were performed at an optimized Tm (55°C-62°C) for each primer set. Cycling conditions as 
follows 5min 92°C, 30-40x (45sec 92°C, 45sec Tm, l-2min 72°C), 7min 72°C. 
T bl 1 P . a e . nmers use or -d£ RT PCR I . anatysts 
Primer name Sequence (5'-3') Product Ace. number 
size 
mTAB2-0RF forw ATACGAATGGCCCAAGGAAGC 2085 BC004813 
mTAB2-0RF rev AGAAATGCCGAGGCATCTCAC 
mTM9SF2 forw CTGGTTGCCATCTTGGCCCTCTG 854 NM 080556 
mTM9SF2rev GCTATCGTATTTACAAATGCAC 
B-catenin forw ATCCAAAGAGTAGCTGCAGGGG 619 NM 007614 
B-catenin rev CCTAAAACCATTCCCACCCTACC 
Dvl2 forw GAGACGAAGGTGATTTACCAT 308 NM_007888 
Dvl2 rev TGGAGGCGGAGGAACCAGTTC 
Cui Zn SOD forw CATCCACTTCGAGCAGAAGG 442 X06683 
Cui Zn SOD rev AGTCTGAGACTTCAGACCAC 
BUBIB forw GTTTGGTACCAGTATATAAAC 941 NM 009773 
BUBIB rev AATACACAGTGAAAGGAGA 
B-actin forw CCTGAACCCTAAGGCCAACCG 398 X03672 
B-actin rev GCTCATAGCTCTTCTCCAGGG 
Dvl forw GAGACCAARATCATCTACCAC 374 Ul0115 
Dvll rev GCTACTGGCAACATTTGGTTG 
Dvl3 rev TGCGTGCTCCGGGCCATC 458 U41285 
TCFl forw GCYATYAACCARATYCTSGG 566 X61385 
TCFl rev TGGGAGCTGGTCATGTTGCC 
LEF rev TCGCTGCCTTGGCTTTGCAC 270 NM 010703 
TCF3 rev GAGACAGCCTGCATAGAACC 673 AJ223069 
TCF4rev AAGCTTGGATCTGAAGAGGG 409 AJ223070 
Wnt5Aforw GACAGTATACAACCTGGCAG 379 M89798 
Wnt5Arev AGCGTTCGGTCTGCACTGTC 
Wnt3 forw GAAGGATCCTGGGCATGACAG 447 NM 009522 
Wnt3 rev GTGTGCAGCCTCTCTTCCTC 
Western blot and Immunohistochemistry 
A confluent 9 em dish of3T3 cells and 5x107 MPRO cells were lysed in RIPA buffer and 
further processed as recommended by the manufacturer of the TAB2 antibody. 5x107- 108 Jurkat and 
Ros 17 cells were lysed in Laemlli sample buffer. Protein samples were separated on a 10% SDS 
polyacrylamide gel according to standard procedures and blotted against Immobilon-P (Millipore) 
PVDF membrane. The blot was incubated with anti-TAB2 antibody and subsequently visualized with 
HRP-conjugated anti-goat antibody and Enhanced Chemiluminesence (ECL, Amersham). 
Embryos were snap-frozen into TissueTek O.C.T. compound (Sakura). Sections of 6-8 f.!M 
were generated with a cryostat apparatus and placed onto Superfrost glass slides (Menzel-Glaser). 
Sections were fixed with 2% paraformaldehyde/ PBS and incubated with anti-TAB2 antibody (sc-
11851 Santa Cruz). Staining was visualized with the ABC staining kit (Santa Cruz) and sections were 
dehydrated and embedded in Entallan (Merck). 
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Results 
Isolation and identification of genes differentially expressed in the AGM region 
between ElO and Ell 
To increase our understanding of the genetic program involved in the induction 
and regulation of HSCs in the midgestation mouse AGM, DD RT-PCR was performed 
(Figure lA). Three independent DD RT-PCR screening rounds were performed on AGM 
material obtained prior to (early ElO) and subsequent to (Ell) the induction of HSCs. DD 
RT-PCR was performed as described previously with 8 arbitrary primers20 • 
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AMUGR 
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Figure 1. DD RT-PCR Strategy. 
Overview of the strategy and results identifying 
differentially expressed genes in the EJO and 
Ell AGM (A) AGM material from mouse 
embryos at EJO and Ell was collected for RNA 
isolation. Generated eDNA from these tissues 
was used to perform DD RT-PCR to detect 
differentially expressed genes. (B) Summary of 
the results from three DD RT-PCR screening 
rounds. In total 62 clones derived from the DD 
RT-PCR were sequenced and run through the 
NCB! EST and non-redundant nucleotide 
databases. Clones were classified either as 
housekeeping or known genes, new mouse 
genes, ESTs or other sequences based on the 
sequence retrieved from the NCB! nucleotide 
databases with the highest homology to the 
sequence of the subsequent clone. In total 43% 
of the clones corresponded to h_-nown genes of 
which 16% were housekeeping genes and 27% 
other known genes. 16% of the clones 
corresponded to ESTs and 3 6 % of the clones 
were classified as other sequences and 
corresponded to either ribosomal RNA, DNA 
fragments or had no homologous DNA 
sequence present in the NCB! nucleotide 
databases. In 5% of the clones (3 clones) we 
found only a human homologous gene and 
hence, these clones are referred to as novel 
mouse genes 
For the first screening, RNA was extracted from complete ElO and Ell AGMs 
(containing the aorta, mesenchyme and urogenital ridges). This screening yielded 15 
differential (up- and down-regulated) bands that were excised from the sequencing gel and 
cloned. DNA from each excised band was cloned into PGEM-Teasy vector and 8 resulting 
colonies were analyzed in the false positive screening as previously described20 . 
Subsequently, the nucleotide sequence of 1-2 clones from the corresponding differential 
band was determined and run through the NCBI nucleotide non-redundant and EST 
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databases. In general, the inserts of the clones were approximately 200-600 bp long and 
represented the 3' mRNA sequence. This first screening yielded clone El-2 with a novel 
mouse gene sequence, highly homologous to the human transmembrane protein, TM9SF2. 
Other clones (see Table 2) were found to have sequence homology to several different 
ESTs, and the mouse Bub] b, Fibronectin and Dvl2 genes. 
To isolate genes more specifically up- or down-regulated during the onset of HSC 
induction in the aorta of the AGM, a second screening was performed on RNA isolated 
from subdissected AM tissue derived from ElO and Ell AGMs (Figure IA). DD RT-PCR 
screening was performed, yielding 15 differential bands. Clones corresponding to Globin 
epsilon, Cu/Zn superoxide dismutase (Cu/Zn SOD), Trapl50, Sag and a large number of 
housekeeping genes were identified. In addition, a novel mouse gene was identified and 
found to be homologous to human lipoprotein binding protein (Table 2). 
In the third screening, RNA extracted from complete EIO AGM and subdissected 
Ell AM and UGR material was used for DD RT-PCR. The use ofUGR material allowed 
for the discrimination and exclusion of bands related to this subregion of the AGM. The 
screening yielded 12 differential bands. The sequence of clone S 1-7 revealed that it was a 
novel mouse gene highly homologous to human TAB2. Clones corresponding to ~catenin 
and some ESTs were found, along with a large number of clones with no homology to 
sequences in the NCBI non-redundant and EST databases (Table 2). 
Table 2. Summary of a limited number of sequenced clones derived from DD RT-PCR 
screening 
Clone Expression profile Acce~sion -=~~~~~~-- Gene homology 
(screening) DD Dot blot/ number 
RT- RT-PCR* 
PCR* 
*transcripts that are expressed at higher levels in Ell aortal AGM tissue in comparison to ElO AGM 
are referred to as upregulated (indicated by i) and transcripts that are expressed at lower levels in Ell 
aorta or AGM tissue in comparison to ElO AGM are referred to as downregulated (indicated by l). 
ND is non determined. 
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In total, 62 cloned sequences derived from the DD RT-PCR were run against 
NCBI non-redundant and EST nucleotide databases. Based on the highest homology with 
the sequence retrieved from NCBI nucleotide databases, the corresponding DD RT-PCR 
clone was classified either as a known or housekeeping gene, EST, new mouse gene or 
other sequence. The combined results of the three DD RT-PCR screening rounds are 
summarized in Figure lB 
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Figure 2. Expression patterns of DD RT-
PCR clones and other related genes. 
Dot blot screening or RT-PCR analysis was 
pe1jormed with RNA derived from embryo 
and adult tissues to determine gene 
expression patterns of some DD RT-PCR 
clones and related genes. (A) For dot blot 
analysis RNA isolated from a panel of tissues 
was used for eDNA synthesis. eDNA 
(equivalent to 1 j.ig RNA) was dot blotted on a 
nitrocellulose membrane which was probed 
with 32P-labelled DNA fragments derived 
from DD RT-PCR clones to verify differential 
expression. As a control the blot was stripped 
and reprobed with GAPDH to check for 
equal amounts of dot blotted eDNA. The 
corresponding homologous genes of the 
indicated clones are listed in Table l.(B) For 
each primer set, optimal PCR conditions and 
annealing temperature was determined and 
PC'R was performed with 30-40 cycles (H is 
the water control). Three of the genes, Tab2, 
mTm9sj2 and jJ-catenin are up-regulated 
between EJO and Ell in the AGM The other 
genes that did not show a differential 
expression pattern represent false positive 
DD RT-PCR clones. 
To verify that the sequenced clones derived from the DD RT-PCR are 
differentially expressed in embryonic and adult hematopoietic tissues, we performed dot 
blot screening (Figure 2A). In addition, RT-PCR analysis was used in some cases as a more 
specific means to verify differential expression (Figure 2B). We found by eDNA dot blot 
analysis that Globin epsilon (Kl-6), Enolase (Hl-3), Trapl50 (not shown) and the two 
novel mouse genes Tm9sj2 (El-2) and Tab2 (Sl-7) are differentially expressed in the AGM 
between ElO and Ell. Globin epsilon (clone Kl-6) is up-regulated between ElO and Ell in 
the AGM, with highest expression in the E9 YS and Ell and El2 fetal liver. The high 
expression levels in these tissues correlates with the presence of erythroid cells in these 
sites. As expected, no Globin epsilon expression was found in any of the adult tissues 
examined. Enolase (Hl-3) was down-regulated between ElO and Ell in the AGM, but high 
levels of expression could be detected in E9 YS and fetal liver. Both novel mouse genes 
Tm9sj2 (El-2) and Tab2 (Sl-7) were up-regulated between ElO and Ell in the AGM and 
both were also expressed in the fetal liver. Tm9sj2 was expressed at high levels in adult 
tissues and mTab2 expression could also be detected in adult tissues, with highest 
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expression in the thymus. RT-PCR analysis further confirmed the differential expression of 
the two novel mouse genes in the AGM between ElO and Ell. Also, up-regulated jJ-
catenin expression was verified between ElO and Ell AGM. In contrast, several clones 
including Dvl2, Bubl band Cu!Zn SOD were found not to be differentially expressed in our 
eDNA dot blot analysis (not shown) or by RT-PCR (Figure 2B) and thus, these clones 
represent false positives. From these data we conclude that three DD RT-PCR clones 
representing two novel mouse genes Tm9sj2 and Tab2, and jJ-catenin are up-regulated in 
the AGM between ElO and Ell. We further investigated these three clones. 
Several Wnt signaling components are up-regulated in the AGM region between ElO 
and Ell 
Wnt genes encode a large family of secreted proteins that act as intercellular 
signaling molecules in several developmental processes (as reviewed in 8,60), including the 
regulation of hematopoietic cells 1,38,55 . Since jJ-catenin and Dvl2 were identified in our DD 
RT-PCR screening, we next examined the expression of several Wnt signalling components 
by RT-PCR (Figure 3). This analysis verified the upregulation of jJ-catenin in the AGM 
after ElO, with high level expression in Ell and El2 AGM and Ell liver. While Dvl2 
expression is constant, expression of Dvll and Dvl3 is up-regulated between ElO and Ell 
in the AGM. Compared to Dvl2 and 3, the expression of Dvll is low in all tissues 
examined. In addition, the transcription factor genes Lef, Tcfl and Tcj3 (not shown) are 
expressed, but Tcj3 and Lef are expressed at low levels in the fetal liver and AGM. Wnt5a is 
up-regulated between ElO and Ell in the AGM and is found also in Ell and El2 liver. 
Although at very low levels, Wnt3 expression was detected in ElO AGM, El2 AGM and 
liver (data not shown). Thus, several components of the Wnt signaling pathway are 
transcribed in both the AGM and fetal liver, with some of the Wnt signaling components 
up-regulated in the AGM at the important ElO and Ell developmental time when HSCs are 
being generated. 
E10 E11 E11 E12 
AGM AGM liver AGM 
RT - + - + + + 
E12 
liver 
+ H 
Figure 3. RT-PCR analysis reveals 
expression of several components of 
the Wnt signaling pathway in the 
A GM region and fetal liver. 
RT-PCR analysis was pe1jormed for 
several components of the Wnt 
signaling pathway. Primers are listed 
in Table I and specific PCR 
conditions and the number of PCR 
cycles (30-40) were optimized for 
each primer set. (H is the water 
control) Several components of the 
Wnt signaling pathway can be 
detected in the AGM and fetal liver 
between ElO and EIJ. Besides the 
differential expression of ~catenin 
between ElO and Ell in the AGM, we 
could also detect upregulation of 
Dvll and 3, and Wnt5a in the AGM 
between EIO and EI I. 
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A highly conserved 9 transmembrane protein encoding gene is differentially expressed 
in the AGM region 
The isolation of the differentially expressed El-2 clone and its identification as a 
novel mouse gene encoding a transmembrane protein highly homologous to human 
TM9SF2 (also known as human p76 or emp70) prompted our further investigations into its 
sequence and structure. The hum~n TM9SF2 protein contains 9 transmembrane regions but 
no other obvious protein domains. It is localized in endosomes and is proposed to function 
as a channel or small molecule transporter 43 . When the human TM9SF2 sequence was blast 
searched against the NCBI mouse EST database, several ESTs spanning the entire open 
reading frame (ORF) of human TM9SF2 were found (data not shown), strongly indicating 
the existence of a mouse Tm9sj2 homologue. Soon after our identification of clone El-2, a 
full-length clone of mouse Tm9sj2 was submitted to the NCBI sequence database by the 
IMAGE consortium (accession number BC003862). 
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Figure 4. High homology 
between different species 
indicates conservation of 
the TM9SF2 protein. 
Alignment of mouse 
TM9SF2 protein sequence 
(NM_080556) with 
homologous proteins from 
several species including 
human (Q99805), C.elegans 
(NP _509429), Drosophila 
(AAF50762), S.cerevisiae 
(S64915) and A. thaliana 
(T50793). Accession 
numbers of the protein 
sequences are indicated by 
the numbers in the brackets 
and the alignment of the 
proteins was peiformed 
with ClustalW software. 
Conserved amino acid 
residues are indicated by 
the black boxes and similar 
amino acid residues are 
indicated by gray boxes. 
We compared the mouse protein to that of the human and found 95% homology 
(Figure 4). Alignment of the mTM9SF2 protein sequence with similar proteins from 
Drosophila, C.elegans, S.cerevisiae, A.thaliana also shows high homology, suggesting 
conservation of this gene and its function throughout evolution (Figure 4). To gain more 
insight into the genomic structure of Tm9sj2, the mRNA sequence available from NCBI 
nucleotide database (BC003862) was blast against the Celera mouse genome database. 
52 
Identification of differentially expressed genes in the AGM region 
A 
I I I 
2 3 
11111111 Ul I I 
4 5 6 8 10 12 14 16 17 
7 9 11 13 15 
r---------------------------------------------~53kb 
ex on 1: 293 bp 
exon 2:68 bp 
exon 3:94 bp 
exon 4: 128 bp 
B 
c 
'--~ <D 
:f: .n 
exon 5: 130 bp ex on 9: 1 09 bp 
exon 6: 125 bp ex on 1 O: 133 bp 
exon 7: 112 bp exon 11: 122 bp 
exon 8: 80 bp exon 12: 58 bp 
>- "' c 
<D t Ol E <D c 
"' 
<D 
" 
c >- a. <D 
:.::2 ..c .2 
= "' 
exon 13: 161 bp 
exon 14: 153 bp 
exon 15: 84 bp 
exon 16: 172 bp 
exon 17: 685 bp 
c 
32D.cl3 
DA3 
TM9SF2 MEL 
actin DA2 
28S DA8 
~ (/) 
"" ~ 
-
Figure 5. Structure and expression pattern of the mouse TM9SF2 gene. 
::r: 
5: 
~ 
-
' 
-
-
-
(A) Schematic representation of the mouse Tm9sj2 gene. The mRNA sequence ofTm9sj2 (BC003862) 
was blast against the Celera mouse genome database. The mouse Tm9sj2 gene contains 17 exons 
spanning approximately 53 kb and is located at mouse chromosome 14. The intron-exon boundaries 
are based on the consensus splicing sequence and therefore, the actual exon lengths may differ by 1-
2 bp from the predicted exon length (B) Northern blot probed with Tm9sj2 shows specific expression 
in all adult mouse tissues examined with highest expression in liver and kidney. The probe hybridizes 
to a fragment of approximately 3-3.5 kb. (C) eDNA dot blot analysis shows Tm9sj2 expression in 
several hematopoietic cell lines, with highest expression in myeloid (32D.cl3, DA3) and B-lymphoid 
(DA8) cell lines. 
Alignment of the 2746 bp mRNA sequence of Tm9sj2 with mouse genomic sequences 
revealed 17 exons containing the complete ORF, spanning approximately 53 kb of the 
genome, with the ATG start codon in the first exon (Figure 5A). Alignment of the 2.8 kb 
hTM9SF2 transcript to human genomic sequences revealed that the structure of the 
hTM9SF2 and mTm9sj2 genes is similar, but hTM9SF2 spans approximately 61 kb of the 
genome. mTm9sj2 is located on chromosome 14 and hTM9SF2 is located on chromosome 
13qll-34. However, since Northern blot analyses for mTm9sj2 (Figure 5B) and hTM9SF2 
(Schimoller et al.) indicate that both transcripts are slightly longer than the mRNA 
sequences in the NCBI database, it is possible that both genes contain additional exons with 
5~UTR or 3'UTR mRNA sequences. 
To further characterize the expression of Tm9sj2 in the adult mouse, we hybridized 
a Northern blot containing RNA from several adult mouse tissues with a probe derived 
from clone El-2. The probe hybridized to a fragment of approximately 3-3.5 kb and Tm9sj2 
expression was detected in all tissues examined, with highest levels in kidney and liver 
(Figure 5B). This corresponds in part to the expression pattern in human tissues, where the 
highest expression levels are detected in heart, brain, muscle, kidney and pancreas 43 . To 
investigate Tm9sj2 expression in hematopoietic cells, we hybridized a dot blot containing 
eDNA from several hematopoietic cell lines with the E1.2 probe. Tm9sj2 expression was 
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detected in all hematopoietic cell lines examined, with highest levels in myeloid (32D.cl3, 
DA3) and B-lymphoid (DA8) and lower levels in erythroid (MEL) and T-lymphoid (DA2) 
and cell lines (Figure 5C). Thus, the differential expression of Tm9sf2 in the El 0/Ell AGM 
and expression in hematopoietic tissues and cell lines suggest that is an interesting gene for 
further studies in hematopoietic cell development. 
Differential expression of mTAB2: a component of the IL-l signaling pathway 
Previously, human TAB2, has been shown to be part of the IL-l and RANK 
signaling cascade as a binding partner of TAKl (TGF~ activated kinase 1) 3051 . Further 
studies showed that the TAKll TAB1/TAB2 protein complex is involved in NFKB and 
JNK activation upon IL-l stimulation of cells 303751 • Both IL-l and RANK function within 
the hematopoietic system and NFKB is an important hematopoietic transcription factor 
12
.1 4•2152·61 • Our identification of clone Sl-7 in AGM DD RT-PCR screening and the verified 
up-regulated expression between ElO and Ell of the mouse homologue to human TAB2 
prompted further studies. 
To investigate the gene structure of mouse Tab2 and to compare it to human 
TAB2, we retrieved both genomic sequences from the Celera genome database. Alignment 
of both mRNAs to the genomic sequences revealed 6 exons, with similar intron-exon 
boundaries containing the complete ORFs of the two genes. The mouse Tab2 gene spans 
approximately 20kb and the ATG start site is located in the second exon (Figure 6A). Tab2 
is located on mouse chromosome 10 in a region homologous to human chromosome 6q25, 
where human TAB2 is located. The high level of conservation of the genomic structure of 
TAB2 between mouse and human suggests that these genes are regulated in a similar 
manner. Furthermore, the high homology in nucleotide sequence of the ORF and also the 
high homology of 94 % at the protein level (Figure 6B) suggest conservation of function 
between mouse and human. Protein motif searches in bioinformatics programs, including 
Pro site (http//us.expasy.org/prosite ), SBASE (http/ /www3 .icgeb. trieste.it/~sbasesrv) and 
CD-search (NCBI) revealed a coiled coil domain (aa. 529-619). No other domains with 
high homology were found based on the primary amino acid sequence. However, a search 
for conserved domains in the CD-database ofNCBI indicated that there was homology to a 
CUE (coupling ofubiquitin conjugation to ER degradation) domain at theN-terminus and a 
Zinc finger domain at the C-terminus of TAB2. The CUE domain is suggested to play a 
role in ubiquitination ofT AB2 . 
. We verified the up-regulated expression of Tab2 in the AGM between ElO and 
Ell by Northern blotting (Figure 6C). Full-length transcripts approximately 3.5-4 kb were 
also detected in Ell liver. When a Northern blot with adult tissue RNA was probed with 
the DNA fragment of clone S 1-7 (Figure 6D) Tab2 transcripts were detected in all tissues 
examined: with highest expression levels in kidney, thymus, spleen and BM and lower 
levels in liver and brain. Additionally, by eDNA dot blot analysis (Figure 6E), high level 
expression of Tab2 was observed in two myeloid cell lines (32D.cl3 and DA3) and low 
level expression in B and T lymphoid (DA8 and DA2) and erythroid (MEL) cell lines. 
Thus, by expression pattern and putative function based on homology with the human 
protein, mTAB2 represents an interesting molecule for further study in hematopoietic 
development. A full-length IMAGE clone of Tab2 was deposited into the sequence 
database of the NCBI by the IMAGE consortium (accession number: BC004813), after our 
identification of clone S 1-7. 
54 
Identification of differentially expressed genes in the AGM region 
A 
exon 1 : 180 bp exon 4: 93 bp 
exon 2: 1505 bp exon 5: 77 bp 
exon 3: 160 bp ex on 6: 1440 bp 
B 
; I:II:.JII$l$!!i.l:~ M!!!:UMI!Ii:l!lilllli:l!!lMi¥1lill !!;llliili 
::~: i~:llllllelliili!.!ll!:l:~~~ 
~~:; gi 111!1:9:11!!$!5!!1UJ:m*l!'itlUt$1:!1!l$!l!IRi!il.!!!31fSI!iS 
::::: :;; 51!!!3l!i!3ll!l!!l!$l!G:Ii3!~il!llll:l:!i!$lll~Hl 
;:;;::; ~j~ ~:I:UiiZiitiMI!d!fJIIIP:UiiflJUI:UEflfliUI$13.!'6ili 
c 
E 
::E ::E 
C> C) ~ « « 
0 
w w w 
TAB2 
GAPDH 
TAB2 
actin 
:::::: ::; !l~ll:ll:t:illl1l:li!!!i!!l! l!llflllilll!l:ll!l:l!!ll.lll!lllil!:l!;ffl;S 32D.cl3 
~:; ~~i~Jt115!1f.!H:!5i.!!JOOJi0:!3JI!II: DA3 
MEL ...._ 
DA2 -· 
DA8 
Figure 6. Structure and expression 
of the mouse Tab2 gene. 
(A) Schematic representation of the 
mouse Tab2 gene. The mRNA 
sequence of mouse Tab2 (BC004813) 
was blast against the Celera mouse 
genome database The Tab2 gene 
contains 6 exons spanning 20 kb and 
is located at mouse chromosome 10. 
(B) Alignment of mouse and human 
TAB2 protein shows 94% homology 
indicating conservation of the gene. 
(C) Northern blot showing 
differential expression ofTab2 in the 
AGM between EJO and Ell. (D) 
Northern blot revealing high levels 
of Tab2 expression in the adult 
mouse kidney, thymus, spleen and 
BM (E) eDNA dot blot analysis 
shows high expression of Tab2 in 
two myeloid cell lines (32D.cl3 and 
DA3) and lower expression in Band 
T lymphoid (DA8 and DA2) and 
erythroid (MEL) cell lines 
mTAB2 is expressed in the endothelium ofthe dorsal aorta at Ell and E12 
To investigate the specific expression pattern of mTAB2 in the AGM, 
immunohistochemistry was performed. First we tested a commercial antibody raised 
against human T AB2 on a Western blot for its ability to recognize the highly homologous 
mTAB2 protein. Protein extracts from two mouse (fibroblast and myeloid) and two human 
(B and T lymphoid) cell lines were used for Western blotting. In all extracts a single band 
of the predicted size of77 kD was detected (Figure 7A). 
Cryosections of El0-El2 embryos at the level of the AGM were prepared for 
TAB2 immunostaining. In both Ell and El2 trunkal sections we could detect high levels of 
mTAB2 expression in cells within and lining the neural tube, including the neuroepithelial 
cells; the dorsal root ganglia and the marginal layer (data not shown). Interestingly, mTAB2 
expression was also detected in the endothelium of the Ell (not shown) and El2 dorsal 
aorta and some underlying mesenchymal cells (Figure 7B). Consistent with the low to 
undetectable levels of mTAB2 RNA in the ElO AGM, no mTAB2 expression was found in 
ElO dorsal aorta endothelium and neural tube. Thus, mTAB2 is expressed in the 
endothelium of the Ell AGM at the time when HSCs are first being generated, suggesting 
a role for mTAB2 in the induction or regulation ofHSCs 
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Figure 7. AGM immunostainingfor mTAB2. 
(A) Western blot analysis on two mouse and two 
human cell lines shows that the antibody raised 
against human TAB2 recognized a single protein 
band with the expected molecular mass of 77kD in 
both the human and mouse protein lysates. (B) 
Immunohistochemistry with an antibody against 
TAB2 was peiformed on 6-8j.1111 transverse 
cryosections of El2 embryos at the level of the 
AGM High level TAB2 expression was detected in 
the cells surrounding the neural tube (not shown). 
Lower levels ofmTAB2 expression were detected in 
the endothelium of the El2 dorsal aorta and in 
some cells surrounding the dorsal aorta. 
Differential Display PCR as a means of identifying novel genes expressed 
differentially in embryonic tissues 
To increase our understanding of the genetic program involved in the generation 
of the first HSCs within the mouse AGM between ElO and Ell, we performed DD RT-
PCR screening. When we initiated these studies, DD RT-PCR was chosen over other 
methods, as a non-biased means of identifying differentially expressed novel genes. In three 
independent DD RT-PCR screenings we found in total 42 differential bands, with 7 
confirmed differentially expressed clones. In addition to the clones encoding differentially 
expressed genes, we also found a number of false positive clones 31 . As a known technical 
drawback of DD RT -PCR, excised differential bands generally contain 2-3 different PCR 
fragments, of which some are differentially expressed and some are not 25 . As shown in 
Table 2, differential band S 1 yielded at least two different clones, S 1-2 and S 1-7, 
respectively corresponding to a RNA binding protein and the novel mouse Tab2 gene. The 
multiple different PCR fragments present within an excised band provide an explanation for 
the finding that some clones have an expression pattern opposite to the original differential 
band (i.e. El-2, M2-2) or do not show differential expression at all (i.e. G2-5, G4-l, Kl-5, 
S2-6). Thus, our approach using DD RT-PCR to identify novel genes gave expected and 
verifiable results. 
56 
Identification of differentially expressed genes in the AGM region 
The 8 arbitrary primers we used for DD RT-PCR were sufficient to identifY two 
novel genes differentially expressed in the ElO/Ell AGM. However, for a complete 
overview of all the (novel or known) genes differentially expressed between two 
populations of cells, more primers should be used in future studies. Additionally, the recent 
availability of mouse El2 AGM micro-arrays holds promise for comprehensive analysis 
and rapid advancement in the gene expression profiles of AGM HSCs and their precursors. 
Differentially expressed components of the Wnt signaling pathway are candidates for 
signal transduction in the AGM region. 
In our screenings we found two clones corresponding to Dvl2 and ~catenin, both 
of which are components of the Wnt signaling pathway. Generally, Wnt signals are known 
for their regulatory role in several developmental processes (reviewed in 8,60). As 
regulators of the hematopoiesis, Wnt5a and Wntl Ob have been shown to increase the 
number of human CD34+ cells in culture and number of colonies in CFU-Mix assays 55. 
Wnt5a, WntlOb and several Wnt receptors (Frizzled) are expressed in Ell YS and El4 fetal 
liver during mouse development 1 and Wnt5a increases the proliferation of murine fetal 
liver hematopoietic progenitor cells 55 1. While no obvious hematopoietic defects are found 
in Wnt5a .;. embryos 63 , redundancy of other Wnts (i.e. Wnt5b) most likely plays a role. 
The expression of Wnt signaling components in the AGM has not been 
investigated previously. In our studies we show that, besides up-regulated ~catenin and 
unchanged Dvl2 expression, several other components of the Wnt signaling pathway 
including Dvll, Dvl3, Wnt3, Wnt5a, Tcfl, Tcj3 and Lef are expressed (some up-regulated at 
the onset of HSC activity, some unchanged) in the midgestation AGM, making it more 
likely that Wnt signaling may be involved in hematopoietic development. Further 
supporting this notion, is the finding that Wnt3a is expressed at E10.5 in the peri-umbilical 
mesenchyme, another site where HSCs are found 40. 
Concerning the other Wnt signaling molecules Tcfl, Lefand Tcj3, our data on Tcfl 
and Lef expression correspond to previous findings of Oosterwegel et al. who reported its 
expression in the E10.5 to El4.5 mesonephros region and surrounding mesenchymal cells 
34
. However, while Tcj3 expression has been shown restricted to early development of the 
brain and become undetectable by El0.5 as determined by in situ hybridization 22, we were 
able to detect expression of Tcj3 in the midgestation AGM and liver. This discrepancy 
might be due to low expression of Tcj3 that is detectable by sensitive methods as RT-PCR 
but is below the detection limit of in situ hybridization. Altogether, the simultaneous 
expression of numerous Wnt signaling components in the Ell AGM and fetal liver suggest 
that the Wnt signaling pathway is functional. Furthermore, it is of great interest that ~ 
catenin, a key component of the signaling cascade is up-regulated in the AGM within the 
time frame that HSCs emerge in this tissue. Thus, future studies will address the functional 
role of Wnt signaling in AGM cells, in particular the HSCs and the microenvironment 
which supports HSC induction 
A conserved protein encoded by the mouse Tm9sj2 gene is differentially expressed in 
the AGM region between ElO and Ell. 
One of the novel mouse genes, Tm9sj2, identified in our DD RT-PCR screening 
encodes a transmembrane protein. Previously, the hTM9SF2 protein was shown to localize 
in endosomes and was suggested to function as a channel or small molecule transporter. 
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Interestingly, the yeast TM9SF2 homologue is a precursor protein of which the 24kD 
cleavage product has been implicated in intracellular vesicle transport 3"50 . To date it is 
unclear whether the mouse and human TM9SF2 also require protein processing in order to 
fulfill their putative cellular functions. 
Our interest in Tm9sj2 arose from its up-regulated expression in the Ell AGM and 
because it showed some low level homology to the MDR-1 protein, which functions as a 
transporter in multidrug resistance and is expressed by HSCs 4"16• However, the homology 
is limited to the transmembrane domain, with no clear homology with the rest of the 
MDR-1 protein. Additionally, the intracellular localization of the MDR-1 protein and the 
hTM9SF2 protein is different (cell surface versus endosomallocalization respectively) and 
the MDR-1 protein has 12 transmembrane domains 16 while hTM9SF2 has only 943 . 
Therefore, we do not consider it likely that these proteins are closely related or within the 
same family of proteins. However, differential expression of Tm9sj2 in the AGM between 
ElO and Ell, makes this conserved gene an interesting candidate for future studies of its 
function and potential role in development and/or regulation or the hematopoietic system. 
Tab2: A novel mouse gene and involvement in the IL-l signaling cascade 
While we identified Tab2 as a novel mouse gene in our DD RT-PCR screening of 
the midgestation AGM, its homologue, human TAB2, has been previously studied for its 
role in signaling within hematopoietic cells. T AB2 was originally identified as a specific 
IL-l signaling component with the ability to interact with of TAKl (TGF~-activated 
kinase) 51 • TABl, another TAKl-binding protein, was shown to be necessary for TAKl 
activation upon TGF~ 1, BMP and IL-l stimulation 46.47'51 • Based on biochemical studies 
hTAB2 was assigned a role as adapter protein in linking TRAF6 to TAKl, but it is unclear 
whether it fulfills additional functions. More recently it was shown that hTAB2 is also 
involved in RANK signal transduction 30. Studies in Xenopus have shown that TAKl and 
TABl play a role in BMP signaling and in mesoderm patterning 46•62. Additionally, in 
Drosophila it has been shown that TAKl is involved in Toll signaling in the innate immune 
system 56. As the Toll and IL-l signaling pathway is conserved between Drosophila and 
vertebrates, TAB2 might also play a role in the innate immune system. Furthermore, 
several studies in human cell lines have shown that TAKl and hTAB2 are involved in the 
activation ofNFKB 12•30•375 1.61 . More recently, Tab2 deficient mice were generated by Sanjo 
et aL These studies revealed that lack of Tab2 results in an embryonic lethal phenotype due 
to fetal liver defects42 . As the fetal liver is an important hematopoietic organ during 
development, these results strongly suggest that T AB2 either directly or indirectly is 
involved in the regulation of the hematopoietic system. Altogether these data indicate that 
in vertebrates, both TAKl and TAB2 might play an important role in the hematopoietic 
system. 
Of interest to our developmental studies is the fact that signaling via TAKl and 
NLK negatively regulates the Wnt signaling pathway. TAKI-induced NLK activation 
resulted in phosphorylation of TCF/LEF factors and subsequent inhibition of ~-catenin­
TCF interaction with DNA. Although the biochemical studies were performed in cell lines 
by transient transfections, the physiological relevance of these findings was confirmed by 
studies in Xenopus, where overexpression of NLK suppressed the ~-catenin-induced axis 
duplication 18. Additionally, studies in Celegans showed that MOM-4 (TAKl homologue) 
and LIT-1 (NLK homologue) are negative regulators ofTCF activity 2. Since components 
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of both signaling cascades, i.e. IL-l and Wnt, are differentially expressed in the AGM 
between ElO and Ell, the interplay between these pathways in the midgestation AGM 
awaits further study. 
Finally, the upregulation of Tab2 in the AGM coincides with the emergence of 
HSCs within this region and parallels the presence of HSCs in the fetal liver. As shown by 
immunohistochemical staining, T AB2 expression is localized to the endothelium of the 
dorsal aorta and in some underlying mesenchymal cells in the Ell AGM. Previous studies 
in our laboratory, have shown that HSCs are located within the endothelium of the E 11 
dorsal aorta and in the closely associated mesenchyme 10•11 • Our preliminary investigations 
of mTAK.l expression in the AGM, show that mTAK.l expression is also confined to 
endothelium and the underlying mesenchymal cells. Based on the spatial and temporal 
expression pattern of Tab2, we suggest that Tab2 is involved either directly or indirectly in 
the induction and/ or regulation of HSCs within the AGM. Currently it is unclear whether 
mTAB2 is involved in IL-l, RANK or another not-yet-identified signaling cascade. Future 
studies should yield more insight into the precise role played by Tab2 and its potentially 
exciting role in AGM HSC development. 
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Appendix: Results DD RT -PCR screenings 
Expr Expr. Homology to Homology Remarks 
on gel Profile gene product to 
(*) dot blot accession 
= Q,j screen I number Q,j Q,j 
= .... 0 RT-PCR ~ <:j ~ (*) 
1 Dl-1 t ND mouse EST AK007682 homologous to human 
1 D2-3 t ND myeloid! lymphoid or 
mixed-lineage 
- leukemia 5 
1 El-2 -1- t human TM9SF2 NM004800 new mouse gene 
1 Gl-3 
-1- -1- mouse Enolase/ BC024644 
mycbinding 
protein (MBP) 
1 G2-4 -1- ND mouse tubulin NM 011653 
1 G2-5 -1- similar mouseBUBIB AF107296 
1 G3-4 t ND mouse EST BC004697 
1 G4-1 -1- similar mouse Dvl2 NM007888 
1 G4-7 -1- ND mouse NM 015781 
nucleosome 
assembly protein 
1-like 1 
1 Hl-3 t -1- mouse Enolase/ BC024644 
mycbinding 
protein (MBP) 
1 H2-7 t ND mouse XM 129845 
fibronectin 
1 Il-5 t ND mouse EST XM 129565 
1 Il-7 t ND vector sequence AF173954 
1 I2-8 t ND mouse EST BC019518 
2 Kl-5 t similar mouse Cu/Zn X06683 
superoxide 
dismutase 
2 Kl-6 t t mouse globin M26897 
gamma/ epsilon 
2 K2-l t ND mouse Sjogren NM-009278 RNA binding protein 
syndrome 
antigen b 
2 K2-8 t ND mitochondrial J01420 DNA contamination 
DNA 
2 K3-7 t ND Rb binding XM 109424 
protein Rbbp4/ 
mRbAp48 
2 Ll-1 -1- ND Xist XM 136007 
Ll-5 
2 L2-3 -1- ND Xist XM 136007 
L2-8 
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Expr Expr. Homology to Homology Remarks 
on gel Pro:fJ.le gene product to 
(*) dot blot accession 
= screen I number ~ ~ 
~ = ;..., 0 RT-PCR ~ 
-"' 
~ (*) 
2 Ml-1 t ND No 
Ml-4 homology 
2 M2-2 ~ similar mouse TRAP150 NM005119 
2 M2-7 ~ ND rat/human U90725 new mouse gene 
lipoprotein 
binding protein 
2 Nl-1 t ND mouse SMT3 XM 122275 
-
Nl-8 homolog2 
2 N2-2 t ND genomic DNA DNA contamination 
2 N2-6 t ND ribosomal 
protein 
2 N3-l t ND ribosomal 
N3-7 protein 
2 N4-2 t ND mouse EST XM 129041 similar to hypothetical 
-
protein BC014003 
2 N4-8 t ND ribosomal 
protein 
2 N5-2 t ND ribosomal 
protein 
2 N5-8 t ND genomic DNA contamination 
sequence 
2 Pl-1 t ND zinc RING finger AF092877.1 
Pl-5 protein SAG 
2 Ql-2 t ND mouse similar to XM 124966 
-Ql-5 Elongation factor 
1-gamma 
2 Q2-1 t ND no homology 
2 Q2-2 t ND peptidylprolyl NM 008908 
-
isomerase C 
3 Rl-3 ~ ND humanRb AK008164 new mouse gene? 
binding protein 
3 Rl-4 ~ ND mouse homolog AK012432 
to 60S ribosomal 
protein 14 (Ll) 
3 R2-3 t ND mouse 101420 DNA contamination 
mitochondrial 
DNA 
3 R2-5 t ND no homology 
3 Sl-1 t ND no homology 
3 Sl-2 t similar homolog of NM019868 RNA binding protein 
human ftp-3 highly expressed in 
Ell/El2 liver 
3 Sl-7 t t human TAK-1 AF241230 IL-lR signaling, new 
binding protein mouse gene 
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Expr Expr. Homology to Homology Remarks 
on gel Profile gene product to 
* dot blot accession 
= screen I number ~ ~ ~ 
= .... 0 RT-PCR <:) 
-
"' 
<:) 
* 
3 S2-4 t t f3-catenin NM 007614 Wnt signaling 
3 S2-6 t similar EST BG071065 
3 Tl-5 t ND human zinc NM_021220 low homology 
finger protein 
339 
3 Tl-8 t ND mouse fibrillin 2 NM 010181 
3 T2-l t ND human zinc NM 021220 low homology 
T2-2 finger protein 
339 
3 T3-l Ell ND human DNA low homology 
T3-4 liver 
3 V1-1 t ND similar to XM 132858 
V1-8 chromodomain 
helicase DNA 
binding domain 
3 V2-5 t ND genomic DNA DNA contamination 
3 V2-8 t ND hypothetical XM 155909 
protein 
XP 155909 
3 V3-4 t ND no homology 
3 V3-8 t ND mouse Btk locus U58105 
3 V4-2 t ND no homology 
3 V4-5 t ND mouse DNA AC098723 DNA contamination 
clone RP23-
-3D10 
3 V5-l t ND no homology 
3 V5-6 t ND human DNA Al359259 DNA contamination 
clone RP11 
182B22 
(*)transcripts that are expressed at higher levels in Ell aorta/ AGM tissue in comparison to 
ElO AGM are referred to as upregulated (indicated by I) and transcripts that are expressed 
at lower levels in Ell aorta or AGM tissue in comparison to ElO AGM are referred to as 
dowmegulated (indicated by~). ND is non-determined. 
In Differential Display RT-PCR screening 1 complete ElO AGM was compared to 
complete Ell AGM material. In screening 2 El 0 aorta was compared to Ell aorta material 
and in screening 3 complete ElO AGM was compared to Ell aorta and Ell UGR material. 
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Abstract 
TAKl, a MAPK member, and TAKl binding (TAB) proteins are highly conserved 
between several species. TAKl has been implicated as a component of BMP, Wnt, IL-l, 
RANK and other signaling pathways and TAB 1 was ·shown to be crucial for the activation 
of TAKl. In addition to TABl, two other TAB proteins, TAB2 and TAB3 are similarly 
thought to act as adapter proteins. However, little is known about the role and regulation of 
TAB2 and TAB3. As the expression pattern could reveal more insight into the function of 
these molecules we analyzed the expression of Tab2 and Tab3 at the RNA level and also 
investigated TAB2 protein expression in the mouse. We found Tab2 and Tab3 transcripts in 
several adult tissues and cell lines and show that the Tab2 and Tab3 expression pattern 
partially overlaps. Furthermore, we report TAB2 protein expression in several adult tissues, 
including the thymus, spleen, brain, lung and bone marrow. Interestingly, the TAB2 protein 
expression pattern shows similarities to reported pattern of NFKB activity suggesting a 
functional link. 
Introduction 
Mitogen activated protein 3 kinase 7 (MAP3K7) is better known as Transforming 
growth factor~ (TGF-~) activated kinase 1 or TAKl. As suggested by its name, TAKl was 
originally identified in a screen for proteins involved in TGF-~ signaling39. In the adult, 
TAKl is expressed ubiquitously, with highest expression levels in thymus and brain39 . 
During development, TAKl expression at El0.5 was observed in the spinal cord and the 
brain. From El2.5 onwards high levels of TAKl expression were observed in the gut 
epithelium and the mesonephric and metanephric kidneys. TAKl expression was also 
detected in E14.5 testis, lung and pancreas14. 
Soon after the identification of T AKl, the identification of two binding proteins, 
TABl and TAB2 was reported31. TABl is ubiquitously expressed and constitutively 
associated with TAKl. As overexpression of TABl resulted in enhanced TAKl .kinase 
activity, it was proposed that TABl is a positive regulator of TAKl. Later it was shown 
that a conserved C-terminal a-helix motif in TABl is involved in the binding and activation 
of TAK1 23 . Apart from' limited Northern and RT-PCR RNA analysis, the temporal 
expression pattern of Tab] during adult and embryonic stages in the mouse has not been 
determined to date. However, Tab] deficiency leads to perinatal lethality due to lung and 
cardiovascular abnormalities, indicating an important role for TAB 1 in the development of 
these tissues18. 
Both TAKl and TABl are highly conserved, and homologous proteins have been 
identified in human, mouse, Xenopus, Drosophila and C.elegans. The TAKl and TABl 
homologues in C.elegans (MOM-4 and TAP-1) were shown to antagonize Wnt signaling 
during developmenfu6. In mammalian cells and during Xenopus development a similar 
antagonizing effect of TAKl was shown to downregulate Wnt induced ~-catenin/ TCF 
transcriptional activation10-12. Moreover, TAKl and TABl were implicated in BMP 
signaling during Xenopus developmene0·38• Further investigations revealed that BMP-4 
could activate TAKl and thereby exert a negative effect on neural specification in Xenopus 
development6• Additionally, TAKl has been implicated in several other signaling pathways 
including the interleukin (IL-l) and lipopolysaccharide (LPS) signaling pathways9·35• 
Apart from the relatively well characterized TABl protein, two other TAB 
proteins have been identified, TAB2 and TAB3. In contrast to TABl which has a clear role 
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in TAKl regulation, the role of TAB3 and to a lesser extent TAB2 in TAKl regulation 
remains unclear. T AB2 was originally reported as a adapter protein required for interaction 
of TAKl and TRAF6 in IL-l receptor signaling34. Biochemical protein analysis revealed 
that upon IL-l stimulation both TAKl and TAB2 are translocated from the plasma 
membrane to the cytosolic fraction. This is consistent with the idea that TAKl and TAB2 
would interact with the IL-l receptor prior to transducing signals to other proteins16•34·35 . 
However, recent stUdies by Beak et al. showed that TAB2 is localized in the nucleus of 
neuronal cells and translocated to the cytoplasm upon IL-l stimulation1. They proposed that 
T AB2 in the nucleus fulfilled a role as modulator of NFKB-mediated gene activation 1. 
Further evidence that TAB2 might not play a crucial role as an adapter protein in IL-lR 
signaling, was provided by Tab2 gene disruption experiments27 . Tab2 deficient mice die 
around El2.5 due to fetal liver degeneration. Upon IL-l stimulation, Tab2-deficient cells 
responded similarly to wildtype cells in the expression of IL-l target genes and the 
activation of JNK and NFKB27. Thus, the exact role of TAB2 in IL-l signaling remains 
controversial. The last identified TAB -protein, TAB3 was shown to be involved in BMP 
signaling in Xenopus. Based on its high homology to T AB2, it was proposed to function as 
an adapter protein linking TAKl to the BMP receptor. 
Currently, little information is available about the expression ofTAB2 and TAB3. 
As these proteins are highly homologous and therefore may fulfill overlapping functions we 
examined the expression pattern of Tab2 in the adult mouse and compared it to that of 
Tab3. Here we show that both Tab2 and Tab3 are ubiquitously transcribed in most adult 
mouse tissues examined, although Tab3 is expressed at lower levels than Tab2. Moreover, 
by protein analysis we show TAB2 expression in certain cell subsets in the brain, spleen, 
thymus and in the bone marrow. 
Material and Methods 
Mice and cell culture 
Animals were housed according to institutional guidelines, with free access to water and 
food. Animal procedures were carried out in compliance with the Standards for Humane Care and 
Use of Laboratory Animals. (CBAxC57/BLlO)Fl Mice were sacrificed by cervical dislocation and 
tissues collected in PBS/I O%FCS. 
3T3 fibroblasts were maintained in DMEM/ 10% FCS and transiently transfected with 
Lipofectamine2000 (Life Technologies) according to manufacturers instructions and harvested 24 
hours after transfection. 
RNA expression analysis by RT-PCR and Northern blotting 
Total RNA was isolated with TRIZOL (Gibco/ Life Technologies) according to 
manufacturer's instructions and DNAse treated (RQI DNAse Promega). For eDNA synthesis 1-5 ).Lg 
of total RNA was reverse transcribed with Superscript II reverse transcriptase (Invitrogen/ Life 
Technologies) according to manufacturer's instructions. PCR reactions were performed in 50 J.Ll with 
IU Amplitaq (PerkinElmer) and provided buffer, 100 ng of each primer, lmM dNTPs, and 2 J.Ll of 
eDNA. PCR cycles as follows: 5 min 92°C, 30-35x (40 sec 92°C, 40 sec 58°C, 1 min 72°C), 7 min 
72°C. PCR primers are listed in Table 1. 
For Northern analysis 1 0-20).Lg total RNA was separated on a formaldehyde gel and blotted 
to Hybond-N membrane (Amersham Pharmacia Biotech). Probes were labeled with 32P by nick 
translation method (Amersham Pharmacia Biotech). Tab2 probe contained the complete open-reading 
frame sequence and Tab3 probe consisted of fragment 731-1540 based on sequence XM-111986. 
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.pnmers 
Primer Sequence (5'-3') product accession 
size number 
B-actin forw CCTGAACCCTAAGGCCAACCG 397 X03672 
J3-actin rev GCTCATAGCTCTTCTCCAGGG 
IL-lRacP forw GAAATAGCCTCAGCTCACACAG 458 NM 008364 
IL-lRacP rev CTCTGTTCCACCTCAGACTC 
IL-lRI forw ACCTCACTTCTCCTGGATCC 300 NM 008362 
IL-lRI rev GGGGTACAAAGAACAAGGCG 
IL-l RIIforw CCAGCATCATTGGGGTCAAG 435 NM 010555 
IL-lRII rev CCTGGTTGTCAGTCCGTAGC 
TABl-910 forw CAGGCCAACCAGGATTGC 454 NM 025609 
TABl-1360 rev GAGCTGGAGCTGCTGCTCTG 
TAB2-1680 forw TGCTGGTGCACCAGAAGGCCAGGATG 686 BC004813 
TAB2-2350 rev GTCTCTCAGGCCTTTCAGGTG 
TAB3 forw CTCAGAATGCTCCATGG 809 XM 111986 
TAB3rev ATCCAGAACTAGAGCTC 
TAKl (3') forw GTGGTACATTACAGAGGGAC 412 BC006665 
TAKl (3') rev CCGATAGCTCAGCTCAAGCC 
Western blotting 
Protein lysates were made with RIP A lysis buffer. Proteins were separated on 10% SDS-
p AGE and blotted to PVDF membrane (Immobilon, Millipore ). Blotted membranes were blocked 
with 4% non fat dry milk (Biorad) /TBS-T and incubated overnight with primary antibody in 
2%milk!TBS-T, then incubated with HRP labeled secondary antibody and visualized by ECL 
detection. Antibodies used were TAB2 (against N-terminus, k-20; Tebu Bio), TAB2 (against C-
terminus, PA1-853 Affinity BioReagents) and a-HA (Santa Cruz). 
MACS sorting for hematopoietic lineage negative and positive BM cells 
BM from adult mice was collected in PBS/ 10% FCS and stained with antibodies against 
CDllb, CD5, Gr1, Ter119, B220 (BD Pharmingen and Immunotech) for 30 min on ice. Subsequently 
cells were incubated with goat-anti rat microbeads (Miltenyi Biotec). Lineage negative and positive 
cells were separated with the autoMACS system (Miltenyi Biotec). Purity of cell fractions was 
checked by F ACS analysis and the lineage negative fraction had a purity of 80-85%. 
Immunofluorescence and histochemistry 
Adult tissues were snap-frozen and 7-10)-LM cryosections were made. Sections were fixed in 
2% paraformaldehyde/ PBS and incubated with primary antibody overnight at 4°C. Staining was 
visualized with Santa Cruz or Vector Laboratories ABC staining kit in combination with TSA biotin 
system (PerkinElmer) according to provided instructions. Sections were counterstained with 
hematoxylin, dehydrated and embedded in Entallan. 
For immunofluorescence studies cytospins of BM cells were made. Cells were fixed and 
stained as described above. Staining was visualized with a secondary FITC labeled antibody. 
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Results 
T AKl binding proteins are conserved between several species 
To date three different TAKl binding proteins have been described, TABl, TAB2 
and TAB3. These TAKl-binding proteins are highly conserved between several species 
including C.elegans, Xenopus, mouse and human with approximately 90% homology 
between mouse and human. As shown in Figure lA, TABl is the smallest (approximately 
500 amino acids) of the TAKl binding proteins and contains a conserved phosphatase 
domain, although to date no phosphatase activity has been observed for TABl. TAB2 and 
T AB3 are also highly conserved between several species with approximately 90% 
homology between mouse and human. The protein structure ofTAB2 and TAB3 is similar 
and these proteins are larger than TABl. Both TAB2 and TAB3 contain anN-terminal 
CUE domain, a C-terminal zinc finger domain and a coiled coil domain. The CUE domain 
has been suggested to play a role in ubiquitination and possible degradation or regulation of 
these proteins 17• The coiled coil domain most likely fulfills a role in protein-protein 
interactions and the zinc finger domain might also be involved in protein-protein 
interactions, although DNA-protein interaction cannot be excluded. In addition, TAKl is 
highly conserved at the protein level between human and mice (95%) and to a somewhat 
lower extent with Xenopus (data not shown). TAKl contains a conserved kinase domain 
and a coiled coil region, which most likely plays a role in protein-protein interactions 
(Figure lA). o 
As described by Baek et al., TAB2 is localized in the nucleus of neuronal cells and 
is translocated to the cytoplasm upon IL-l stimulation1. A nuclear export signal (NES) 
within the coiled coil domain of TAB2 was detected. Site-directed mutagenesis of this 
domain resulted in constitutive localization of T AB2 in the nucleus 1. Protein sequence 
comparison reveals that a similar NES sequence is present in mouse and human T AB3 
(Figure lB) suggesting that TAB3 might also be localized in the nucleus and regulated in a 
similar fashion to T AB2. Furthermore, as shown in the protein sequence alignment mouse, 
human and Xenopus TAB2 and TAB3 are highly homologous with approximately 46% 
overall protein similarity (Figure lC). Highest similarity (~80%) is found at the C and N-
terminus of these proteins. As both TAB2 and TAB3 have similar domains and both 
contain a NES sequence, it is possible that the localization of these proteins is similar and 
that they have redundant or overlapping functions. 
TABl, 2 and 3 and TAKl expression in mouse cells 
T AB2 was originally identified as a binding partner ofT AKl and was proposed to 
fulfill an important role in IL-l signaling34. Previously, we reported Tab2 RNA expression 
in the midgestation AGM and liver and in several adult mouse tissues, including the 
thymus, spleen and BM 24. Additionally, TAB2 expression has been observed in neuronal 
cells1• To investigate whether the different TAKl binding proteins are co-expressed in adult 
mouse tissues, we performed RT-PCR analysis. As shown in Figure 2A, Takl is 
ubiquitously expressed in all tissues examined. Tab2 is expressed at high levels in liver, 
kidney, stomach and spleen. Tab] and Tab3 are expressed in these same tissues, but at 
much lower levels than Tab2 (35 RT-PCR cycles were necessary to detect expression of 
TABl and 3 as compared to 30 cycles for TAB2). Thus, Takl and Tabl, 2 and 3 transcripts 
are co-expressed in several adult tissues. 
71 
Chapter3 
A 
C:::~:::::f:~shTAB1 so4aa C ... :::::.:lmTAB1 502aa 
579aa 
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lJlilil :@lhTAB2 693aa 
L§l l@]mTAB2 693aa 
c 
IJiEl I@@ hTAB3 712aa 
'-="------------'---'--'1"""'@!?1 mTAB3 746aa 
kinase domainl$f:$l CUE domain 
coiled coil - PTPase domain 
ZnF domain 
B 
consensusLXz_, LXXXLXI(L) 
mTAB2 LQRELEM QKKKLDKL 
hTAB2 LORELEI OKKKLDKL 
mTAB3 LAKOLKL EKEELERL 
hTAB3 LAKQLKL EKEELERL 
Figure 1. Protein structure and conservation ofTAKI and TAB proteins 
(A) TAKJ and TAB protein domains are similar between mouse and human. Conserved protein 
domains in TAKJ are theN-terminal kinase domain and the C-terminal coiled coil domain. In TABJ a 
conserved phosphatase (PTPase) domain is present. TAB2 and TAB3 contain similar domains; anN-
terminal CUE domain, a C-terminal coiled coil domain and Zinc finger (ZnF) domain. aa= amino 
acids. (B) Alignment of the NES of mouse and human TAB2 and TAB3 is shown. (C) Alignment of 
mouse, human and Xenopus TAB3 with mouse and human TAB2 protein reveals high homology at the 
protein level of related proteins. The highest similarity of TAB2 and TAB3 is found at the C-terminus 
and theN-terminus of the vroteins. 
Tab2 and Takl transcripts have been found in hematopoietic cell populations in 
the BM 13•25 . To examine the hematopoietic expression pattern of the Takl and more 
specifically of all three Tab genes in the bone marrow (BM), mature hematopoietic lineage 
negative and positive cells were sorted by MACS, followed by RT-PCR analysis. The 
lineage negative fraction of the BM is enriched for hematopoietic stem and progenitor cells, 
while the lineage positive fraction is enriched for the mature types of hematopoietic cells. 
As we had detected Tab2 and Takl expression in the 416B hematopoietic precursor cell 
line in other experiments, eDNA from this cell line was used as a positive control for the 
RT-PCR reaction. As shown in Figure 2B, expression of Takl and all three Tabs was 
observed in both BM fractions, with the tendency towards higher expression in the lineage 
negative fraction. Since T AB2 has been implicated in IL-l signaling, we also tested 
expression of the IL-l receptor in the two BM fractions. Expression of the two signaling 
IL-l receptor subunits (Il-l ri and Il-l racp) and the non-signaling IL-l receptor (Il-l riJ) 
was observed in both BM fractions. 
To quantify more accurately the expression levels of Tab2 and Tab3 we performed 
Northern Blot analysis. To minimize cross-reactivity, we used as a Tab3 probe a fragment 
with low nucleotide homology to Tab2. As shown in Figure 2C, both Tab2 and Tab3 
overlap in expression in brain, kidney, thymus, spleen and BM. When, we investigated 
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Tab2 and Tab3 RNA expression in several cell lines, the highest expression for Tab2 was 
observed in myeloid (DA3 and 32D) and 3T3 fibroblast cell lines, while low Tab3 
expression was detected in most other cell lines. While it is clear from these data that the 
Tab2 and Tab3 expression patterns are similar in adult mouse tissues, the expression pattern 
and levels in several cell lines is very different. Moreover, Tab3 is expressed at lower levels 
than Tab2. 
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Figure 2. Takl and Tab genes are expressed ubiquitously in mouse tissues and cells. 
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(A) RT-PCR expression analysis for Takl and Tab genes in several adult mouse tissues. The 
expression pattern for Takl and the Tab genes is more or less similar, with high expression in the 
liver, kidney, heart, stomach and spleen. (B) RT-PCR expression analysis ofTakl, Tab genes and 
components of the IL-l receptor in MA CS-sorted lineage marker negative and positive cells from 
adult bone marrow (n= 2). As positive control for the RT-PCR the hematopoietic 416B cell line was 
used. All genes tested are expressed in both the lineage negative and positive bone marrow 
fraction. (C) Northern blot analysis for Tab2 and Tab3 on several adult mouse tissues (left panel) 
and mouse and human cell lines (right panel). Tab3 and Tab2 tissue expression patterns are 
similar. Tab3 expression is generally lower than Tab2 expression. In the panel of the cell lines 
Tab2 expression is highest in myeloid cells (DA3 and 32D) and 3T3 fibroblasts. Expression ofTab3 
is low in all cell lines tested. The Tab3 probe hybridizes to a transcript larger than that ofTab2, 
consistent with the identification of longer Tab3 eDNA sequences (approximately 8 kb; sequence 
AL832071) than those for Tab2 eDNA (approximately 3.5kb; sequence BC004813). Actin is used as 
a RNA normalization control. BM=bone marrow, RT=reverse transcriptase. 
T AB2 protein expression in the mouse 
Previously, we reported mTAB2 expression near and in the endothelium of the 
dorsal aorta at Ell and El2 of mouse development 24. However, the expression pattern of 
TAB2 in the adult has to date not been investigated. To investigate the protein expression 
ofmTAB2 in adult mouse tissues we performed Western blot analysis. 
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In order to confirm the molecular weight of the TAB2 protein, which was claimed 
to be 76 kD, we overexpressed aHA-tagged full length TAB2 (Figure 3A) construct in 3T3 
fibroblast cells. As a positive control for the a-HA antibody we used a HA-tagged Oct6 
protein lysate. As shown in Figure 3B, the protein lysate containing the HA-TAB2 full 
length protein yielded a band on Western with a molecular weight of approximately 75-80 
kD, consistent with the expected size of~ 79 kD (76 kD plus 3 kD) of the TAB2 protein 
with the HA-tag. Additionally, overexpression of the truncated HA-TAB2 construct yielded 
a smaller protein product on Western blot. To confirm that the protein bands as detected 
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Figure 3. TAB2 protein analysis in the adult mouse by Western blotting 
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(A) The HA-TAB2 full length and HA-TAB2C constructs were used for overexpression in 3T3 
fibroblasts. These constructs were used as controls to determine the molecular weight of the TAB2 
protein (B) Western blot containing protein extracts of 3T3 fibroblast cells transfected with HA-
TAB2 constructs (as indicated in Fig.3A) was incubatea with an a-HA antibody and shows that the 
HA-TAB2 full length protein has a molecular weight of 75-80kD and that the truncated HA-TAB2C 
construct has a molecular weight of ~35kD. HA-Oct6 protein extract was used as a positive control 
for the a-HA antibody. (C) Western blot containing protein extracts from several adult mouse 
tissues incubated with TAB2 antibody directed against the C-terminus of TAB2 (Affinity 
BioReagents). A protein band at~ 7 5kD corresponds to the molecular weight band of the HA-T AB2 
foll length protein and therefore likely represents TAB2. The highest TAB2 expression is found in 
liver, kidney and heart. Lower TAB2 expression is found in the hematopoietic organs; bone marrow 
(Blvf), thymus and spleen. The asterisk (*) indicates an aspecific band. As a control for protein 
loading the blot was repro bed with a-tubulin antibody. 
with the a-HA antibody represented TAB2 proteins, we incubated the blot with an a-TAB2 
antibody. Despite the fact that an endogenous TAB2 band was readily detected, we were 
unable to detect a slightly larger HA-TAB2 protein. Most likely, this is due to the very low 
expression level of the HA-tagged TAB2 constructs. Alternatively, the N-terrninal HA-tag 
might have interfered with the recognition of HA-TAB2 by the a-TAB2 antibody that is 
directed against the N-terminal part of TAB2. Nevertheless, when a Western blot 
containing protein lysates of adult mouse tissues was probed with a a-T AB2 antibody we 
detected a protein band with a molecular weight of approximately 75 kD (Figure 3C). 
Bas~d on the protein size as detected in the Western with HA-tagged TAB2, it is highly 
likely that this band corresponds to TAB2. High expression of the 75 kD TAB2 band was 
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observed in brain, liver, kidney, heart and lung and low levels were observed in the 
hematopoietic tissues, thymus, spleen and BM (Figure 3C). Besides the 75 kD band another 
band of approximately 55-60 kD was detected by Western blotting with the TAB2 antibody 
raised against theN-terminal part ofTAB2 (data not shown). It is unlikely that the 55-60 
kD band represents the highly homologous TAB3, as the predicted TAB3 protein has a 
higher molecular weight than TAB2. As this 55-60 kD band was not detected by the 
antibody directed against the C-terminal part of TAB2, this 55-60 kD band could represent 
a C-terminal truncated TAB2 isoform. 
Localization of TAB2 in adult mouse tissues 
To more specifically identifY and localize the cells expressing TAB2 in adult 
mouse tissues, we performed immunohistochemistry. Cryosections of several adult mouse 
tissues, including brain, thymus, spleen, lung, kidney, heart and liver were incubated with 
TAB2 specific antibodies and visualized with the peroxidase substrate DAB chromogen. 
For these analyses we used two different TAB2 antibodies (directed against theN- and C-
terminus of TAB2) and both antibodies gave similar TAB2 expression patterns in the 
tissues tested. Sections were counterstained with hematoxylin to visualize nuclei of the cells 
in the tissue, as an indication of the overall morphology of the tissues. 
In the coronal adult brain sections TAB2 expression was observed in cells 
scattered throughout the grey matter of the cerebellum. High expression was observed in 
cells in the outer layers of the cortex, excluding the outermost layer (Figure 4A-C). The 
cells underlying the outermost layer of the cortex are mainly neuronal cells and almost all 
these cells expressed TAB2. In general the highest percentage of TAB2 expressing cells 
was localized immediately beneath the outermost layer of the cortex. Interestingly, TAB2 
staining overlapped with the nuclear hematoxylin staining, suggesting that TAB2 in 
neuronal cells in the adult brain is localized mainly in the nucleus. 
The spleen is a hematopoietic tissue that is comprised of white pulp and red pulp 
areas. The white pulp area of the spleen harbors mainly lymphocytes while the red pulp 
area harbors mostly erythrocytes and connective tissue. The white pulp areas are separated 
from the red pulp by the marginal zone, where also marginal zone macrophages are located 
19
·
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• Blood cells enter the spleen via the trabecular arteries and leave the circulation via the 
central arterioles. Blood cells re-enter the circulation via the sinusoids and the veins. In the 
spleen, we observed TAB2 expression in the endothelium of the blood vessels, most likely 
the central arterioles and the trabecular arteries, but not in the sinusoids (Fig. 4D-F). 
Moreover, TAB2 expression was observed in a few scattered cells (less than 1 %) 
throughout the spleen. Most of these TAB2 expressing cells were located near blood 
vessels or at the border of the white and red pulp areas, the marginal zone. As the marginal 
zone is known to contain macrophages, these TAB2 expressing cells could represent a (sub) 
population of marginal zone macrophages. 
Similar to the spleen, the thymus is an important lymphoid tissue. It can be 
separated into the outer cortex and the inner medulla area. In the thymus, the less 
differentiated lymphocytes are localized to the cortex, while more mature differentiated 
lymphocytes are localized to the medulla area. Similar to the spleen, TAB2 expression in 
the thymus was observed in the endothelium of blood vessels. Additionally, a low 
percentage of cells scattered throughout both the cortex and the medulla regions expressed 
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Figure 4. TAB2 expression in adult mouse tissues. 
Cryosections of the brain, spleen and thymus stained with TAB2 (k-20; Santa Cruz) antibody. Tissues 
are counterstained with hematoxylin. (A-C) brain (D-F) spleen (G-I) thymus. (A,D,G) negative 
control; staining without TAB2 antibody (B,C,E,F,H,I) TAB2 staining (A-C) In the brain TAB2 
expression can be observed in neuronal cells in the outer layers of the cerebellum, except for the 
outermost layer where no TAB2 expression is observed. TAB2 is localized to the nuclei of the cells. 
(D-F) In the spleen TAB2 staining is detected in the endothelium of blood vessels and in few scattered 
cells at the borders of the red and white pulp area and near blood vessels. W=white pulp area and 
R=Red pulp area. (G-I) In the thymus TAB2 expression is located to the endothelium of blood vessels 
and few scattered cells in both the cortex as the medulla area. C=cortex and M=medulla. In 
(C,E,F,H,I) the closed arrows indicate TAB2 expressing cells and the open arrows indicate 
endothelial cells in the blood vessels expressing TAB2 
TAB2 (Figure 40-J). As the amount ofTAB2 expressing cells in the thymus is very low, it 
is not likely that these cells represent lymphocytes, as lymphocytes are abundant in the 
thymus. Since the TAB2 expressing cells in the spleen, based on their size and localization, 
could represent a (sub) population of macrophages, the TAB2 expressing cells in the 
thymus might also represent (a subpopulation of) macrophages. This would be consistent 
with the observation that in both tissues of low numbers of T AB2 expressing cells are 
present and that the TAB2 expressing cells appear to be rather large cells. Interestingly, in 
contrast to the brain where the intracellular localization ofTAB2 appeared to be nuclear, in 
the spleen and thymus TAB2 expressing cells, TAB2 staining surrounded the hematoxylin 
staining. This indicates that in spleen and thymus cells the T AB2 protein is cytosolic. 
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Besides TAB2 expression in the brain, spleen and thymus, we also observed 
T AB2 expression in the endothelium of blood vessels and low levels of T AB2 expression 
in the endothelium of some bronchioli in the lung. Additionally, in the El2 developing lung 
T AB2 expression was detected in a layer of cells underlying the lung epithelium and in the 
pulmonary arteries (data not shown). In the heart no clear TAB2 expression was observed 
throughout the myocardial tissue, but clear TAB2 expression was observed in the 
endothelium of blood vessels and in some cells located near blood vessels (data not shown). 
For the liver and kidney tissues examined, we were not able to detect specific TAB2 
expression due to high background staining. We cannot exclude the possibility that T AB2 
is expressed at low levels in these tissues. 
In conclusion, TAB2 expression in the adult mouse is observed in endothelial cells 
of blood vessels in several tissues and in neuronal cells in the brain. Furthermore, few 
scattered cells in the hematopoietic/lymphoid tissues, the spleen and thymus, expressed 
T AB2. Based on their localization in the spleen and their size in these tissues, these cells 
could represent a (sub) population ofmacrophages. 
T AB2 is localized in the nucleus and cytoplasm of bone marrow cells 
To more specifically determine the intracellular localization of TAB2 we 
performed immunofluorescence analysis on cytospins of adult bone marrow cells with an 
a-TAB2 antibody followed by a fluorescent secondary antibody. Since we found Tab2 
transcripts in both the lineage negative and positive fraction of the bone marrow, we 
examined both populations for TAB2 protein expression and intracellular localization. In 
both BM cell fractions we were able to observe TAB2 protein expression (Figure 5 ElF). In 
most cells examined, the staining for TAB2 was similar to the nuclear DAPI staining 
(Figure 5 AlBIC), indicating that T AB2 is localized in the nuclei of these cells. However, in 
some cells also cytoplasmic TAB2 localization was observed. 
The size and shape of the nucleus together with the ratio between the nucleus and 
the cytoplasm allows discrimination between several different cell types in the 
hematopoietic system. Based on the nuclear shape and size as observed by the DAPI 
staining together with the cytoplasmic TAB2 staining (in some cells), we were able to 
distinguish some hematopoietic cell types in these cytospins of these bone marrow cells. 
Mature myeloid cells (granulocytes) have a doughnut shaped nucleus and can be easily 
distinguished. Immature myeloid cells have large and bean-shaped nucleus, while 
hematopoietic progenitor (blast) cells tend to have a small round nucleus and relatively 
small cytoplasm. As shown in Figure 5, within the lineage positive BM fraction both 
immature and mature myeloid cells are observed. The immature myeloid cells show high 
levels ofT AB2 in the nucleus and the mature myeloid cells have low levels ofT AB2 in the 
nucleus and higher levels ofT AB2 in the cytoplasm. In the lineage negative BM fraction, 
some mature myeloid cells have TAB2 localized both in the nucleus and cytoplasm. 
Additionally, the hematopoietic progenitor (blast) cells in the lineage negative fraction 
express high levels of T AB2 in the nucleus. Hence, in contrast to mature myeloid cells, 
hematopoietic progenitor cells and immature myeloid cells express higher levels of TAB2 
with a predominant localization in the nucleus. 
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negative control lineage positive lineage negative 
Figure 5. Intracellular TAB2 localization in adult bone marrow cells. 
Adult bone man-ow cells were sorted into a lineage marker positive and negative fraction by MACS 
and cytospins were made. Cells were fzxed and processed for immunofluorescence staining with a 
TAB2 (Affinity BioReagents) antibody. (A)(B)(C) show nuclear DAPI staining (D)(E)(F) show 
TAB2 staining. (A)(D) negative control for TAB2 staining; (B)(E) lineage positiveji-action (C)(F) 
lineage negative ji-action. In both the lineage negative and positive fractions TAB2 expressing cells 
are present and TAB2 staining is present in both the nucleus as well as the cytoplasm. An-ow with 
closed tip indicates a mature myeloid cell, an-ow with open tip indicates immature myeloid cells 
and the open arrow indicates hematopoietic progenitor (blast) cells. 
Discussion 
TAKl and TAKl binding proteins are conserved between several species 
TAKl and TAKl binding proteins are highly conserved between several species. 
The similarity at protein level between mouse, human and Xenopus T AKl and TAB 1 
ranges from 90% to 95%. Also for TAB2 and TAB3, the conservation between mouse and 
human species ranges from 90 to 95%. This is of interest as TAKl and TAKl binding 
proteins have been implicated to function in a number of conserved signaling pathways, 
including BMP, Wnt and IL-l/Toll signaling10•12•30•34-36. Especially the IL-l/Toll signaling 
pathway, which plays a central role in the innate immune system, is highly conserved from 
Drosophila to mammals3•33 . 
Of interest is the high similarity at protein level between T AB2 and T AB3. The 
overall similarity between these proteins is 46%, but at the N~and C-terminus of the 
proteins the similarity is approximately 80%. As both proteins contain identical protein 
domains, they might be performing similar or overlapping functions. With respect to the 
CUE domain in both proteins, it has been recently shown that the IL-l signaling protein 
Tollip also contains a CUE domain and that these domains are required for intramolecular 
mono-ubiquitination26•32. In contrast to poly-ubiquitination of proteins that results in 
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degradation via the 26S proteosome pathway, protein modulation by mono-ubiquitination 
has been suggested to serve as a regulatory signal that can alter activity and localization of 
proteins2632. Moreover, it was shown that TAKl kinase activity is dependent on 
ubiquitination and these studies also revealed that TAB2 played an important role in the 
ubiquitin-dependent phosphorylation of IKBa by TAKl, although it is unclear what the 
exact role of TAB2 is in this process37. Whether the CUE domain of TAB2 and TAB3 is 
truly involved in localization changes and or altered protein activity remains to be 
investigated. 
Expression ofTAKl and TAB genes 
Although TAKl has been subject of several expression analysis studies, 
expression of the Tab genes has to date not been studied extensively. To examine the 
expression pattern of Tab2 and compare it to Tab], Takl, and especially to the highly 
homologous Tab3, we performed RT-PCR and Northern blot analysis. By Northern blot 
analysis the expression pattern of Tab2 and Tab3 in adult mouse tissues was similar. 
However, clear differences in Tab2 and Tab3 transcript expression were observed when 
several cell lines were tested. This might indicate that in vivo Tab2 and Tab3 are not 
expressed in the same cells within a tissue. Moreover, our data indicate that Tab3 is 
expressed at lower levels or in a smaller amount of cells as compared to Tab2 expression in 
the cells and tissues examined. 
To examine TAB2 protein expression in adult mouse tissues we performed 
Western blot analysis. TAB2 protein expression can be detected in all tissues examined. 
Highest TAB2 expression was observed in brain, liver, kidney, heart and lung and lower 
levels were observed in the hematopoietic tissues, thymus, spleen and BM. The ubiquitous 
TAB2 protein expression is consistent with the results from the RT-PCR and Northern 
analysis. Interestingly, TAB2 has been proposed to function in the IL-l signaling cascade 
and the T AB2 protein expression pattern is similar to that previously reported for the IL-l 
receptor 1 and 2 (IL-lRI and II). High expression of IL-lRI and II has been observed in 
non-hematopoietic tissues in the adult mouse, including heart, skin and brain and low 
expression in lymphoid tissues, such as spleen and thymus4. 
Besides the expected 75kD protein band, we also observed a smaller 55-60 kD 
protein band by Western blot analysis with the antibody directed against theN-terminus of 
TAB2. The ~50 kD band detected with the antibody directed against the C-terminus of 
T AB2 is most likely an aspecific background band. As a single band was detected with 
Northern blotting we ruled out the possibility that two different Tab2 mRNA splice 
isoforms would give rise to two different TAB2 protein isoforms. However, recently for 
human TAB2 two mRNA variants (accession numbers NM_015093 and NM_l45342) have 
been identified. One TAB2 mRNA variant contains a translation stop codon within the 
TAB2 coding sequence, resulting in a C-terminally truncated TAB2 protein of 
· approximately 60kD. As both human TAB2 mRNA variants are similar is size, no 
distinction between these variants could be made by Northern blotting. In a similar fashion 
mouse T AB2 could also be encoded by two different transcript variants, of which one gives 
rise to the full length 76 kD protein and the other to the 60 kD protein. Interestingly, the 
antibody directed against the N-terminus of TAB2 recognized the 55-60kD band with a 
higher intensity than the ~75kD band in the hematopoietic tissues as compared to the non-
hematopoietic tissues. It is currently unclear whether the truncated T AB2 protein has a 
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similar physiological function as the full length TAB2 protein and further biochemical 
studies are required to determine the characteristics of this truncated protein. Furthermore, 
protein sequencing should be performed to conclusively determine the nature of these 
bands as detected by Western blotting. 
T AB2 localization in adult mouse tissues 
To more specifically determine the localization of TAB2 we performed 
immunohistochemistry. Both TAB2 antibodies gave similar results and we were able to 
detect T AB2 expression in brain, thymus, spleen, lung and bone marrow cells. 
Interestingly, both TAKl and TAB2 expression was reported previously in the central 
nervous system and neuronal cells respectively1.14. Similar to the reported expression in 
neuronal cells 1, T AB2 expression in the adult mouse brain appeared to be localized to the 
nucleus of the cells. Since the in vivo localization of TAB2 is similar to that in neuronal 
cells, this could indicate that the proposed role for TAB2 in the regulation ofNFKB target 
genes in neuronal cells1 represents a true physiological function. Besides TAB2 expression 
in the adult brain, we also observed TAB2 expression in the spinal cord and dorsal root 
ganglia in the midgestation (Ell.5-El2.5) mouse embryo, suggesting a role for TAB2 in 
development and/ or function of the nervous system. Moreover, expression of IL-l signaling 
has been reported previously in the brain and was suggested to regulate neurotransmission 
and to be inv~lved in regulating fever responses 4·5. 
In the hematopoietic tissues, thymus and spleen, we were able to detect T AB2 · 
expression in a small number of cells, including the endothelium of some of the blood 
vessels and few scattered cells throughout the tissue. In the thymus, T AB2 expressing cells 
were localized in both the medulla and the cortex. In the spleen few scattered TAB2-
expressing cells near blood vessels and at the border (marginal zone) of the red and white 
pulp area. The marginal zone consists of a continuous ring of marginal zone 
macrophages19•20 . Although, the TAB2 expressing cells did not form a continuous ring 
around the white pulp area, these TAB2 expressing cells could represent a subpopulation of 
the marginal zone macrophages. Additional immunostainings for TAB2 in combination 
with markers for macrophages and/or related cell types need to be performed to reveal 
whether indeed these TAB2 expressing cells are (a subpopulation of) macrophages. 
Expression of both TABl and TAKl has been observed in the lung epithelium in 
midgestation mouse embryos14.1 8. In our studies, we observed low levels of TAB2 
expression in lung epithelium in the adult and in midgestation embryos. A higher level of 
T AB2 expression was detected in the subepithelial layer of the lung in midgestation 
embryos. Previously, Healy et al. showed that VEGF is expressed in the subepithelial layer 
6f the developing lung and that VEGF could stimulate neovascularization of the lung7. 
Interestingly, vascular endothelium cells and HSCs express the receptor (Flk: -1) for the 
VEGF ligand22•29.4°. Whether T AB2 expression in cell types known to express either the 
ligand VEGF or the receptor Flk-1 has any physiological relevance will need to be further 
investigated. Moreover, the interplay between TAB2, TAKl and TABl in the lung (and in 
other tissues) awaits further study. 
Interestingly, Schmidt-Ullrich et al. reported NFKB activity in several tissues and 
organs in the embryonic and adult stages of mouse development (as analyzed in a 
transgenic mouse model with a NjKb promoter driving lacZ expression)28 . These studies 
revealed NFKB activity from El2.5 onwards in the spinal cord and other neural tissues, and 
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in the adult mouse brain in a scattered pattern in the outer layers of the cerebellum. This is 
similar to what we observed for TAB2, although we detected TAB2 expression slightly 
earlier (ElLS) than the reported NFKB activity. Moreover, in the adult spleen, few 
scattered cells were found to be lacZ positive, while in the thymus more lacZ positive cells, 
including lymphocytes could be found. Also lacZ staining was observed in the endothelium 
of blood vessels28 . Therefore, NFKB activity in both adult and embryonic stages seems to 
correspond to the expression pattern of TAB2 we observed in several tissues. This is of 
great interest as it has recently been shown that T AB2 in neuronal cells is a modulator of 
NFKB-mediated gene regulation1. The similarities in the expression pattern of TAB2 and 
the reported NFKB activity, suggest that TAB2 not only in neuronal cells, but also in other 
cell types, is involved in modulating NFKB gene regulation. 
T AB2 is localized in the nucleus and cytoplasm of bone marrow cells 
As expected from the results of our RT-PCR analysis, we were able to detect 
TAB2 expression in both the lineage marker negative and the positive fraction of the adult 
bone marrow. Moreover, we found that TAB2 localized in both the nucleus as well as the 
cytoplasm in some cells, while in other cells TAB2 localization was restricted to either the 
nucleus or the cytoplasmic region. TAB2 has been proposed to localize to the nucleus and 
translocate to the cytoplasm upon IL-l stimulation1. However, as the bone marrow cells are 
likely exposed to endogenous IL-l in the bone marrow and moreover were processed 
during the sorting period in the presence of fetal calf serum (known to contain IL-l), it was 
not surprising to find T AB2 in the cytoplasm of these cells. Within the bone marrow 
fraction analyzed, we observed high TAB2 expression in immature myeloid cells and lower 
TAB2 expression levels in more mature myeloid cells. Also, in some blast-like progenitor 
cells, we observed high TAB2 expression in the nucleus. Obviously, these findings of 
TAB2 expression in different subsets of hematopoietic cells need to be extended by co-
stainings with hematopoietic lineage markers. Nevertheless, the expression of TAB2 in the 
myeloid lineage correlates with the finding that IL-l affects myeloid cells (including 
monocytes and neutrophils) in vivo 2•5•8•15 and with the observed high level of TAB2 
transcript expression in the myeloid cell lines (32D and DA3). Moreover, in 32D cells 
differentiated with the cytokine G-SCF we observed downregulation of Tab2 RNA 
expression. In contrast, when 32D cells were differentiated with GM-CSF or when the 
myeloid precursor cell line MPRO was differentiated with retinoic acid no such Tab2 
expression down-regulation was observed (C.O.; unpublished data). Therefore, these 
interesting findings of TAB2 expression in the myeloid lineage of bone marrow 
hematopoietic cells and the possible differential regulation of Tab2 along the myeloid 
differentiation pathway, could serve as a starting point for further examination of TAB2 in 
this hematopoietic cell type. 
In conclusion, Tab2 and Tab3 gene expression is similar in several adult tissues, 
which are heterogeneous populations of cells. In contrast, little overlap in expression was 
observed in the several clonal cell lines analyzed. At protein level T AB2 is ubiquitously 
expressed in all adult mouse tissues tested. Notwithstanding, when we examined the spatial 
expression pattern of TAB2 by immunohistochemistry, we were able to detect specific 
expression in subsets of neuronal cells in the brain, vascular endothelial cells in several 
adult and embryonic tissues and few scattered cells in the spleen and thymus. Moreover, in 
the bone marrow, different hematopoietic cell types, most notably the myeloid lineage, 
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expressed T AB2. Since the observed expression pattern ofT AB2 resembles that of reported 
NFKB activity in the adult mouse, this might indicate that the function ofT AB2 is related to 
NFKB activity. 
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Abstract 
Definitive hematopoietic stem cells (HSCs) are first detectable during mouse 
development in the aorta-gonad-mesonephros (AGM) region from embryonic day. 10.5 
(E10.5) onwards. Although several studies have investigated the emergence and regulation 
of HSCs in the AGM region, our understanding of the regulatory processes underlying their 
generation is limited. Recently, we reported the upregulation ofT AB2, a component of the 
interleukin-1 (IL-l) signaling pathway, in the AGM region at the developmental time when 
the first HSCs are detected. IL-l is a known regulator of bone marrow HSCs. However, the 
role of IL-l in regulating HSCs during development has not been investigated. Here we 
address the role of IL-l in the regulation of HSCs during midgestation development. We 
show that the expression of several components of the IL-l signaling pathway are 
initiated/upregulated in the AGM region between ElO and Ell and provide evidence that 
IL-l signaling is functioning in the Ell/12 AGM and liver. The IL-lRI is expressed in/ 
near the endothelium of the dorsal aorta from Ell onwards and is found within c-kit, Mac-1 
or CD45 expressing cell populations in the AGM and liver. Moreover, IL-l has an effect on 
HSC activity, as AGM and liver explants cultured in the presence of IL-l show increased 
HSC activity by in vivo repopulation assays. Taken together, these data provide evidence 
that IL-l regulates the fate of HSCs from the earliest stages of development onwards. 
Introduction 
In the adult mouse, hematopoietic stem cells (HSCs) are located in the bone 
marrow and form the basis of the hematopoietic hierarchy. HSCs are characterized by their 
ability to self-renew and to give rise to mature )lematopoietic cells of all lineages 
throughout the entire life-span31•50 . During mouse development, the first primitive 
hematopoietic cells can be found in the yolk sac from embryonic day 7.5 (E7.5) onwards. 
These primitive erythrocytes develop in close association with the vasculature of the yolk 
sac, in so-called blood islands44. From E9 onwards multipotent hematopoietic progenitors, 
with the ability to repopulate the hematopoietic system of newborn recipients and RAG2yc 
deficient adults, but not that of adult lethally irradiated recipients, can be found in both the 
yolk sac and within the embryo proper457. Such multipotent progenitors are first generated 
in the intra-embryonic para-aortic splanchnopleura4. The first definitive hematopoietic stem 
cells, with the ability to repopulate adult recipients, become detectable and are 
autonomously generated at El0.5 within the embryo proper in a region referred to as the 
aorta-gonad-mesonephros (AGM) region34•37. This region consists of the dorsal aorta 
surrounded by mesotlephros and the gonads. Closer examination of the AGM region 
revealed that the first definitive HSCs are localized in the area around the dorsal aorta 634•37. 
Within the dorsal aorta, clusters of cells that express several hematopoietic (stem) cell 
markers, have been observed at the ventral aspect of the aorta and these clusters are 
believed to contain HSCs 27.40.4J,s3. From Ell onwards, definitive HSCs become also 
detectable in the circulation, the yolk sac and the fetalliver303437. From El2 until the end of 
gestation the fetal liver is the main hematopoietic organ and HSC numbers increase 
dramatically in the fetal liver up to El4 13•30. 
Research has focused on the factors that play a role in the regulation of HSCs 
during development and although several factors have been proposed to play a role, the 
understanding of the processes taking place is still limited. In our search for regulators of 
HSCs we recently reported that the novel gene Tab2 is upregulated between ElO and Ell in 
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the AGM region. Moreover TAB2 protein expression was observed in/near the Ell 
endothelium of the dorsal aorta within the AGM region, the site where HSCs are located 
6
•
34
•
37
.43. Human T AB2 was originally identified as a binding partner of the MAPK family 
member TAKl (TGF~ activated kinase 1) and shown to be involved in IL-l and RANK 
signaling 3551 . TAB2 has been proposed to function as an adapter protein, involved in 
binding TAKl to TRAF6 and bringing the signaling proteins in close proximity of the IL-l 
receptor complex, resulting in NFKB and JNK activation 51 '52 . In addition, in neuronal cells 
T AB2 is found in a complex with NFKB at the promoter of several IL-l responsive genes 1. 
The pro-inflammatory cytokine interleukin-1 (IL-l) has been studied intensely for 
its role in normal physiology and disease. Depending on the target tissue, the cellular 
context and the local concentration, IL-l can exert several different biological effects, of 
which induction of fever and mediating inflammatory responses are the best known7. 
However, IL-l has also implicated as a regulator of adult mouse and human bone marrow 
hematopoietic stem and progenitor cells. Expression of IL-l and the IL-l receptor has been 
observed, both at the RNA level and at the protein level, in adult bone marrow populations 
enriched for HSCs and progenitor cells25'33·55•56. Furthermore, functional studies show 
several IL-l mediated effects on HSCs and progenitor cells, including radio-protection, 
growth and/or differentiation and changes in cell adhesion and migration. 
The radio-protective effects of IL-l have been shown both in vitro on cultured 
bone marrow cells as well as in vivo upon administration to mice. IL-l addition prior to 
irradiation resulted in enhanced long-term hematopoietic recovery 38.42•59 . It has been 
proposed that contributors to this effect include upregulation of the anti-oxidant enzyme 
Manganese Superoxidase Dismutase (MnSOD) as well as IL-l induced G 1 phase cell cycle 
arrest which correlated with increased resistance to cytotoxiciif· 11 . Moreover, IL-l has 
been shown to increase the production of other cytokines, including IL-6, GM-CSF and 
stem cell factor (SCF or kit ligand), which could play a role in the accelerated 
hematopoietic recovery upon irradiation (reviewed in 7). The finding that blocking 
antibodies against the receptor c-kit or its ligand SCF, IL-6 or IL-l itself could diminish the 
radio-protective effect of IL-l underlines the importance of the cooperation of IL-l with 
other cytokines in exerting its effects39.42. Besides increasing the expression of several 
cytokines, it was shown that IL-l in combination with other hematopoietic growth factors 
could induce expansion of hematopoietic progenitor and myeloid precursor cells 3•16•21 . 
However, other studies report that IL-l induces differentiation rather than expansion of 
hematopoietic progenitor cells or that IL-l completely abrogates HSC activity 2658. As 
these studies were performed with different populations of bone marrow cells, different 
amounts and combinations of (hematopoietic) growth factors, it is difficult to compare 
these results. Nevertheless, the fact that in some studies IL-l has a positive effect on the 
proliferation of hematopoietic stern/ progenitor cells together with the reported expression 
of IL-l and the IL-l receptor in hematopoietic stern/ progenitors cells25•32•33 suggests that 
IL-l is a positive regulator of adult HSCs and hematopoietic progenitor cells under certain 
circumstances. 
Despite the intense investigations regarding the role of IL-l as a regulator of HSCs 
in the adult, very little is known about the regulatory role of IL-l during development. 
Since expression ofthe IL-l signaling component mTAB2 in the dorsal aorta endothelium 
correlates with the emergence of HSC activity in this region, we set out to investigate 
whether IL-l is a regulator of HSCs in the midgestation embryo. Here we show that several 
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components of the IL-l signaling pathway are expressed and that IL-l signaling is 
functioning in AGM and liver from Ell onwards. More detailed expression analysis of the 
IL-lRI revealed expression in/ near the endothelium of the Ell and El2 dorsal aorta and is 
co-expressed on c-kit, Mac-1 + and CD45+ AGM and liver hematopoietic cells. 
Furthermore, long-term transplantation studies reveal IL-l mediated increases in HSC 
activity in the AGM region and fetal liver upon organ culture. To our knowledge this is the 
first study to address the role of the cytokine IL-l as a regulator of HSCs in the 
midgestation mouse embryo. 
Material and Methods 
Embryo generation and cell culture 
Animals were housed according to institutional guidelines, with free access to water and 
food. Animal procedures were carried out in compliance with the Standards for Humane Care and 
Use of Laboratory Animals. To generate embryos, matings were set up between (CBAxC57/BL10) 
Fl females and males. For the transplantation studies transgenic males (Ly6A-GFP and ln72 human 
~-globin) were used for generating embryos. The day of the vaginal plug was counted as day 0. 
Pregnant mice were sacrificed by cervical dislocation and AGM regions and livers were dissected as 
described 6•37. For obtaining single cell suspensions of embryonic material, tissues were collagenase 
treated (0.125% collagenase in PBS/ 10% FCS) for 1 hour at 37°C. 
3T3 fibroblasts were cultured in DMEM/ 10% FCS and for some experiments overnight 
serum starved with DMEM/ 1% FCS. Cell suspensions from several AGM (or liver) tissues were 
pooled and equivalents of2-4 tissues were seeded in 6 well plates in DMEM/ 10%FCS. The next day 
cells were stimulated with IL-l~ for target gene induction and IKB degradation studies. 
RNA isolation, eDNA synthesis and RT-PCR analysis 
Total RNA was isolated with TRIZOL (Gibco/ Life Technologies) according to 
manufacturer's instructions and DNAse treated with RQl RNase free DNAse (Promega). For eDNA 
synthesis 1-5 11g of total RNA was reverse transcribed with Superscript II reverse transcriptase 
(Invitrogen/ Life Technologies) according to manufacturer's instructions. 
PCR reactions were performed in 50 ~-tl with lU Amplitaq (PerkinElmer) and provided 
buffer, 100 ng of each primer, lmM dNTPs, and 2 ~-tl of eDNA. PCR cycles as follows: 5 min 92°C, 
27-40x (40 sec 92°C, 40 sec 58°C, 1-2 min 72°C), 7 min 72°C. PCRprimers are listed in Table 1. For 
semi-quantitative RT-PCR analysis several eDNA dilutions were used for RT-PCR. PCR products 
were run on 1.2% agarose/lxTBE gels with EtBr and scanned on a Typhoon scanner (Molecular 
Dynamics) and analyzed with ImageQuant software. 
IL-l induced target gene induction and IKB degradation 
3T3 cells were treated with 10 pg/ml-1 00 ng/ ml IL-l~ (Tebu Bio) for indicated times. Cells 
were scraped from tissue culture plates in cold PBS, pelleted by centrifugation and lysed in TRIZOL. 
eDNA synthesis and RT-PCR analysis as described. Cells from AGM (or liver) tissues were 
stimulated with IL-l~ for indicated times and all cells (non-adherent and adherent) were harvested for 
RNA isolation and RT-PCR analysis. 
To examine if gene induction was independent of protein synthesis, cells were pre-treated 
with cyclohexamide (Sigma) at a final concentration of 10~-tg/ml for 1 hr prior to IL-l~ stimulation. 
For blocking IL-l~, 2000 fold excess (200ng) IL-l blocking antibody (R&D systems) was incubated 
with IL-l~ (1 00 pg) for 2 hours on ice prior to addition to the cells. 
For IKB degradation studies, El2 liver cells and 3T3 cells were stimulated with lOng/ml 
and lOOng/ml IL-l~ respectively for 0-30 min. Protein lysates were made with RIP A buffer, separated 
on 10% SDS-PAGE and blotted against PVDF membrane (Millipore). Blotted membranes were 
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blocked with 4% non-fat milk (Biorad)/TBS-T and incubated with IKB antibody (Cell signaling 
Technology) followed by a-Rabbit-HRP (DAKO) and visualized with ECL detection. 
Organ cultures and in vivo transplantation assays for HSC activity. 
Ell AGM and liver tissues (marked with GFP or human ~-globin) were dissected and 3 day 
organ cultures were performed as described previously 34 in the presence of 0, 1 or 10 ng/ml IL-l~ 
(TebuBio). After the culture single cell suspensions were obtained and different cell dilutions 
(measured as embryo equivalents) were injected intravenously together with non-marked 2x105 
spleen cells into 9.5 Gy irradiated (CBAxC57BL/lO)Fl recipient mice. For the expression analysis, 
cultured tissues were homogenized in TRIZOL and processed as described. 
Repopulation was assayed at 1 and 4 months post-transplantation by donor specific PCR 
(human ~-globin or GFP) on peripheral blood DNA as described previously 5. Only mice with> 10% 
engraftment were considered repopulated. For multi-lineage repopulation analysis DNA was isolated 
from spleen, thymus, bone marrow and peripheral blood and assayed for donor contribution by PCR. 
T bl 1 RT PCR a e . - . pnmer sequences 
Primer name Primer Sequence (5'-3') product accession 
size number 
~-actin for CCTGAACCCTAAGGCCAACCG 397 X03672 
B-actin rev GCTCATAGCTCTTCTCCAGGG 
Bcl-2 for GCACAGATGTCCAGTCAGCTG 268 NM 009741 
Bcl-2 rev GCCATATAGTTCCACAAAGGC 
IL-lRacP for GAAATAGCCTCAGCTCACACAG 458 NM008364 
IL-lRacP rev CTCTGTTCCACCTCAGACTC 
IL-lRI for ACCTCACTTCTCCTGGATCC 300 NM008362 
IL-lRI rev GGGGTACAAAGAACAAGGCG 
IL-lRIIfor CCAGCATCATTGGGGTCAAG 435 NM010555 
IL-1RII rev CCTGGTTGTCAGTCCGTAGC 
IL-6 for GACTTCACAGAGGATACCAC 442 NM 031168 
IL-6 rev CTCCAGCTTATCTGTTAGGAG 
IRAK4for CATGACCAGCCGAATCGTGG 282 AF445803 
IRAK4rev CAGACACTGGCTAGCAGCAG 
JunB for GCAGCTCACACACTGGACTC 296 BC003790 
JunB rev CTTTAGACACGAAGTGCGTG 
MMP9 for ATGTGTCCCACTATACCTCC 464 X72794 
MMP9rev GACCCAACTTATCCAGACTC 
MnSOD for CATCCACTTCGAGCAGAAGG 442 X06683 
MnSODrev AGTCTGAGACTTCAGACCAC 
SCF for CTTTGGTGAACTTTCATGTG 1042 NM 013598 
SCFrev TGTGGATCACTCCTAAGCCC 
TABl-910 for CAGGCCAACCAGGATTGC 454 NM 025609 
TABl-1360 rev GAGCTGGAGCTGCTGCTCTG 
T AB2-1680 for TGCTGGTGCACCAGAAGGCCAGGATG 686 BC004813 
TAB2-2350 rev GTCTCTCAGGCCTTTCAGGTG 
TAK1-3'UTRfor GTGGTACATTACAGAGGGAC 412 BC006665 
TAK1-3'UTRrev CCGATAGCTCAGCTCAAGCC 
TRAF6for CATTTATGCACCTGGAAGCC 423 NM 009424 
TRAF6rev CCCATGGAAGCACAGTGAAG 
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FACS analysis 
Single cell suspensions were stained with IL-lRl (BD biosciences) antibody followed by a-
rat-biotin (BD biosciences), streptavidin-PE (Caltag) antibodies on ice for 30 minutes. Cells were co-
stained with FITC labeled antibodies for c-kit, MAC-1 or CD45 (Pharmingen). Dead cells were 
excluded by 7AAD (Molecular Probes) and FACS analysis was performed on FACScan (Becton 
Dickinson). 
Immunohistochemistry 
Embryos were snap-frozen in TissueTek (Sakura) and 7-lO~M cryosections generated. 
Sections were fixed in 2% paraformaldehyde/ PBS and endogenous peroxidase activity was blocked 
with 1.2% H20 2/ MeOH. Sections were blocked with TSA blocking buffer and incubated with IL-Rl 
antibody (BD biosciences) overnight at 4°C. Subsequently, sections were incubated with a-rat-biotin 
antibody and streptavidin-HRP (DAKO) in combination with TSA biotin system (PerkinElmer) 
according to provided instructions. Staining was visualized with DAB chromogen (Sigma) and 
sections counterstained with hematoxylin. Sections were embedded with Entallan (Merck). 
Results 
IL-l signaling components are expressed in the midgestation AGM and liver. 
Recently, we reported upregulated expression of mTAB2 in the mouse AGM 
region, at the time when the first adult repopulating HSCs are being generated43 • As TAB2 
is the binding partner of TAKl in the IL-l receptor signal transduction pathwal1'52, we 
examined whether other components of the IL-l signaling pathway are expressed in the 
midgestation AGM region and liver. Therefore, RT-PCR expression analysis was 
performed for the IL-l receptors I and II, the IL-l co-receptor IL-lRAcP (receptor 
associating protein) and for IL-l signaling mediators (TABl, TAB2, TAKl, TRAF6 and 
IRAK-4) on El 0 AGM and Ell and El2 AGM and liver cDNAs. 
As shown in Figure 1, the transcription of Tab2 and Takl is initiated between ElO 
and Ell in the AGM region. Tabl is expressed in the ElO AGM (data not shown) and 
thereafter all 3 genes are expressed in the Ell and El2 AGM and liver. IL-l receptor 
signaling is mediated via the IL-l RI and the IL-l RAcP co-receptor. Expression of both Il-l 
receptor genes was observed in the Ell and El2 AGM and liver. Moreover, the expression 
of Il-lfJ and the non-signaling Il-lrii can be detected from Ell onwards in the AGM and 
liver. No expression of Il-lfJ, Il-lri and Il-rii could be detected in the ElO AGM. Thus, Il-
lrL Il-lrii and Il-lfJ transcription is initiated between ElO and ElL In contrast, initiation 
and upregulation of the Il-lracp occurs one day earlier (at ElO). Also, the essential 
signaling mediators of the IL-l signaling cascade, Traf6 and Irak-4, are highly expressed 
from E 10 onwards in both AGM and fetal liver tissue. 
These data show at transcriptional level that several components essential for IL-l 
receptor signaling are initiated and expressed at ElO and/or thereafter in the AGM region. 
Interestingly, this temporal expression pattern of the Il-l receptors parallels the emergence 
ofHSC activity in this region. 
IL-l signaling is functional in the AGM and fetal liver from Ell onwards 
To determine whether the IL-l signaling pathway functions in the midgestation 
AGM region and liver, we tested for the activation of IL-l target genes in in vitro cultures. 
IL-l receptor signaling can be measured by NFKB or JNK activation in target cells upon 
IL-l stimulation (via reporter assays, kinase assays or via IKE degradation)9 or by 
regulation of known IL-l target genes, such as JunE, Il-6 or Mnsod7,! 2. 
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Figure 1. Expression analysis of IL-l 
signaling components in the AGM 
region and liver. 
RT-PCR analysis was peiformed to 
determine the expression of the IL-l 
receptors I and II (IL-lRI and IL-lRII), 
the IL-l accessory receptor (IL-lRAcP) 
and several downstream signaling 
components, including TAK-1, TAB2, 
TRAF6 and IRAK-4 in the midgestation 
AGM region fetal liver. RNA was 
isolated from El0-El2 AGM and liver 
and used for eDNA synthesis and RT-
PCR under standard conditions. For 
IRAK4 each primer set optimal conditions were 
determined and PCR was peiformed for 
TRAF6 30-40 cycles. Besides the differential 
expression of TAB2, also TAKl, IL-lRI, 
actin IL-lRII, IL-lRAcP and IL-1/3 are 
differentially expressed between ElO and 
Ell in the AGM region. Moreover, the 
downstream signaling components IRAK-4 and TRAF6 are expressed from ElO onwards in the AGM 
and liver. RT=reverse transcriptase 
Conditions for the transcriptional induction of JunB by IL-l were tested first in 
embryonic 3T3 fibroblasts. Cells were either left untreated or stimulated with lOng/ml IL-
lp for 30 minutes, 1 hour or 2 hours. Subsequently RNA was isolated and used for eDNA 
synthesis. Semi-quantitative RT-PCR for JunB (Figure 2A) was normalized against Actin 
expression levels to calculate the fold induction of JunB gene expression by IL-l P (Figure 
2B). This analysis revealed that JunB levels increased upon IL-l stimulation peaking at 1 
hour with a 4.5 fold higher expression level as compared to untreated cells. Furthermore, 
3T3 cells were stimulated with (lOpg/ml) IL-lP in the presence of cyclohexamide or an 
antibody that neutralizes IL-lP activity (Figure 2C). Since JunB is an immediate early 
target gene of IL-l signaling, inhibition of protein synthesis by cyclohexamide should not 
result in a decrease of JunB induction by IL-l. As expected IL-l induced JunB expression 
is not reduced in the presence of cyclohexamide and the fold induction is similar to that 
found in the previous experiment (3.5 fold versus 4.5 fold Fig.2B). More importantly, the 
IL-l blocking antibody is able to reduce JunB expression levels similar to that found in 
untreated cells, confirming that the increase of JunB expression is indeed specifically 
induced by IL-lp. Hence, this RT-PCR analysis can be used to specifically measure IL-lP 
target gene induction in cells. 
ElO, Ell and El2 AGM and liver tissues were dissected and cells were cultured 
overnight prior to IL-lP stimulation. Increased JunB expression (range 2.5-60 fold; n=5) 
was detected in Ell and E12 AGM and liver cells treated with IL-lP for 30 min up to 2 
hours as compared to untreated cells (Figure 2D/E). Additionally, IL-lp induced 
upregulation of other target genes, including Mnsod and Il-6, was observed (Fig. 2D/ E and 
data not shown). In order to more specifically quantify the results from the RT-PCR 
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analysis we performed eDNA dot blot analysis. Similar results were obtained (data not 
shown). Treatment of Ell AGM cells with cyclohexamide prior to IL-l stimulation did not 
result in a complete inhibition of IL-l induced JunE expression (Figure 2F). Consistent 
with our RT-PCR expression analysis in which we did not observe expression of the IL-l 
receptor in ElO AGM cells, we were unable to detect induction of junB expression upon 
IL-l stimulation in these cells (data not shown). 
Another well established method to determine IL-l signaling is based upon IL-l 
induced IKB degradation, which is a prerequisite for NFKB activation and signaling. 
Therefore, we also performed Western blot analysis for IKB on untreated and IL-l 
stimulated 3T3 and El2 liver cells. As shown in Figure 2G, IL-l stimulation results in IKB 
degradation in both El2 liver and 3T3 cells. The observation that in El2 liver cells 
moderate levels of IKB protein can still be detected after IL-l stimulation is likely due to 
the fact that IKB is expressed in cells that do not express the IL-lR, and therefore IKB in 
these cells is not targeted for degradation. 
Altogether, these experiments show that IL-l~ is able to increase the expression of 
known IL-l target genes in Ell/ El2 AGM and liver cells and these results correlate with 
the detected expression of the IL-l receptor and its signaling components within these 
tissues. Moreover, also at the protein level as measured by IKB degradation, IL-l signaling 
is functional in El2 liver cells. Together, these data show that a population of cells within 
the Ell/ El2 AGM and fetal liver are IL-l responsive and contain functional IL-l signaling 
properties. 
The IL-lRI is expressed on hematopoietic cells in the Ell AGM and liver. 
To further investigate whether expression of the IL-lRI coincides with a specific 
population of cells (i.e. hematopoietic), flow cytometric analysis was performed on AGM 
and liver cells. Expression of the IL-lRI was examined in combination with CD45, c-kit or 
Mac-1. CD45 is a pan-hematopoietic marker, while c-kit and Mac-1 have been used to 
enrich for HSCs in the Ell AGM and liver46• 
As shown in a representative experiment (Figure 3A), expression of the IL-lRI in 
Ell AGM tissue can be readily detected above background levels (top panels). Moreover, 
we observed the expression of c-kit, CD45 and Mac-1 on IL-lRI expressing Ell AGM 
cells (lower panels). Further FACS analyses (summarized in Figure 3B) reveals that in the 
Ell AGM and liver approximately 0.5-3.7% of the cells are IL-1RY/CD45+ and that almost 
all (85%) IL-lRl+ cells are CD45+. FACS analysis for the IL-lRl in combination with c-kit 
in the Ell AGM and liver shows that 0.5-5.0% of the cells are IL-lRI+/c-kit. 
Approximately half(42-52%) ofthe IL-lR+ cells in these tissues also expressed c-kit, while 
only 7-19% the c-kit+ cells also express the IL-lRl. Also 36-38% ofthe IL-lRY AGM and 
liver cells are Mac-1+ and in the liver more Mac-1+ cells are IL-lRI+ (62%) than in the 
AGM region (33%). Thus, there appears to be great overlap in the expression of HSC 
markers and the IL-l RI in the cells of E 11 tissues that harbor HSCs, suggesting that HSCs 
express the IL-lRI. This is further supported by FACS data from subdissected Ell aorta 
tissue in which 0.6% of the cells arc IL-lRI+/c-kit+, 1.1% of the cells are IL-1RI+/CD45+ 
and 0.9% of the cells are IL-lRI+/Mac-1+ (data not shown). 
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Figure 2. IL-l signaling in 3 T3 fibroblasts and midgestation A GM and liver cells. 
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- (A) 3T3 fibroblasts were stimulated with IL-lfJ (10 nglml) for 0 min, 30 min, 1 or 2 hrs and RNA was 
isolated and used for eDNA synthesis. Serial dilutions of the eDNA were used for semi-quantative RT-
PCR and analysis was peiformed with Typhoon and ImageQuant software. IL-lfJ stimulation of 3T3 
fibroblasts results in increased expression of the IL-lfJ target gene JunE as determined by semi-
quantitative RT-PCR. (B) Fold induction of JunE expression induced by IL-lfJ stimulation in 3T3 
cells. Results calculated from RT-PCR values. (C) Schematic presentation of the RT-PCR results (fold 
induction) show that IL-l fJ induced JunE gene induction in 3T3 fibroblasts can be blocked with an IL-
lfJ blocking antibody (Ab) and th'at cyclohexamide (CHX) does not inteifere with the induction of the 
immediate early JunE target gene. (D) Single cell suspensions of Ell AGM and liver cells were 
treated with IL-lfJ (10 ng/ml) for 0, 30, 90 or 120 min. RNA was isolated and eDNA generated and 
used for semi-quantitative RT-PCR analysis. Representative semi-quantative RT-PCR for the IL-lfJ 
target genes JunE and MnSOD. In Ell AGM and liver cells a clear induction of JunE expression is 
observed within 30 min after IL-lfJ stimulation. For MnSOD only in. Ell AGM a clear gene 
expression induction is observed upon IL-lfJ stimulation. In Ell liver cells, the IL-lfJ stimulation does 
not increase the high basal level of MnSOD gene expression. (E) Fold induction of JunE and MnSOD 
expression after IL-lfJ stimulation of AGM and liver cells as calculated from RT-PCR values. (F) IL-
lfJ induced JunE target gene expression in Ell AGM cells is slightly inhibited by cyclohexamide 
(CHX). (G) IL-lfJ stimulation of El2 liver cells (left panel) or 3T3 fibroblasts (right panel) results in 
rapid IK:B degradation. 
To test whether co-expression of the IL-lRl with the hematopoietic (stem) cell 
markers CD45, c-kit and Mac-1 is restricted to hematopoietic cells during development or 
whether this could also be observed in the adult, we performed similar F ACS analysis on 
adult bone marrow samples (n=3). Again we observed co-expression of the IL-lRl with 
CD45+, c-kit and Mac-1 +cells. In contrast to the Ell AGM and liver where approximately 
85% of the IL-l Rl+ cells express the CD45, in the bone marrow all IL-l R + cells express 
CD45, suggesting that the IL-lRl in the bone marrow is expressed exclusively on 
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IL-1Rrlc-kit+ 5.2 (3.8-8.6) 25.4 (13.0-33.1) 7.9 (6.1-10.5) 
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IL-1RI-/CD45+ 0.8 (0.5-1.0) 9.4 (7.7-11.2) 81.9 (76.2-85.3) 
IL-1RI+/CD45+ 1.7 (0.5-2.3) 2.3 (1.6-3.7) 6.8 (3.9-12.3) 
IL-lR.f' /Mac-r 0.7 (0.2-1.3) 1.1 (0.9-1.4) 1.8 (1.3-2.9) 
IL-lRI-/Mac-1+ 0.6 (0.5-0.7) 2.9 (1.8-4.2) 49.6 (47.4-52.2) 
IL-lRI+ /Mac-1 + 1.2 (0.4-1.8) 1.8 (1.2-2.2) 4.6 (2.1-8.6) 
Figure 3. Expression of the IL-JRI with c-kit, CD45 and Mac-] in the Ell AGM and liver and 
adult bone marrow. 
As the IL-IRI is known to be expressed in primary cells with few receptors per cell (as low as 50 
receptors per cell 7) FACS staining for the IL-IRI was peiformed with intermediate biotin-
streptavidin-PE steps to enhance the signal. (A) The representative FACS analysis plots in the 
top row show the results of Ell AGM cells with no antibody (left), without the IL-IRI antibody 
(only the secondary antibody and streptavidin-PE; middle) or stained with the IL-IRI antibody 
(right). In the bottom panel the results for AGM cells stained with IL-IRI in combination with c-
kit, CD45 or Mac-] are shown. The percentages of positive cells are shown in each quadrant. 
(B) The table summarizes the FACS data (percentages of single and double positive cells) from 
Ell AGM and liver from 4 independent experiments with 6 litters of embryos. The data for adult 
bone marrow are derived from 2 independent experiments with 3 adult male mice. 
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hematopoietic cells. Most interestingly, approximately 30% of the c-kit+ BM cells express 
the IL-lRl, suggesting that the IL-lRI may indicate a subpopulation ofBM HSCs. 
Taken together, these data demonstrate that the IL-lRI is expressed mainly on 
hematopoietic cells and possibly HSCs in the midgestation AGM and liver and, in the adult 
BM is expressed only on hematopoietic cells. 
High IL-lRI expression is localized to the midgestation dorsal aorta. 
To more specifically localize IL-lRI expressing cells in the Ell and El2 AGM we 
performed immunohistochemistry. As shown in Figure 4A, expression of the IL-lRI can be 
found in/ near the endothelium of the dorsal aorta at E 11. Highest expression is found at the 
ventral aspect of the aorta, the site harboring hematopoietic clusters which are believed to 
contain HSCs. At El2 the staining for the IL-lRI is more intense at the ventral aspect and 
can also be found around the entire circumference of the dorsal aorta (Figure 4B). IL-lRI 
expression is localized in/near the endothelium of the dorsal aorta. Thus, the temporal and 
spatial expression of the IL-lRI suggests that it may play a role in HSC development. 
A 
B 
Figure 4. IL-JRI is expressed in the 
aorta of midgestation A GM region 
Transverse cryosections of the trunk 
region ofE11/El2 embryos. The dorsal 
site is at the top and ventral site is at 
the bottom of each section. 
Immunohistochemistry was performed 
with an IL-lRI antibody. The left 
panels show the negative control (no 
IL-lRI antibody) and the right panels 
show sections stained with the IL-l RI 
antibody (A) Ell section (original 
magnification lOOx). (B) El2 section 
(original magnification 200x). In the 
E 11 embryos the staining for the IL-
lRI is located mainly at the ventral side 
of the dorsal aorta and at El2 the 
staining for the IL-lRI is more intense 
and located around the dorsal aorta. 
IL-lP increases HSC activity in the AGM and fetal liver 
As IL-l signaling is functional in AGM cells and the IL-lRI is expressed in the 
Ell/ El2 dorsal aorta as well as on c-kit expressing cells, we investigated whether IL-l~ 
affects HSC activity in the Ell AGM and liver by explant cultures. The previously 
described 3 day organ culture system was used, in which HSCs are increased and/or 
maintained in the AGM and liver tissues6·30J 7. Ell AGM or liver explants were cultured in 
the presence or absence of 1 ng/ml or 10 ng/ml IL-l~ for three days. After the culture a 
single cell suspension was obtained and different amounts of cells (0.3-2ee; embryo 
equivalents) were injected into lethally irradiated recipients (Figure SA). Four months post-
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transplantation, PCR analysis for the donor marker was performed on peripheral blood 
DNA of the recipients. 
As shown in Figure 5B, upon transplantation of 1 ee, the HSC activity in AGM 
tissue cultured in the presence of a low concentration (lng/ml) IL-l~ is higher as compared 
to AGM cultured without IL-1~ (100% vs. 57% mice). However, a higher concentration 
(lOng/ml) IL-l~ did not clearly affect HSC activity in the AGM (50% mice repopulated) as 
compared to the tissues cultured in the absence ofiL-1~. Similar results were obtained with 
0.3ee of transplanted AGM tissue. For cultured Ell liver tissues, regardless of the 
concentration of IL-l~' the presence of IL-l~ during the culture period increased the HSC 
activity. Multi-lineage analysis was performed on a number of repopulated recipients. In all 
cases high level repopulation was observed in all hematopoietic tissues tested (data not 
shown). 
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FigureS. IL-l increases 
HSC activity in Ell 
AGM and liver organ 
cultures. 
(A) Schematic overview 
of the protocol used to 
examine the effects of 
IL-l on HSCs. From 
Ell embryos (marked 
with Sca-1-GFP or 
human fJ-globin) AGM 
or liver tissues were 
dissected and cultured 
for 3 days on a filter at 
a liquid-air interface in 
the presence or absence 
of IL-l fJ. After _3 days, 
single cell suspensions 
were obtained by 
collagenase treatment 
and injected into 
lethally-irradiated 
recipients at 0.3-2 
embryo equivalents (ee). 
Four months after the 
transplantation PCR 
analysis for the donor 
marker (GFP or human fJ-globin) was peiformed to determine hematopoietic repopulation of the 
recipients. Only those recipients with greater than 10% donor-derived reconstitution are considered 
repopulated. (B) Results of the transplantation assay from the organ experiments in the presence ofO, 
1 or 10 ng/ml IL-lfJ. Addition of 1 ng/ml IL-1/3 to the AGM and liver organ cultures results in 
increased numbers of repopulated recipients at different doses of injected cells. At the concentration 
of 10 ng/ml IL-1/3 no clear effect is observed in the AGM organ cultures. Increased numbers of 
repopulated recipients are observed with liver tissue cultured with 1 or 10 ng!mliL-lfJ as compared 
to the recipients injected with control liver tissue (Ong/ml IL-lfJ). Results in this graph are derived 
from 4 independent transplantation experiments. The bars represent the percentage of repopulated 
recipients and the numbers above the bars indicate the number of repopulated recipients out of the 
total number of recipients injected. 
96 
lnterleukin I signaling in the AGM region; novel insights into HSC regulation 
Expression analysis of cultured Ell AGM and liver tissues 
Based on the results from the transplantation assays showing long term, high level, 
and multi-lineage engraftment ofthe recipients, we conclude that IL-l~ can increase LTR-
HSC activity in both the Ell AGM region and liver upon culturing. Moreover, we show 
that the effect of IL-l~ is concentration-dependent, with lower concentrations having a 
more potent effect than a higher concentration on the LTR-HSC activity in the Ell AGM 
and liver. 
The effect of IL-l resulting in increased HSC activity in the cultured AGM and · 
liver tissues could be due to increased HSC proliferation, decreased HSC apoptosis or 
altered properties of the HSCs or the microenvironment. To gain insight into the processes 
affected by IL-l during the culture of AGM and liver tissues, we performed RT-PCR 
expression analysis on freshly isolated (non-cultured) Ell AGM and liver and tissues 
cultured either in the presence or absence of IL-l~· Since IL-l is known to regulate 
expression of the IL-l receptors and of IL-l itself, we first investigated expression of these 
genes. As shown in Figure 6, expression of the Il-lrl and Il-lracp remains unchanged 
during the culture period, either in the presence or absence of IL-l. Moreover the 
expression level is similar to that of non-cultured AGM or liver tissue. However, the 
expression of Il-l and the non-signaling Il-lrii seems to be upregulated in tissues cultured 
in the presence of IL-l. In addition, the expression level of the IL-l signaling component, 
Tab2 is similar in non-cultured and cultured tissues. 
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Figure 6. Expression analysis of cultured Ell A GM and liver tissue. 
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RNA was isolated from fresh, non-cultured Ell AGM and liver tissue or from tissues cultured for 
three days in the presence ofO, 1 or 10 ng/ml IL-1{1 in an organ culture system as used for eDNA 
synthesis. RT-PCR analysis reveals that expression ofTAB2, 1L-1RI, IL-1RAcP and stem cell factor 
(SCF) remains relatively constant throughout the culture period as well as compared to non-
cultured tissues. Expression of both the decoy IL-1RII and IL-1{1 appears to slightly increase 
during the culture period in tissues cultured in the presence of IL-1{1. Interestingly, expression of 
the matrix metalloproteinase-9 (MJYfP9) is induced in AGM and liver tissue cultured in the 
presence ofiL-1{1. 
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To investigate whether IL-l could play a role in proliferation or apoptosis ofHSCs 
during the culture period we also examined the expression of the HSC growth factor Scf 
(kit-ligand) and the anti-apoptotic Bcl-2 gene. The expression of both genes remained at 
similar levels in the liver cultures in the presence or absence of IL-l and in comparison to 
non-cultured liver tissue. However, Bcl-2 expression appears to increase in AGM explants 
as compared to non-cultured tissue. For another anti-apoptotic gene, Bcl-x, we observed an 
increase in expression in the liver tissue cultured in the presence of IL-l as compared to 
tissue cultured in the absence of IL-l. In cultured AGM tissue Bcl-x expression was 
unchanged in the presence of IL-l (data not shown). Most interestingly, the Matrix 
metalloproteinase-9 (Mmp-9) gene was upregulated dramatically when AGM and liver 
tissue was cultured in the presence of IL-l~- Previously, MMP-9 has been implicated in 
both IL-l and SCF processing22•24A8 and thus the expression changes observed after the 
culture of AGM and liver with IL-l suggest a role for IL-l signaling in hematopoietic and! 
or HSC regulation. 
The role ofT AB2 in IL-l induced effects. 
The previously reported TAB2 expression in the AGM region43 and the IL-lRI 
expression as reported here, show that TAB2 is expressed in a temporal and spatial manner 
similar to the IL-lRI. Since it was been reported that in neuronal cells TAB2 is translocated 
from the nucleus to the cytoplasm upon IL-l stimulation\ we investigated whether this IL-
l induced translocation ofTAB2 could also take place in hematopoietic cells. 
Therefore we tested a hematopoietic progenitor cell line 416B and control 3T3 
fibroblast cells for their ability to translocate T AB2 upon IL-l stimulation. The 416B 
hematopoietic progenitor cell line was chosen for this study because of the technical 
limitions imposed by the scarcity of AGM and fetal liver HSCs. In untreated 416B and 3T3 
cells we observed highest levels ofTAB2 in the nucleus and lower levels in the cytoplasm. 
Upon IL-l stimulation, we were unable to observe TAB2 translocation from the nucleus to 
the cytoplasm in either cell line. Thus, IL-l induced TAB2 translocation may be specific to 
neuronal cells. A-lternatively, the cell lines used for these experiments may be transformed 
or may lack some (functional) component required for TAB2 translocation. Further 
investigations are required to reveal how TAB2 is involved in IL-l signaling in 
hematopoietic cells. 
Discussion 
Components of IL-l signaling pathway are expressed and functioning in the 
midgestation AGM and liver 
Hematopoiesis during development is a highly dynamic process and several 
factors are believed to be involved in the emergence and regulation of hematopoietic cells. 
Although several growth and differentiation factors have been identified to play a role in 
the induction and regulation of HSCs in the embryo, there are still gaps in our 
understanding of the processes that take place. Especially little is known concerning the 
role that cytokines play during development, while their role in adult hematopoiesis has 
been delineated to a great extent. Here we report that several components of the IL-l 
signaling cascade, including the cytokine Il-l, the receptors Il-l rl, II and Il-l racp as well as 
several signaling mediators are differentially expressed between ElO and Ell in the AGM 
region. Appearance of their expression coincides with the emergence of HSC activity in 
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this region. Besides expression of these genes we also show that IL-l signaling is functional 
by means of induction of gene expression of known IL-l target genes and by IKE 
degradation. 
A large number of lL-1 target genes are known (reviewed in 7) and these include 
cytokines and their receptors, adhesion molecules, acute phase reactants, pro-inflammatory 
mediators and transcription factors. TAKl, the binding partner of TAB2, was shown 
previously to mediate the IL-l induced JunE gene expression12• Since both TAKl and the 
IL-l receptor are differentially expressed from Ell onwards in the AGM region, JunE was 
one of the most obvious target genes for our investigations. Indeed, we found potent JunE 
induction upon IL-l stimulation in Ell AGM and liver cells. However, JunE expression 
can also be induced upon cellular stress. Therefore, we confirmed the specificity of the IL-l 
mediated JunE gene expression induction with an IL-l blocking antibody. In 3T3 cells the 
induction of JunE expression by IL-l is similar in the presence or absence of the IL-l 
blocking antibody, showing that JunE induction is mediated via IL-l and is not due to 
cellular stress. Moreover, we also observed Mnsod induction, another target gene 
downstream of IL-l induced by NFKB signaling. Thus several downstream mediators of 
IL-l signaling are functioning in the midgestation AGM and liver. 
Figure 7. TAB2 intracellular localization in 3T3 fibroblasts 
3T3 cells were cultured on gelatin coated covers lips. serum-starved and subsequently stimulated with 
lOOng/mllL-lfJfor 0 min and 2 hours. Cells werejTXed andprocessedfor TAB2 immunojluoresence 
staining. (A)(B)(C) nuclear DAPI staining (D)(E)(F) TAB2 staining. (A)(D) negative control for 
TAB2 staining; (B)(E) untreated 3T3 cells (C)(F) 3T3 cells stimulated for 2 hours with IL-lfJ. TAB2 
is localized in both the nucleus and to a lower extent in the cytoplasm and no change in the 
intracellular TAB2localization is observed upon IL-lfJ treatment of the cells. 
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To further confirm that IL-l signaling indeed is functional we also employed 
Western blotting to detect degradation of IKE in 3T3 and liver cells. Upon IL-l receptor 
signaling the canonical NFKE pathway is activated in which IKE, the inhibitor ofNFKB, is 
phosphorylated and targeted for degradation, thereby relieving NFKE and allowing NFKE 
translocation to the nucleus and further regulation of target genes. As expected, we indeed 
found a decrease ofiKE protein expression rapidly after IL-l stimulation in El2 liver cells 
and in 3T3 cells. The fact that IKE protein expression in the El2 liver cells did not decrease 
as dramatically as seen in the 3T3 cells is likely due to the mixed population of cells within 
the El2 liver with only a small population of cells expressing the IL-lRl. 
Expression of the IL-lRI in midgestation hematopoietic organs and the effect of IL-l 
on HSC activity 
A closer investigation of protein expression analysis by F ACS and 
immunohistochemistry revealed that the IL-lRl in the Ell AGM is expressed in/near the 
endothelium of the dorsal aorta, with highest expression in the ventral aspect. However, in 
the El2 AGM, the IL-lRl expression is not restricted to the ventral aspect, but expression is 
observed in/ near the endothelium surrounding the entire aorta. Furthermore, F ACS 
analysis revealed that the IL-lRl is expressed on 19% of the c-kit+ cells, which marks the 
HSCs in the AGM. Also in the El2 AGM and Ell/E12.liver we found IL-lR+/c-kit cells. 
Together these results indicate that IL-l might be directly regulating HSCs. We further 
investigated this by performing organ cultures in the presence of IL-l~- These studies 
revealed that HSC activity, as detected by in vivo repopulation, in both the AGM and liver 
are increased upon IL-l~ stimulation as compared to non-treated control tissues. Together 
with the results showing expression of the IL-lRl in a population of cells in the E 11 AGM 
region and liver known to contain HSCs, these functional data indicate that IL-l might be 
an in vivo regulator acting directly on HSCs. Despite the fact that we observed a clear 
impact on HSC activity upon addition of IL-l~ during organ culture of AGM and liver 
tissue, previous studies of IL-l ligand and receptor deficient mice did not reveal a crucial 
role for IL-l during development. Mice deficient for Il-l a, ll-ljJ or the Jl:Jr] are viable, but 
display impaired immune function, most particularly within the innate immune system and 
lymphocyte activation18;23 . However, it cannot be excluded that other IL-l related proteins 
are functionally redundant with IL-l and mask the effects of IL-l deficiency8•29,49. 
Moreover, the observation that a lower concentration of IL-l had a more potent effect on 
AGM and fetal liver HSC activity than a higher concentration is similar as reported 
previously for adult BM HSCs 28. 
It is currently unclear what the impact of IL-l on AGM and liver HSCs is. 
Increased proliferation, decreased apoptosis or altered cellular characteristics of HSCs 
could be induced by IL-l. Further investigations will be aimed to determine these effects. 
These studies will include determining the amount of c-kit cells after organ culture in the 
presence or absence of IL-l, as well as BrdU incorporation studies to investigate the 
amount ofproliferation within the HSC population. Moreover, FACS analysis for Annexin 
or other apoptotic markers (i.e. TUNEL staining) could provide insight into apoptotic 
processes taking place under the influence of IL-l. Also, expression analysis for a panel of 
anti-apoptotic and pro-apoptotic genes, such as Bcl-2, Bim and Bcl-x, will be examined to 
gain insight in the role of IL-l on apoptosis in the AGM and liver HSC population. 
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Interestingly, during inflammatory processes IL-l is well known for its effects on the 
vascular endothelium by upregulating cell adhesion molecules, such as ICAM, for 
recruitment of leukocytic cells and for inducing the expression of chemo-attractant 
cytokines, such as IL-8, in epithelial and fibroblast cells7' 15'36 . IL-l has also been implicated 
in the mobilization of HSCs from the adult BM to the peripheral blood 17 and to enhance 
the adhesion of CD34+ bone marrow cells to bone marrow vascular endothelial cells 45'54. 
For this reason investigating the effects of IL-l on AGM HSC adhesion and migration 
would be interesting. Moreover,---the expression analysis in organ cultures revealed that 
Mmp-9 is upregulated in both the AGM and liver tissues upon organ culture in the presence 
of IL-l~- It had already been shown by others that IL-l induces Mmp-9 expression in 
vascular cells 10•14•19•20 . Moreover MMP-9 has been implicated in regulating the bio~activity 
of IL-l and SCF and in HSC migration within the adult bone marro~224A8 . Therefore 
Mmp-9 might be a very interesting IL-l target gene in the AGM and liver and may be 
involved in regulating HSC migration from the AGM to the liver and subsequently to the 
bone marrow. Further investigations should provide insight into the protein expression and 
functional activity ofMMP-9 in the AGM region and liver. 
The role ofTAB2 in IL-l signaling 
Although the role of TAB2 in IL-l signaling in the AGM region was not 
addressed in our present studies, we would like to discuss its potential role here. Our 
interest in the IL-l signaling pathway in the AGM region began when we found Tab2 gene 
expression upregulated in this tissue at the time of HSC emergence. TAB2 was originally 
proposed to function as an adapter protein in IL-l signaling. More recently, it was shown 
that IL-l signaling is not impaired in Tab2 deficient mice47 . However, Tab2 deficiency does 
results in an embryonic lethal phenotype around El2.5 due to fetal liver degeneration. 
Although the fetal liver is the main hematopoietic site in the embryo at El2.5, it was not 
investigated whether hematopoiesis or IL-l signaling in these cells is disturbed in Tab2 
deficient mice47 • Nonetheless, others have shown that in neuronal cells TAB2 is involved in 
NFKB activity regulation upon IL-l stimulation1, suggesting that TAB2 does play a role in 
IL-l signaling, although a different role than originally proposed. As shown in neuronal 
cells, we also wanted to investigate whether IL-l could regulate T AB2 translocation from 
the nucleus to the cytosol. However, we were unable to observe T AB2 translocation upon 
IL-l stimulation in 3T3 fibroblast and 416B hematopoietic cells. It is currently unclear why 
we failed to observe this translocation, although for the 416B cell line we also did not 
observe IKB degradation upon IL-l stimulation (data not shown) suggesting that IL-l 
signaling might be impaired in this transformed cell line. The fact that in 3T3 cells without 
IL-l treatment TAB2 is localized within both the nucleus and the cytosol might have 
interfered with detecting T AB2 translocation to the cytosol. However, we cannot exclude 
the possibility that some component required for TAB2 translocation is not functional in 
3T3 cells. Based on previous studies by others, -it appears that there is a role for TAB2 in 
IL-l signaling1'51 and that T AB2 may play an essential role in the main hematopoietic organ 
during midgestation development, the fetal liver, and possibly also in the AGM region, but 
that the specific function ofT AB2 is restricted to specific cell types. 
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In conclusion, this study reveals the differential expression of functional IL-l 
signaling components in the AGM coincident with the appearance of HSC activity in this 
region. We observed that IL-lR expression is detected in cell populations known to contain 
HSC activity and that IL-l can increase HSC activity of midgestation AGM and liver cells. 
Together these data strongly suggests that IL-l is a regulator of the first detectable adult 
repopulating HSCs during mouse development. 
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Abstract 
Apoptosis is an essential process ongoing throughout development and in tissue 
remodeling in the adult. It is also an essential process within the hematopoietic hierarchy, 
allowing tight regulation of subsets of hematopoietic cells. Overexpression of the anti-
apoptotic Bcl-2 protein in transgenic mice has been a useful approach to study the role of 
apoptosis in several hematopoietic lineages. Previously, it has been shown that ubiquitous 
Bcl-2 overexpression in the hematopoietic system increases the viability and activity of 
hematopoietic cells under normal and/or stressful conditions in the adult. However, a role 
for apoptotic processes in the embryonic hematopoietic system has not yet been established. 
Therefore, we generated transgenic mice overexpressing Bcl-2 under the control of the 
transcriptional regulatory elements of the hematopoietic stem cell (HSC) marker Sea-l. We 
show increased numbers and viability of Sea-l positive cells in the aorta-gonad-
mesenophros region (AGM), the first site of HSC generation. Moreover, we find increased 
HSC activity within the AGM and fetal liver. Together with data showing the normal 
expression of several pro-apoptotic and anti-apoptotic genes in the aorta, our results 
strongly suggest that apoptotic processes play a role in the development of HSCs. 
Introduction 
The hematopoietic system of adult mammals has its foundation in rare 
hematopoietic stem cells (HSC) harbored in the bone marrow. These cells are highly potent, 
contributing ultimately to the billions of mature hematopoietic cells in the blood and 
hematopoietic tissues throughout the lifetime of the individual 22.47. In the mouse embryo, 
the first HSCs are autonomously generated in the aorta-gonad-mesonephros (AGM) at 
midgestation 27 • The onset ofHSC activity occurs at embryonic day 10.5 (El0.5) and HSC 
activity increases until El4 in the liver 12•21 "27"31"33 . Thereafter, the number ofHSCs remains 
generally constant throughout life. The constant numbers ofHSCs in the adult bone marrow 
are thought to be maintained through self-renewing cells divisions, in which one daughter 
cell retains HSC function, while the other differentiates along the hematopoietic 
hierarchy10.41. 
The signals and processes by which HSCs are generated, expanded and/or 
maintained in embryonic, fetal and adult stages are largely unknown. The fact that HSC 
numbers increase significantly in the midgestation mouse while remaining constant in the 
adult suggests that there are differences in the processes controlling HSC numbers at 
different times in ontogeny 21 •27 . Although temporally-limited hematopoietic cell fate 
determination processes may be primarily responsible for generating more HSCs in the 
embryo, it is possible that the balance of programmed cell death and survival also plays a 
role in determining HSC numbers. 
Programmed cell death or apoptosis, is a highly conserved process involved in 
tissue remodeling during development and adult tissue homeostasis (as reviewed 13,28). 
Apoptosis is characterized by a number of stereotypic changes in cell structure, including 
DNA fragmentation and changes in the plasma membrane which are mediated by members 
of the caspase protein family, ultimately leading to cell death (reviewed in 6,15). 
Evolutionary conservation of this process extends from C.elegans to mammals, as 
illustrated by the high degree of functional and structural homology between several 
apoptosis related proteins. Within mammalian embryos apoptosis is involved in the 
remodeling of the limbs, kidney and other structures 2834• Hence, the correct temporal and 
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spatial expression of these proteins is a prerequisite for normal tissue development and 
homeostasis 4'14'28,42. 
The mammalian Bcl-2 protein family is divided into three subfamilies; the Bcl-2 
subfamily which promotes cell survival, the pro-apoptotic Bax subfamily, and the pro-
apoptotic BH3-only subfamily which includes Bim 1• Based on several biochemical and 
cellular findings it has been proposed that pro- and anti-apoptotic proteins counteract each 
other's function via protein-protein interactions (reviewed in 3,49). Bcl-2 expression is 
found in immature hematopoietic and lymphoid cells, cells of the peripheral nervous 
system, epithelial cells and in the stem cells of the intestine 16'29• Another pro-survival 
member of the Bcl-2 family, Bcl-x is also expressed within the hematopoietic system, 
nervous system and intestine 20'32• Differences in the expression patterns of these two 
closely related proteins, suggest some non-redundant roles for Bcl-2 and Bcl-x in vivo. 
Since Bcl-2 is highly expressed in mature thymocytes 23 (as compared to Bcl-x expression 
in immature thymocytes 24) it is thought to play a role in the thymocyte selection process. 
Indeed, overexpression of a Bcl-2 trans gene in T -cells increased cell survival and decreased 
negative selection 19A3A8. 
Apart from the lymphoid system, the role of apoptosis in regulation of 
hematopoietic progenitor and stem cells is far less understood. A number of studies have 
investigated the role of apoptosis in HSCs using transgenic mouse models in which Bcl-2 
overexpression is directed using the hematopoietic specific Vav promoter 39 or by use of the 
more generaVubiquitous H-2K promoter ll_ In both cases, overexpression of Bcl-2 within 
the HSC/hematopoietic progenitor compartment resulted in enhanced cell survival and 
radio-resistance of these cells 10' 11 '39 . However, the studies were limited to the analysis of 
adult and fetal hematopoietic cells, and did not study the effects of Bcl-2 overexpression in 
AGMHSCs. 
To more specifically analyze the role of Bcl-2 in HSCs during development, we 
describe the generation of transgenic mice overexpressing Bcl-2 under the transcriptional 
control elements of the Sea-l gene, Ly-6E/A. The Sea-l cell surface protein is expressed on 
HSCs and is commonly used f~r the enrichment of HSCs 46·50. We have previously 
demonstrated, using Sea-l LacZ or GFP transgenic mice, that functional repopulating 
HSCs from adult bone marrow, fetal liver and midgestation dorsal aorta (the site of the first 
emerging HSCs) can be enriched significantly by flow cytometric sorting for ~­
galactosidase or GFP marker 7'25'26'30. Thus, to study the role of apoptosis in the first HSCs 
within the embryonic dorsal aorta, we analyzed Sea-l Bcl-2 overexpressing transgenic 
mice. Here we show that Sea-l-directed Bcl-2 overexpression results in increased numbers 
of Sea-l positive cells in the AGM. The viability of these cells is increased and most 
importantly, AGM HSC activity is increased with Bcl-2 overexpression. Moreover, both 
anti-apoptotic and pro-apoptotic genes are normally expressed within the midgestation 
aorta as it is generating HSCs. These data strongly suggest that apoptotic processes play an 
important role in the regulation of HSCs beginning at the earliest stages of HSC 
development in the AGM. 
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Material and Methods 
Generation of transgenic mice 
An 865 bp murine Bcl-2 eDNA fragment 36 was inserted in the Ly6E.l expression cassette 
30
•
44
.45. The 14.9 kb Notl linearized fragment was microinjected into (CBAxC57BL/lO)Fl oocytes 
Out of 17 founder mice born, 6 transmitted the trans gene and two lines were used for further studies. 
Matings were set up between Bcl-2 transgenic males and (CBAxC57BL/lO)Fl females. The day of 
the vaginal plug was counted as day 0. Pregnant mice were killed by cervical dislocation and embryos 
were collected in PBS/ 10% FCS. Animals were housed according to institutional guidelines and 
animal procedures carried out in compliance with the Standards for Humane Care and Use of 
Laboratory Animals. 
Genotyping, copy number determination and expression analysis. 
For Bcl-2 and YMI' genotyping (Myo control), PCR conditions were: 100-200 ng DNA, 100 
ng of each primer (Table 1 ), lx buffer, 0.2mM dNTPs and 1 U AmpliTaq (Perkin Elmer) with cycling: 
5 min 92°C; 30x (40 sec 92°C, 40 sec 60°C, 1 min 72°C); 7 min 72°C. For copy number analysis a 
Southern blot with 10-20 J.Lg Hindiii digested genomic DNA was probed with a nick translated 
(Amersham Pharmacia Biotech) 32P-labelled 865 bp Bcl-2 fragment. Analysis was performed by 
phosphorimaging (Molecular Dynamics) and ImageQuant software. 
For Northern blot analysis 20 J.Lg RNA isolated from several tissues with TRIZOL 
(Invitrogen/ Life Technologies) was blotted against Genescreen membrane (NEN life science 
products). The blot was probed with a 32P-labelled 865 bp Bcl-2 eDNA fragment. Ly6 and GAPDH 
probes are as described previously 30. For RT-PCR analysis, embryos were (sub)dissected and tissues 
stored in RNAlater (Ambion) at 4°C. Embryos were genotyped and tissues from similar genotypes 
were pooled and homogenized in TRIZOL (Invitrogen/ Life Technologies). RNA was isolated 
according to manufacturer's instructions. 1-5 J.Lg DNase treated RNA (RQl RNase free DNase 
Promega) was used for eDNA synthesis with Superscript II Reverse Transcriptase (Invitrogen/ Life 
Technologies). RT-PCR was performed in a 50J.Ll volume with lOOng of each primer (Table 1), 
0.2mM dNTPs, AmpliTag and buffer (PerkinElmer) together with a 40-100 ng RNA equivalent of 
eDNA. Cycling conditions: 5min 92°C, 28-30x (40sec 92°C, 40sec 58°C, 1 min 72°C), 7min 72°C. 
PCR products were run on 1.2% agarose/lxTBE gels with EtBr and scanned on a Typhoon scanner 
(Molecular Dynamics). 
T bl 1 P . a e . nmer sequences 
primers primer sequences based on lengthPCR 
5'-3' sequence fragment 
or reference 
BC2PE GTGCAGCTGACTGGACATCTCTGC 30,35 450 
PES ACTCTGCCTGCAACCTTGTCTGAG 
YMT2-1 CTGGAGCTCTACAGTGATGA 27 342 
YMT2-2 CAGTTACCAATCAACACATCAC 
Myo-1 TTACGTCCATCGTGGACAGC 33 245 
Mvo-2 TGGGCTGGGTGTTAGTCTTA 
mBcl-2 forw GCACAGATGTCCAGTCAGCTG NM 009741 268 
mBcl-2 rev GCCATATAGTTCCACAAAGGC 
mBcl-xforw GGCGATGAGTTTGAACTGCG U51278 915 
mBcl-x rev CCTCACTCAATGGCTCTTGG 
mBimforw GAGAAGGTGGACAATTGCAG AF032461 290,380 
mBimrev GCCTTCTCCATACCAGACGG 
beta-actin forw CCTGAACCCTAAGGCCAACCG X03672 398 
beta-actin rev GCTCATAGCTCTTCTCCAGGG 
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For Western blot analysis, protein extracts from several adult tissues were made in Laemmli 
buffer, separated on a 10 % SDS polyacrylamide gel and blotted to PVDF membrane (Millipore). 
Blots were blocked and incubated with an anti-Bcl-2 antibody (Alexis) in 2% milk/TBS-T followed 
by an anti-rabbit-HRP antibody (DAKO) and ECL detection. 
Survival and cell viability assays. 
Healthy transgenic and non-transgenic littermates of7-13 (Ln 2) and 8-22 (Ln 479) weeks 
of age were randomly divided into 3 pools which received an equal split dose of 10.5, 9.5 or 8.5Gy 
gamma-irradiation. Mice received antibiotics and were checked daily for survival. 
Whole bone marrow cells from Bcl-2 transgenic and non-transgenic littermates were 
collected in PBS/1 0% FCS, suspended as single cells and counted (Coulter). Bone marrow cells were 
seeded at a density of 2xl05 cells/ ml in DMEM/10% FCS/Pen/Strep at 37°C, 5% C02. At 1, 2, 4, 8 
and 11 days viable cell counts were determined by Trypan blue exclusion. 
FACS analysis, immuno- and TUNEL staining. 
AGM and liver tissues were dissected and explant cultures for 3-4 days were performed as 
described previously 21 •27 . During the culture period, embryos were genotyped and tissues with similar 
genotypes pooled. Before staining, tissues were collagenase treated as described. Bone marrow cells 
were directly made into a single cell suspension. Cell staining was done in PBS/10% FCS with FITC 
or PE conjugated antibodies against Sea-l, c-kit, CD4, CDS, CDllb (Mac-1), Grl, B220 and 
Annexin V (Pharmingen) and fluorescence measured on a FACScan or FACSVantage (Becton-
Dickinson). Briefly, cells were stained with the antibody for 20 minutes on ice, washed and 
immediately measured. Dead cells were excluded by 7AAD or Hoechst 33258 (Molecular Probes) 
staining. 
For immunofluorescence, single cell suspensions from AGM cells from Ly6A-GFP 
embryos made. Cytospin cells were fixed (2% paraformaldehyde/PBS) and stained with Bcl-2 
antibody and a-rabbit-Texas Red or Cy3 secondary antibody. 
Embryos were frozen in Tissue-Tek (Sakura) and cryosectioned (7-8 J.lM). TUNEL staining 
was performed with the in situ cell death detection kit! POD (Roche) based on manufacturer's 
instructions. Staining was visualized with peroxidase substrate AEC and sections were dehydrated 
and embedded in Entallan (Merck) 
In vivo repopulation assays for HSCs. 
For all transplantations male donor cells were injected intravenously into 
(CBAxC57BL!lO)Fl females irradiated with a 9.5Gy split dose of gamma-irradiation. Repopulation 
was assayed at 1 and 4 months post-transplantation by a Y-chromosome (YMT) specific PCR on 
peripheral blood DNA. Multilineage repopulation was analyzed on several recipients either by PCR 
on DNA from hematopoietic tissues or as described previously 8. 
Donor male Bcl-2 transgenic and non-transgenic littermates (1 0 weeks old) were sacrificed, 
bone marrow cells collected and injected into recipients at several cell doses in combination with 105 
female competitor bone marrow cells. For repopulation assays on Ell and El2 AGM and liver cells, 
tissues were dissected and collagenase treated (0.125%) in PBS/ 10% FCS. 0.3 ee of AGM cells ( ~2 x 
105 cells/ee for Ell; ~3 x 105 cells/ee for El2) or 0.03 to 0.003ee ofliver cells (~3 x 106 cells/ee for 
El2) were injected with 2xl05 female spleen cells into recipients. Only recipients injected with male 
embryonic cells were assayed for engraftment. For secondary transplantations, bone marrow was 
collected from primary recipients reconstituted at high levels and 105 cells were injected into 
secondary recipients. Secondary recipients receiving bone marrow from primary recipients injected 
with El2 AGM or liver were co-injected with 105 female bone marrow cells. 
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Results 
Anti- and pro-apoptotic genes are normally expressed in the midgestation aorta. 
To date, little is known concerning the expression of anti- and pro-apoptotic 
regulators in the midgestation AGM region and particularly HSCs. To determine ifBcl-2 is 
normally expressed in AGM HSCs, immunostaining was performed on cytospins of El2 
Ly-6A (Sea-l) GFP transgenic AGM cells. Previous studies in such transgenic embryos 
have shown that all AGM HSCs are GFP+ 7•26 . When we performed Bcl-2 specific antibody 
staining on such cytospins, we observed Bcl-2 expression in many AGM cells (Figure 1 C), 
among which are GFP+ aortic HSCs and mesonephric tubule cells (Figure lB). Overlay of 
the two fluorescent signals shows that the GFP+ cells co-express the Bcl-2 protein (Figure 
lD). To more specifically determine ifBcl-2 is expressed in HSCs, cytospins of cells from 
subdissected Ell aortas were immunostained. Bcl-2 expression was found in many aortic 
cells (Figure 1 G). A small number of GFP+ cells indicative of HSCs were also found in the 
cytosypins (Figure lF). Overlays of Bcl-2 and GFP signals demonstrate the co-expression 
of both molecules, strongly suggesting that Ell aorta HSCs express Bcl-2. 
Figure 1. Sea-l+ AGM HSCs express Bcl-2. 
Immunostaining was performed on Ly-6A (Sea-l) GFP transgenic El2 AGM and Ell aortic 
cells. AGM and aorta cells were isolated as a single cell suspension and deposited on 
microscope slides by a cytospin. Panels (A, E, I) DAPI staining; (B, F, J) Ly-6A GFP 
fluorescence; (C) anti-Bcl-2 Texas Red fluorescence, (G) anti-Bcl-2 Cy3 fluorescence, (K) 
incubated with no primary antibody. (D, H, L) overlay of GFP and Texas Red/Cy3 fluorescence. 
Panels A-D are a cytospin of El2 AGM cells stained with anti-Bcl-2 antibody conjugated with 
Texas Red. Panels E-H show a cytospin of Ell aorta cells stained with anti-Bcl-2 antibody 
conjugated with Cy3. Panels I-L show a cytospin of Ell AGM cells incubated with no primary 
antibody 
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Bcl-2 expression in AGM HSCs was further confirmed by RT-PCR analysis. AGM cells 
sorted on the basis of c-kit expression (a marker for HSCs but not mesonephric cells 40) 
showed Bcl-2 expression in the c-kit AGM fraction (not shown). 
A 
c 
DA 
UGR UGR 
AGM 
+ 
M 
Non-transgenic 
Liver Aorta UGR 
+ + + 
B 
DA 
UGR UGR 
D Bcl-2 transgenic 
Aorta UGR 
- + + RT 
Bcf-2 
Bcf-x 
Bim 
Actin 
Figure 2. Apoptotic processes and molecules are present in the Ell AGM. 
TUNEL straining was peiformed on transverse sections from the truncal region of an Ell embryo 
(Bcl-2 transgenic) to localize apoptotic cells in the AGM region. A representative section is shown in 
(A) lOx magnification and (B) 40x magnification. TUNEL positive (black/gray-colored) foci and 
diffuse scattered individual cells are observed. DA = lumen of dorsal aorta; UGR = urogenital 
ridges; M = mesentery. TUNEL staining was peiformed 3 times on 2 wild type and 2 transgenic 
embryos. No obvious difference in the TUNEL staining pattern was observed when sections from Bcl-
2 transgenic embryos were compared with sections from non-transgenic embryos (not shown). (C) 
Expression of the anti-apoptotic genes Bcl-2 and Bcl-x and the pro-apoptotic Bim gene in the Ell 
AGM, aorta, UGRs and liver region of a non-transgenic embryo. RT-PCR analysis was peifonned on 
cDNAs made from the indicated midgestation tissues. Signal intensity from the actin PCR ji-agment 
was used as a normalization control. Note, that as expected, the Bim primers amplifY two different 
transcript isoforms (splice variants). (D) RT-PCR analysis of a Bcl-2 transgenic embryo reveals 
altered levels of Bcl-2, Bcl-x and Bim gene expression in the Ell aorta and UGR. RT-PCR analysis 
was peiformed 3 times and corifirmed on 3 independent sets of cDNAs. 
To examine whether apoptosis normally occurs in the AGM, TUNEL analysis was 
performed on transverse sections through the truncal regions of midgestation embryos. 
Several TUNEL positive foci are found scattered throughout the representative Ell truncal 
section shown in Figure 2A. In the AGM region many highly positive foci are in the 
mesonephic tubules of the urogenital ridges (UGR) while only one strongly positive focus 
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was found a short distance from the dorsal side of the dorsal aorta (Figure 2B). Also, 
surrounding the dorsal aorta in the mesenchyme are diffuse individual weakly positive 
cells. Since we found a large number of AGM cells expressing Bcl-2 in the cytospins, the 
presence ofTUNEL positive foci in AGM suggests that in these cells the balance is shifted 
towards the expression of pro-apoptotic regulators. 
We next examined the expression levels of anti-apoptotic genes Bcl-2 and Bcl-x 
and the pro-apoptotic gene Bim in the whole AGM, aorta, UGRs and liver by semi-
quantitative RT-PCR. As shown in Figure 2C, Bcl-2 expression is approximately two fold 
higher in the Ell AGM as compared to the Ell liver. Similar results were obtained with 
El2 tissues (not shown). In the Ell AGM, Bcl-2 is expressed in both the aorta and UGRs, 
with the highest levels of expression in the UGRs. Bcl-x and Bim expression levels are 
comparable between the Ell AGM and liver and also between the Ell aorta and UGR 
subregions, although Bim expression appears to be slightly higher in the UGRs. Thus, both 
anti-and pro-apoptotic genes are expressed in the embryonic sites (aorta and liver) 
harboring the earliest HSCs. Taken together, these data indicate that apoptosis is taking 
place in discrete areas of the AGM, and although Bcl-2 is expressed in a majority of AGM 
cells, a regulated balance between cell survival and apoptosis is maintained within most of 
this midgestation tissue. 
Sea-l Bcl-2 transgenic mice overexpress Bcl-2 in hematopoietic cells. 
To study whether apoptotic/cell survival processes are functional within the 
embryonic hematopoietic system, we generated transgenic mice in which overexpression of 
the anti-apoptosis gene Bcl-2 was directed by the Sea-l (Ly-6E/A) transcriptional control 
elements. A Bcl-2 eDNA fragment36 was inserted into the first untranslated exon of the 14 
kb Ly6E genomic fragment30,44 (Figure 3A) and two transgenic lines (Ln 2 and Ln 479) 
were analyzed in detail. 
The copy number was determined by Southern blot analysis, comparing signal 
intensity of the endogenous 1.4 kb Bcl-2 gene fragment to the 4.7 kb transgenic Bcl-2 band 
(Figure 3B). The transgene copy numbers of Ln 2 and Ln 479 are 7 and 20, respectively. 
Northern blot analysis demonstrated overexpression of the Bcl-2 trans gene in kidney, liver 
(Figure 3C), thymus and spleen (data not shown). Non-transgenic littermates showed low, 
or undetectable levels of endogenous Bcl-2 RNA. Western blotting revealed that Bcl-2 
protein expression was also elevated in transgenic animals (Figure 3D). Only low or 
undetectable levels of endogenous Bcl-2 protein were found in wild type littermates. Thus, 
the Sea-l transcriptional regulatory elements direct Bcl-2 expression at high levels in 
several hematopoietic and non-hematopoietic tissues in the transgenic animals and this 
expression pattern correlates with the Ly-6EIA expression pattern as previously reported 
7.25,26,30 
Bcl-2 overexpression results in radio-protection and increased hematopoietic cell 
viability in the adult. 
To test the validity of our transgenic model we examined the effects of Bcl-2 
overexpression in the adult hematopoietic system. We performed survival experiments to 
assess whether Sea-l directed Bcl-2 overexpression could rescue cells from radiation 
induced apoptosis in vivo. Transgenic animals and normallittermates were challenged with 
different doses of total body gamma irradiation and the number of viable animals was 
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determined daily for up to 30 days. At doses of 10.5 (Figure 4A), 9.5 and 8.5 Gy (not 
shown) both Ln 479 and Ln 2 (not shown) transgenic animals showed higher survival rates 
at day 30 in comparison to their wild type littermates. 
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Figure 3. Sea-l Bcl-2 transgenic mice overexpress Bcl-2 in hematopoietic tissues. 
(A) Transgene construct. A 865 bp Bcl-2 eDNA fragment was inserted into exon one of a 14kb Sea-
l (Ly6E) expression cassette. H=Hindiii. (B) Transgene copy number determination. A Southern 
blot containing Hindi!! digested DNA was probed with a Bcl-2 fragment to reveal the 1.4 kb 
endogenous gene and 4. 7 kb transgene. Ln 479 contains 20 and Ln 2 contains 7 copies of the 
transgene. (C) Northern blot analysis for Bcl-2 transgene expression in several adult tissues. Bcl-2 
is expressed in liver and kidney in Ln 479 and Ln 2 Bcl-2 transgenic (tg) animals. (D) Western blot 
analysis of Bcl-2 protein expression in Ln 2 and Ln 479 transgenic animals. Bcl-2 transgene is 
overexpressed in several tissues including kidney, thymus, spleen and bone marrow as compared to 
non-transgenic (wt) littermates. In general, no obvious abnormalities were found in the transgenic 
adults. Blood smears showed no morphologic differences or leukemic cells, and hematocrits did not 
differ between the transgenic and non-transgenic adults (data not shown). 
To test whether this increased survival could be related to protection of cells of the 
hematopoietic system from apoptosis, we performed in vitro experiments using bone 
marrow (Figure 4B) cells from Bcl-2 transgenic and wild type littermates. Over a period of 
11 days in the absence of added hematopoietic growth factors, the survival of non-adherent 
cells was determined. The number of viable cells derived from Bcl-2 transgenic bone 
marrow and spleen (not shown) was much greater than those derived from wild type 
littermates. Hence, the increased survival rate of the Bcl-2 transgenic mice is due, at least in 
part, to increased viability of hematopoietic cells. 
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Figure 4. Effects of Bcl-2 overexpression on adult mice and cells. 
(A) In vivo survival curves Bcl-2 overexpressing transgenic mice and non-transgenic littermates. 
Adult mice of 7-22 weeks of age were subjected to a split dose of gamma-irradiation of 10.5 Gy. 
Survival of both Ln 479 (shown) and Ln 2 (not shown) transgenic mice and littermates was checked 
daily over 30 days. Results are derived from 2 separate experiments for each transgenic line. The 
number of mice irradiated at 10.5 Gy was n= 10 for Ln 479 tg and n= 12 for wt littermates. For 
other irradiation doses (not shown), 10-15 mice were used per group. (B) Viable cell numbers of 
bone marrow cells of Ln 479 tran:;genic (Bcl-2) and a wild type littermate (wt). Bcl-2 
overexpression results in higher viable cell numbers in vitro over a period of 11 days. Note that the 
scale on the Y-axis is logarithmic. These graphs show a representative experiment out of a total of 5 
experiments (7 Bcl-2 tg and 7 wt littermates ranging 10 to 24 weeks of age). (C) Percentages of 
cells obtained after Annexin V and 7AAD FACS analysis of the bone marrow of 3 transgenic (n=2 
Ln 2 and n= 1 Ln 479, mice aged 9-23 weeks) and 3 non-transgenic littermates. Differences 
observed between the transgenic and non-transgenic in the Annexin-7AAD-, Annexin+7AAD+ and 
Annexin-7 AAD+ subsets are statistically significant as determined by the students t-test. 
We next examined bone marrow cells for stage specific involvement in the 
apoptotic process by flow cytometric analysis with Annexin V, an early marker of 
apoptosis, and 7 AAD 53 • The results of three independent experiments in which non-
transgenic cells were cultured under stressful hematopoietic growth factor-free conditions 
showed the expected pattern of cell death, with 31% of cells in the apoptotic and necrotic 
quadrants (7 AAD+). In contrast, Bcl-2 transgenic cultures showed only 4% 7 AAD+ cells, 
with a much higher percentage of cells in a viable state (91% Annexin-7 AAD-). The 
percentage of cells in the early stages of apoptotis (Annexin+7AAD-) was almost 3-fold 
higher in the non-transgenic cultures as compared to the Bcl-2 transgenic cultures. Thus, 
Bcl-2 decreases the number of BM cells entering into apoptosis in growth factor-free 
hematopoietic cultures. 
To investigate whether lower apoptosis/higher cell maintenance was occurring in 
specific hematopoietic cell subsets we examined T and B lymphoid cells in the thymus and 
spleen (Table 2). Although the total body weight of Bcl-2 transgenic adults was unchanged 
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from that of the wild type littermates, thymus cell numbers were slightly increased in the 
transgenic mice (but these changes did not reach statistical significance). We found 
increases in the percentages of CD4TD8-, CD4+ and CD8+ thymocytes and a concomitant 
large decrease in CD4+CD8+ thymocytes (Table 2). We also found that mature T cell 
numbers are increased in the spleen, with the absolute number of CD4+ and CD8+ 
splenocytes increased 2.5- to 4-fold. These changes are consistent with the expected 
expression pattern of the trans gene and suggest that the most immature and mature subsets 
are maintained or positively selected 48 at the expense of the differentiating CD4+CD8+ 
thymocyte subset. Interestingly, the absolute number of spleen cells was increased a factor 
of 2.2 to 3.3, but this increase is not limited to T lymphocytes. In the spleen it was found 
previously that 10% of cells express Sea-l 5 and that some of these cells are B220+. Indeed 
the absolute number ofB220+ splenocytes was increased by 2 to 3-fold. Taken together, the 
increase in the absolute number of spleen cells (approximately 17-25 x 107) can be 
accounted for by the increase in the mature lymphocyte CD4+ and CD8+ and B220+ subsets 
and may be attributed to increased cell survival by overexpression of Bcl-2. Thus, our 
transgenic animal model results in observable and expected Bcl-2 induced changes within 
the adult hematopoietic system. 
Table 2. Lymphoid tissue and cell subset analysis of Bcl-2 transgenic adults 
Non- Ln479 Non- Ln2 transgenic transgenic 
Body weight (g) 29.4 ± 5.7 29.4± 5.8 31.4 ± 4.0 32.0±4.7 
Absolute Cell Numbers (x 1 07) 
Thymus 7.7 ± 1.4 9.4 ± 1.1 10.8 ± 4.3 11.1±3.6 
Spleen 14.7 ± 1.6 31.9±6.4 11.4 ± 1.1 37.3 ± 1.9 
Subsets of Thymus cells (%) 
CD4-CD8- 3.7 ± 1.0 4.6 ± 1.7 2.0, 3.8 5.1 ± 1.7 
CD4+CDS+ S3.5 ± 3.6 75.6 ± 4.2 S7.S, S3.3 70.9 ± 5.2 
CD4+ 9.9 ± 3.1 13.7 ± 2.0 11.9, 9.2 1S.S ± 2.4 
CDS+ 3.0 ± 0.6 6.1 ± 0.7 1.0, 0.9 5.2 ± 1.4 
Subsets of Spleen cells (x 1 07) 
CD4+ 3.1 ± 0.6 S.5 ± 1.1 2.S, 1.1 7.4 ± 1.9 
CDS+ 1.6 ± 0.5 4.0± 0.3 1.0, 0.5 2.S ± 1.6 
B220+ 10.0 ± 0.7 21.4±5.1 S.O, 2.9 1S.6 ± 2.7 
Tissues were isolated from mice ranging in age from 10-20 weeks. Both male and female mice 
are included in each of the groups. For the total thymus and spleen cell counts, sample numbers 
are as follows: Ln 479 mice (n=6) and non-transgenic litterrnates (n=6); Ln 2 mice (n=ll) and 
non-transgenic litterrnates (n=7). For the spleen and thymus subset cell determinations n=3 
except for non-transgenic Ln 2 control group. 
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Bcl-2 overexpression results in increased numbers and viability of Sea-l positive cells 
in theAGM. 
The first HSCs emerge in the AGM region beginning at E10.5 and are increased in 
number by more than 15-fold when this tissue is cultured as an explant for 3 days. To 
determine whether apoptotic/cell survival processes are functional in these AGM HSCs and 
are affected by Bcl-2 overexpression, we examined the numbers of Sea-l+ cells in Ell 
AGM control and transgenic explants by F ACS analysis. As shown in Figure 5A, the 
percentage of Sea-l+ cells is increased in the Bcl-2 transgenic AGMs as compared to non-
transgenic AGMs. A 1.4- to 2.2-fold increase was consistently observed in transgenic AGM 
explants (Figure 5C) and moreover, everi greater increases in the percentages of Sea-l+ 
cells in Ell transgenic liver explants were observed (1.7 to 3.9 fold; Figure 5C). To 
examine whether this increase in Sea-l+ cell number is related to changes in apoptotic 
processes, we tested for the expression of Annexin V within the Sea-l+ fraction of AGM 
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Figure 5. Increased numbers 
and viability of Sea-l+ cells in 
the AGM and liver. 
Ell AGM tissue was dissected 
and culture in an explant culture 
system for 3-4 days during which 
the embryos were genotyped. 
A G M tissue from embryos with a 
similar genotype were pooled 
soo 1ooo and single cell suspensions made 
and stained for Sea-l and 
Annexin V (A) representative 
6.5% FACS plot for Sea-l in non-
transgenic and Bcl-2 
overexpressing AGM tissue 
shows that Bcl-2 overexpression 
results in increased numbers of 
Sea-l+ cells. Number of events fn 
non-transgenic plot = 1.5 xl 04 
and in transgenic plots= 1.3xl04. 
800 1000 (B) Within the Sea-l positive 
AGM 
Liver 
fraction, the percentage of 
Annexin V cells was determined 
as indication for the amount of 
apoptotic cells. Bcl-2 
overexpressing tissues contain 
less Annexin V cells within the 
Sea-l+ fraction after the culture 
period. Number of events in non-
transgenic plot= 2.1 xl 03 and in 
transgenic plots= 1. 7xl oJ. (C) 
Combined results of total 5 
experiments for Sea-l staining 
and 3 experiments for Annexin V 
staining of the Sea-l+ fraction of 
Ell AGM cells. 
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and liver cells. As shown in Figure 5B, the percentage of Annexin y+ cells is decreased in 
the Bcl-2 transgenic AGM explant. This decrease ranged from 1.4- to 3.8 fold in Bcl-2 
AGM explants and 1.3- to 2.0-fold in liver explants (Figure 5C). Thus, Bcl-2 
overexpression leads to a quantitative increase in HSC numbers by decreasing apoptosis of 
Sea-l+ cells in midgestation hematopoietic tissues. 
As the overexpression of Bcl-2 increases Sea-l+ cell survival in the embryo, we 
sought to determine whether the expression levels of the anti-apoptotic Bcl-x and pro-
apoptotic Bim genes were also affected. Semi-quantitative RT-PCR analysis of Bcl-2, Bcl-x 
and Bim expression in midgestation embryonic transgenic tissues (Figure 2D) showed that 
not only was Bcl-2 gene expression increased (2-10 fold), but also Bim expression 
increased (approximately 1.5-4 fold) when transgenic aorta was compared to non-
transgenic aorta. Bcl-x expression remained as in the non-transgenic. Interestingly, RT-PCR 
analysis of non-transgenic AGMs prior to and after explant culture, showed increased Bcl-2 
and Bcl-x expression after 3 days of culture. The level of Bcl-2 and Bcl-x remained the 
similar between cultured and non-cultured liver (C.O. and E.D., manuscript in preparation). 
Taken together, these data strongly suggest that anti-apoptotic pathways are in place, 
functioning and regulated at the level of gene transcription in a balanced manner. 
Hematopoietic stem cell activity is increased in the AGM of Bcl-2 overexpressing 
embryos. 
To test the validity of our animal model for Sea-l directed Bcl-2 overexpression in 
HSCs, we first compared bone marrow from transgenic mice with non-transgenic bone 
marrow for in vivo hematopoietic repopulation. More HSC activity was found in Bcl-2 
transgenic bone marrow (Figure 6A) at a limiting dose of 104 cells than in wild type 
littermate controls. HSC frequencies were calculated (Table 3) and found to be increased by 
2.6-fold (p<0.03) in the Bcl-2 overexpressing mice. Moreover, by flow cytometry on Bcl-2 
transgenic bone marrow (n=3), we found a 1.6- to 3.7-fold (2.6 ± 1.1) increase in the 
number of c-kit+ cells as compared to non-transgenic bone marrow (not shown). Thus, Bcl-
2 overexpression increases the number of bone marrow HSCs indicating the validity of our 
transgenic modeL 
To directly test whether Bcl-2 overexpression promotes the viability/survival of 
HSCs in the midgestation hematopoietic tissues, we performed limiting dilution in vivo 
transplantation experiments. AGMs and livers were obtained from transgenic and wild type 
male embryos at Ell and El2 and injected into irradiated female recipients. Recipients 
were analyzed for donor cell Y chromosome contribution by peripheral blood DNA PCR. 
At 4 months post-injection the HSC activity of Ell Bcl-2 transgenic AGM cells (Figure 
6B) was higher (10 repopulated of 25 recipients) than that from non-transgenic littermate 
controls (only 2 of 19 recipients repopulated). Engraftment was high level (up to 100% 
donor-derived), long term and multilineage (not. shown). By El2, HSC activity in 
transgenic AGMs was similar to that of the El2 non-transgenic AGM, but this may be due 
to saturating numbers ofHSCs in the injected dose. Bcl-2 transgenic El2 liver also showed 
some increases in HSC activity when compared to non-transgenic liver at limiting injection 
doses (Figure 6C). Frequency analysis (Table 3) revealed that HSC numbers were 
significantly increased in the Ell AGM by a factor of 4.5 (p<0.02). 
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Figure 6. Increased HSC activity in the 
bone marrow, AGM and liver of Bcl-2 
overexpressing transgenic animals. 
(A) HSC activity in the bone marrow of Bcl-
2 overexpressing mice. Whole bone marrow 
from a male Ln 479 transgenic (tg) and a 
non-trangenic (wt) littermate was injected at 
different limiting doses (HI, 104, 1rf cells) 
together with 1 rf female bone marrow cells 
into irradiated female recipients. After 4 
months post-transplantation the peripheral 
blood of the recipient was analyzed in a 
semi-quantitative manner for male donor 
hematopoietic cells. Black triangles 
represent individual recipients engrafted 
with tg bone marrow and grey spheres 
individual recipients engrafted with wt bone 
Secondary 
marrow. Results of competitive repopulation 
experiments for Ln 479 transgenic and non-
transgenic littermates are shown. A 10% 
engraftment level in the peripheral blood 
was used as the criterion for positive HSC 
repopulation. Ln2 trangenic bone marrow 
gave similar results (not shown). 
Transplantations were performed with (B) 
Ell AGM, E12 AGM Ln 479 transgenic 
(black bars) and (C) El2 liver cells (black 
wt tg 
0.03 ee 
wt tg 
bars) as well as non-transgenic control cells 
(light bars). The combined results of two 
independent transplantation experiments 
show the percentage repopulated recipients 
(y-axis) and the number of mice positive/the 
number of total mice injected for each 
group. ee=embryo equivalents injected. All 
recipients considered positive at >4 months 
post transplantation showed donor-derived 
cell engraftment levels greater than 1 0% by 
semi-quantitative PCR. In general, a higher 
E121iver percentage of repopulated recipients is seen 
Secondary with Bcl-2 transgenic (tg) midgestation 
AGM and liver cells than with wild type (wt) 
littermate cells. Results of secondary 
transplantations are shown in the right panels of (B and C). Bone marrow cells from primary 
recipients of Ell AGM, E12 AGM and E12 liver were transplanted in limiting dilutions into 
irradiated adult secondary recipients. Percentage repopulated recipients and the number of mice 
positive/the number of total mice injected is shown for each group. The bone marrow cells of the 
primary recipients of Ell AGM and E12 AGM and E12 liver cells that were used for secondary 
transplantation were 75-100% repopulated by donor-derived cells. Results were obtained at >4 
months post transplantation by PCR analysis of peripheral blood DNA. ND=not done. Again, a 
higher percentage of repopulated recipients is seen with Bcl-2 transgenic (tg) as compared with wild 
type (wt) littermate cells. 
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To further check the potency of these HSCs, limiting doses of bone marrow cells 
from the primary Bcl-2 transgenic and non-transgenic AGM- and liver-engrafted recipients 
were injected into secondary recipients. Bcl-2 transgenic secondary transplanted AGM cells 
showed potent HSC activity (Figure 6B, right panel) while non-transgenic cells provided no 
engraftrnent (combined data of transgenic secondary transplants, 9 repopulated of 14 
transplanted as compared to non-transgenic transplants, 0 of 8). Similarly, Bcl-2 transgenic 
secondary transplanted liver cells showed HSC activity while non-transgenic liver did not 
engraft (Figure 6C, right panel). Thus, these transplantation data demonstrate that Bcl-2 
overexpressing embryos possess higher HSC activity in the AGM region and liver than 
non-transgenic embryos and suggest that Bcl-2 survival processes are in place and fully 
functional in these HSCs at the earliest stages of development. 
Table 3. Frequency analysis of HSCs in embryonic and adult hematopoietic tissues 
Tissue Non-transgenic Bcl-2 transgenic 
Transplanted HSC frequency HSC/ee HSC frequency HSC/ee 
Ell AGM 1/2.7 X 105 0.37 110.6 X 105 1.70 * 
E12 AGM 1/0.4 X 105 2.54 110.4 X 105 2.78 
E12 liver 110.017 x 105 58.8 1/0.013 x 105 76.9 
Bone marrow 116.28 x 104 1/2.31 x 104 
HSC frequencies were determined from the primary transplantation data in figure 6 and were 
calculated using the L-Calc software. *statistical significance (p<0.02). ee=embryo equivalent 
Discussion 
It has been widely accepted that a tight quantitative control of HSCs is essential to 
maintain the appropriate and stable representation of progenitors and differentiated cells in 
the adult hematopoietic hierarchy. Because the blood system is highly dynamic, must 
respond rapidly to trauma and must also constantly replenish itself, cell survival and 
apoptotic processes play an important role in regulation of this tissue system. During 
development of the hematopoietic system in the embryo these processes also appear to play 
a role. We have shown here that Bcl-2 overexpression increases the numbers of Sea-l+ cells 
in the AGM, decreases apoptosis of these cells and more importantly, increases the 
numbers of functional HSCs beginning at midgestation in the AGM. 
HSC activity was significantly increased in the Ell AGMs from Sea-l Bcl-2 
transgenic embryos (4.5-fold increase, p<0.02). Such an increase was less apparent in 
transgenic El2 AGM and liver. However, when secondary transplantations were performed 
to confirm the self-renewal ability of AGM and liver HSCs, increased HSC activity was 
observed in the Bcl-2 transgenic primary bone marrow as compared to that from the non-
transgenic recipients, suggesting that saturating numbers of HSCs were present in the 
primary Bcl-2 recipient. Thus, Bcl-2 overexpression affects the repopulating activity of the 
first AGM and liver HSCs. Whether Bcl-2 overexpression has a direct effect only on HSC 
number or has several related effects, such as enhancing engraftrnent through survival 
and/or influencing the cell cycle status ofHSCs (as for adult bone marrow HSCs), is yet to 
be determined. Importantly, whatever the effect of Bcl-2 overexpression on HSCs, these 
cells are normal, contributing to long-term, multilineage repopulation and most-likely 
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enhanced self-renewaL The fact that increased HSC numbers are found in the AGM, liver 
and the adult bone marrow suggests that intriguing possibility that HSCs apoptose more 
often and much earlier than previously appreciated. 
It can be implied from the observed HSC increases in Sea-l Bcl-2 transgenic mice 
that components of Bcl-2 pathway leading to cell survival are intact and functionally 
relevant in these cells. Until our investigation, it was not known whether Bcl-2 is normally 
expressed in this region. We have shown that Bcl-2 protein is expressed in the midgestation 
AGM and furthermore, that some apoptosis is ongoing in this region. Bcl-2 transcripts are 
found both in the aorta and the UGRs, and more specifically in aorta HSCs. While TUNEL 
positive foci are found in the mesonephric tubules (indicating apoptosis), it appears that 
apoptosis occurring in the region surrounding the dorsal aorta is limited to single cells. 
These data suggest that there is a tight regulation of apoptosis in this region and in addition 
to Bcl-2, we postulate that other apoptotic regulators play a role in the balance between cell 
survival and apoptosis in the AGM. 
We have found expression of the Bcl-x anti-apoptotic regulator and the Biro pro-
apoptotic regulator in the midgestation aorta and UGRs. Since the results of others in adult 
hematopoietic cell subsets and tissues 20 show only slight overlap in Bcl-2 and Bcl-x in vivo 
expression patterns, these molecules may be expressed in different AGM cell subsets. 
Indeed, gene targeted mutant mice show different phenotypes 32'34•52: Bcl-2 deficient mice 
complete embryonic development and show increased apoptosis in lymphocyte 
populations, and Bcl-x deficient mice die around E13 with extensive apoptosis of 
hematopoietic cells in the fetal liver. Interesting, recent data show that concomitant loss of 
the pro-apoptotic Bim gene and the anti-apoptotic Bcl-2 gene allows normal physiological 
functions and thus, Biro counterbalances Bcl-2 activity 2 . Moreover, Bim expression has 
been found in several hematopoietic cell lines 1737 and Bim upregulation correlates with 
increased apoptosis induced in El7 fetal liver cells upon hematopoietic growth factor 
withdrawal 9. Therefore, there are important roles for Bcl-2, Bcl-x and Biro in regulating 
apoptosis in hematopoietic cells and the intracellular ratios between these and other pro-
and anti-apoptotic proteins are expected to play a critical role in setting the balance between 
cellular life or death. Semiquantitative transcriptional analysis of these three genes in the 
normal and Bcl-2 overexpressing AGM, aorta, UGRs and liver suggests that the balance of 
pro- and anti-apoptotic molecules is also important during midgestation hematopoiesis. 
When Bcl-2 is overexpressed in aorta in transgenic embryos, a concomitant increase in Bim 
but not Bcl-x is observed. How this balance is achieved at the transcriptional level is 
unknown. Further studies should determine whether these three molecules (or other 
combinations) are expressed in the same population/subset of AGM cells and the precise 
balance between these pro- and anti-apoptotic molecules that leads to increased HSC 
activity in the mouse embryo. 
Finally, in examining the validity of our Bcl-2 overexpression transgenic mouse 
model in the adult hematopoietic system, we found that Bcl-2 overexpression occurs in the 
tissues and hematopoietic cells that are normally expected to express Sea-l 7•25•26•30 . Sea-l 
directed Bcl-2 overexpression affects adult hematopoietic cells, both under normal and 
stressful conditions, most likely by preventing them from entering the apoptotic pathway. 
As expected from the previous results of others 11.48•48, Sea-l directed Bcl-2 overexpression 
results in radio-protection and in increases of bone marrow HSC activity (as determined by 
in vivo transplantation). Frequency analysis revealed that bone marrow HSC numbers were 
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significantly increased in Bcl-2 transgenic adults by a factor of 2.7. This increased bone 
marrow HSC activity may be related to a lower susceptibility of the transgenic HSCs to 
enter into apoptosis during the engraftment of the recipient. Several studies have reported 
that Bcl-2 influences the cell cycle by blocking the transition from G1 to S-G2-M 38'51 • Since 
there is a correlation between the cell cycle status of HSCs and their ability to home to the 
recipient bone marrow (18 and references therein), it is possible that altered cell cycle 
profiles could result in the facilitated engraftment we observed for Sea-l Bcl-2 
overexpressing HSCs. Notwithstanding, the Bcl-2 related increase in HSC activity is also 
due to an increase in the absolute number ofHSCs, since we have found more c-kit cells in 
Bcl-2 transgenic bone marrow. Interestingly, both the bone marrow and AGM contained 
approximately 2-fold more HSCs. Given the notion that Bcl-2 overexpressing HSCs enter 
into apoptotic stages at a much lower frequency and remain viable for longer periods of 
time, it may now be possible to isolate cell lines of this difficult to culture Sea-l+ 
hematopoietic subset from the AGM and adult bone marrow. Such cell lines would greatly 
facilitate molecular analyses of developmentally specific HSC genetic programs. 
Taken together, our studies show that anti- and pro-apoptotic processes are intact, 
active and functioning in the earliest expanding HSCs in the AGM region of the mouse 
embryo and that apoptosis/cell survival plays an important role in these first HSCs. 
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During mouse development hematopoietic cells can be found in several tissues in 
a distinct spatial and temporal manner. The first hematopoietic cells can be found in the 
extra-embryonic yolk sac from E7.5 onwards. These primitive, nucleated erythrocytes are 
later in midgestation development replaced by definitive, enucleated erythrocytes34. The 
first definitive adult-repopulating hematopoietic stem cells (HSCs) can be detected and are 
autonomously generated in an El0.5 intra-embryonic region, referred to as the aorta-gonad-
mesonephros (AGM) region. Slightly later, from Ell onwards, these HSCs also become 
detectable in the circulating blood, the liver and the yolk sac2530•32. Further mapping 
revealed that the first detectable HSC activity in the AGM is confined to the aorta region at 
Ell 10•11 . Moreover, HSCs can expand within the AGM region upon organ culture, 
suggesting that the AGM harbors a unique micro-environment with the ability to support 
hematopoietic stem cell emergence and/or self-renewal (proliferation)15'25 • Although a large 
number of genes have been implicated in the regulation of hematopoietic stem cells during 
development, a complete and comprehensive understanding of these regulatory processes is 
still lacking. 
Differentially expressed genes in the AGM region between ElO and Ell could 
represent regulators ofHSC activity. 
To gain further insight in the emergence and regulation of the first detectable 
adult-repopulating HSCs in the AGM region we set out to identify genes that were 
differentially expressed between E 10 and E 11 of mouse gestation, as described in chapter 2. 
These time points were chosen because at ElO there are no HSCs in the AGM region while 
at Ell, AGM HSCs are abundant. The AGM region is a complex tissue, consisting of the 
kidney anlagen and gonads as well as the dorsal aorta and surrounding mesenchyme. To 
increase the probability of detecting genes specifically involved in HSC regulation, the 
AGM region was subdissected to yield the aorta/mesenchyme region, the subregion where 
the first HSCs are found. A differential gene expression screening was performed using the 
aorta/mesenchyme tissues derived from ElO and Ell embryos. Additionally, two other 
screens, one with complete AGMs and one with complete ElO AGM as compared to Ell 
aorta/mesenchyme subregions, were performed to find differentially expressed genes. 
Currently, differential screenings are routinely performed with micro-array 
screening methods, in which a large number of genes can be screened simultaneously for 
differential expression between two populations of cells. However, at the onset of the 
studies for this thesis, micro-array screening methods were still very expensive and more 
importantly, the technique was still in its infancy. Therefore, a differential screening 
method developed in 1992, Differential Display RT-PCR28 was used to search for 
differentially expressed genes. Despite the known drawbacks of this technique, such as high 
number of false positives 27'29, and the fact that we were searching for differentially 
expressed genes in a complex tissue, we were able to identify and verify a number of truely 
differentially expressed genes. Among the identified and verified differentially expressed 
genes we detected two novel mouse genes, Tab2 and Tm9sj2. In addition, we found that an 
essential component of the Wnt signaling pathway, fl-catenin, was differentially expressed. 
Besides these genes, that were further studied, other interesting genes were identified in the 
screen. Expression of a zinc finger protein encoding gene, named Sag, proposed to function 
as an apoptosis regulator14'42, the Bub 1 b gene implicated as a mitotic spindle checkpoint 
regulator46, and Myc and Rb binding protein encoding genes were found in the midgestation 
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AGM region. However, as it was not possible to further investigate all the interesting genes 
identified, my primary research focus was on the novel gene, Tab2, its role in the IL-l 
signaling pathway, and the role of IL-l signaling in HSC development. I also examined 
expression of other Wnt signaling members in midgestation hematopoietic tissues. 
Wnt signaling components in the AGM 
Expression ofWnt signaling components was investigated by RT-PCR analysis on 
E1 O-E12 AGM and liver material. We observed that transcription of several components of 
the Wnt signaling pathway, including Disheveled (1, 2 and 3), Wnt5a and Wnt3, is initiated 
and upregulated between ElO and Ell in the AGM region. Also, other essential 
components, such as, fJ-catenin, Lef, Tcfl and Tcf3, are expressed in the Ell AGM. Thus, 
several important mediators of the Wnt signaling pathway are present at the molecular level 
and their presence suggests some function in hematopoietic development. Although the 
functionality of Wnt signaling in the midgestation AGM and liver was not investigated, 
several studies by others have implicated the importance ofWnt signaling and regulation of 
hematopoiesis and HSCs. For example, Austin et al. 4 reported that Wnt5a is expressed in 
the yolk sac and the fetal liver and in vitro studies showed that Wnt5a could expand fetal 
liver hematopoietic progenitors. Moreover, it was recently reported that Wnt3 can act as a 
HSC growth factor and was proposed to be an important in vivo regulator of HSC self-
renewal 4'35,48. Together these studies implicate an important role for Wnt proteins in HSC 
regulator and based on their expression in the Ell AGM region, these proteins might play a 
role from the earliest stages of HSC development onwards. However, to study the 
functionality of Wnt proteins in the AGM raises several technical difficulties. The most 
obvious manner to examine the impact of Wnts on AGM hematopoiesis would be to 
perform organ cultures or to culture purified AGM HSCs in the presence of Wnt proteins 
and subsequently determine the effect by in vivo transplantation and in vitro colony forming 
assays. This method encounters the problem that correctly folded Wnt proteins are not 
easily purified. Moreover, Wnt proteins need to interact with the extracellular matrix in 
order to be presented correctly to the cells 9,49• A more elegant, but also more time-
consuming way to investigate the role of Wnt genes on AGM HSCs would be to investigate 
the characteristics of AGM HSCs in mouse models that either overexpress or are deficient 
for Wnts and/or Wnt signaling components. Although the role ofWnt signaling in the AGM 
was not further addressed here, the fact that these genes are expressed at the time that HSC 
activity becomes detectable might serve as a starting point for future investigations 
concerning the role ofWnt signaling in AGM HSC regulation. 
T AB2 expression pattern in the mouse 
Besides the identification of Wnt signaling components that were differentially 
expressed in the AGM region between ElO and Ell, we also identified two novel mouse 
genes homologous to known human genes. One of these mouse genes encoded for a 
transmembrane protein with unknown function and the other gene encoded for Tab2. 
Human TAB2 had been previously implicated as a mediator of interleukin-1 (IL-l) 
signaling44. As IL-l has been reported to regulate HSCs in the adult mouse, it was 
interesting to further investigate the role and function of T AB2 within the hematopoietic 
system. Therefore, we set out to perform several studies regarding the expression pattern of 
127 
Chapter6 
T AB2 and rela,ted genes as well as the possibility of IL-l as a regulator of HSCs in the 
AGM and fetal liver. 
TAB2 was originally identified as a TAKl binding protein and TAKl itself has 
been identified as a kinase in the TGFj3 signaling pathway44•51 . Besides TAB2, two other 
TAKl binding proteins have been identified, TABl and TAB333.4°. Soon after our 
identification of Tab2, a full length mouse Tab2 IMAGE eDNA clone became available. 
Alignment of the predicted protein sequence of the Tab2 IMAGE eDNA clone with the 
hTAB2 protein sequence revealed 95% similarity between these two homologous proteins. 
High similarity was also observed upon alignment of T AKl and TAB 1 protein sequences 
between several species, including mouse, human, Xenopus, C.elegans and Drosophila 
suggesting a conserved function for these proteins. Indeed it has been reported that T AKl 
(and TABl) play an important role in the conserved IL-l/Toll signaling pathway in the 
innate immune system and also in the conserved BMP and Wnt signaling pathways22•39.41.47. 
However, little is known regarding the function and expression pattern of T AB2. As the 
protein structure of TAB2 and TAB3 is highly similar, these proteins could fulfill a 
redundant or overlapping function. Therefore, we examined their RNA expression pattern 
in several adult mouse tissues and cell lines, as described in chapter 3. In the tissues tested, 
we found a similar expression pattern for Tab2 and Tab3. However, in the clonal cell lines 
we tested, we did not observe a clear overlap in expression patterns, suggesting that these 
genes are not expressed in similar cell types and might also be regulated differently. This 
further implies. that the genes Tab2 and Tab3 are expressed in vivo in different cell types 
and might have distinct functions. However, as no protein expression analysis could be 
performed for TAB3, due to lack of a TAB3 specific antibody, the in vivo expression 
pattern remains to be elucidated. For TAB2 we did perform protein expression analysis in 
the adult and the midgestation embryo. By Western blotting, we found ubiquitous 
expression, with lowest expression levels in the hematopoietic tissues. This expression 
pattern ofTAB2 is similar to that reported for IL-lRl expression which was shown to be 
expressed to low levels in hematopoietic tissues and to high levels in other non-
hematopoietic tissues 13• As the Western blot analysis does not provide insight into spatial 
expression ofTAB2 in tissues, we also performed immunohistochemistry. 
Immunostained adult tissue sections revealed TAB2 expression patterns in cell 
subsets in the thymus, spleen and bone marrow. TAB2 expression was also detected in cell 
subsets in the brain and lung. Interestingly, the TAB2 expression pattern observed in adult 
mouse tissues is strikingly similar to the pattern observed in a NFKB reporter mouse, as 
published by Schmidt-Ullrich et al. 37. In this reporter mouse, the NjKbl promoter drives 
lacZ expression. In addition, an artificial· promoter construct was used containing three 
consensus NjKb sites was used to drive lacZ expression in another reporter mice. Since 
those promoters contain NFKB binding sites, it is generally accepted that NjKb activity can 
be· monitored by examining the lacZ expression pattern in adult and embryonic tissues. 
However, some small differences in expression pattern may be induced by or repressed by 
other transcription factors or by the different NFKB dimmers. Notwithstanding, it is very 
interesting that the expression pattern of lacZ in these NjKb reporter mice is similar in the 
adult brain, thymus and spleen to our T AB2 staining pattern. Moreover, the lacZ staining 
observed in the embryonic brain, spinal cord and some of the blood vessels, is also similar 
to the observed TAB2 expression pattern. The only important difference is the absence of 
lacZ expression in the fetal liver, in all but one transgenic mouse line. Whether the lacZ 
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expression is below detection or whether NFKB activity is not present in this tissue is 
unclear. However, an important role for NFKB signaling in liver development has been 
suggested based on the reports of mice deficient for the NFKB member RelA and l!d3 kinase 
2 (Ikk2). Such deficiencies are embryonic lethals due to fetal liver degeneration by 
apoptosis 7•26. However, NjKbl (p50) deficient mice are not embryonic lethal 38 and this is 
explained by the fact that p50 itself lacks transactivating properties and instead modulates 
the activity of other NFKB family members 7•12•26 . Nevertheless, the similarity of expression 
pattern of this NFKB family member and TAB2 and suggests that TAB2 and NFKB 
signaling might be intimately linked. 
Interleukin-1 and the regulation of HSCs 
Previous studies implicating IL-l as a regulator of proliferation, differentiation, 
migration and as radio-protector of HSCs in the adult bone marrow, together with our 
interest in TAB2; prompted us to investigate the expression of the IL-l receptor and its 
signaling components in the midgestation AGM region and liver, and more specifically the 
effect of IL-l on Ell AGM and liver HSCs. As described in chapter 4, we observed 
expression of IL-l signaling components and could even demonstrate an increase in HSC 
activity upon addition ofiL-1 in organ cultures of AGM or liver tissue. The finding that the 
IL-lRJ is expressed in/near the endothelium of the dorsal aorta in the Ell/ El2 AGM 
region and that the IL-lRJ is expressed on c-kit expressing cells in the AGM and liver, 
suggest that IL-l is an in vivo regulator ofmidgestation HSCs. To confliTll that the IL-lRl 
expressing cells are truly HSCs, F ACS sorting experiments and in combination with long-
term repopulation assays need to be performed. Nevertheless, whether acting directly or 
indirectly on HSCs, it is clear that IL-l is a potent positive regulator ofHSC activity during 
organ cultures. 
Currently, it is unclear how IL-l increases AGM HSC activity. It may act to 
decrease apoptosis, increase proliferation or to alter migration/ adhesion properties of 
HSCs. Further studies investigating these possibilities are required to determine the nature 
of the IL-l induced changes in the AGM. For example, to examine whether IL-l plays a 
role in proliferation or apoptosis during the organ cultures, F ACS analysis performed on 
AGM tissue cultured in the presence or absence of IL-l would determine whether HSC (i.e. 
c-kit/ CD34+/ Sea+ cells) numbers increase or decrease. In addition, BrdU incorporation 
studies could be performed to monitor proliferation of HSCs. Moreover, F ACS analysis for 
the apoptosis marker Annexin and TUNEL stainings can be used to monitor apoptosis in 
AGM and liver cells. Also by gene expression analysis of cultured tissues for known 
apoptosis regulators, such as Bcl-2 family members, could reveal IL-l induced changes. 
The effects of IL-l on migration and adhesion are less easily monitored, although 
there is an indication that IL-l might indeed be regulating these processes. By expression 
analysis on cultured AGM and liver tissue in the presence of IL-l we found that Matrix 
metalloprotease-9 (Mmp-9) is strongly upregulated. Recently, it was reported that MMP-9 
plays an important role in regulating the amount of soluble SCF in the bone marrow and 
thereby influencing the proliferation and migration of HSCs19. Since HSCs are proposed to 
migrate from the AGM region to the fetal liver at around Ell-El2, most likely via the 
circulation, migratory aspects are important in the regulation of HSCs during midgestation 
development. Expression changes in cell adhesion molecules induced by IL-l could be 
determined again by F ACS analysis. The functional properties could be assayed in cell 
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migration assays as routinely used by others. Furthermore, it is not clear whether IL-l act 
directly on AGM HSCs or whether it acts on other cell types that induce changes in AGM 
HSCs. As the IL-l RI is expressed almost exclusively on CD45+ (hematopoietic) cells in the 
AGM and liver, it is highly likely that IL-l exerts its effects directly on hematopoietic cells 
and not through an intermediate cell type. Studies with adult bone marrow HSCs showed 
that IL-l usually synergizes with other growth factors to induce proliferation of these cells. 
Whether IL-l also cooperates with other cytokines or growth factors in the midgestation 
AGM and liver remains to be investigated. 
The role ofT AB2 in Interleukin-1 signaling and development. 
The questions that remain are what role does T AB2 play in IL-l signaling in these 
AGM cells and what is the function of IL-l and TAB2 during development? The first 
reports on T AB2 proposed a model in which T AB2 functions as an adapter protein, linking 
TAKl to the IL-lR and thereby mediating IL-l signaling44As (Figure lA). However, these 
initial studies performed by Matsumoto and co-workers overexpressed TAKl and TAB 
proteins in a non-IL-lR expressing cell line co-transfected with the Il-l r gene. In retrospect, 
careful examination of the biochemical method used to detect T AB2 and T AKl 
translocation from the plasma membrane to the cytosol, reveals that the so-called plasma 
membrane fraction also contains the nuclear fraction from these cells. Therefore, no 
conclusions on the localization ofTAKl and TAB2 can be drawn from these experiments. 
Moreover, the proposed crucial function of TAB2 in IL-l signaling was based on the 
observation that a truncated T AB2 protein blocks NFKB and JNK activation upon IL-l 
stimulation. The puzzling fact that mere overexpression of full length T AB2 resulted in 
Nfrcb promoter activity and JNK kinase activity in the absence of IL-l stimulation, 
remained uninvestigated in these studies. 
Consistent with the possibility that T AB2 might be localized in the nucleus, a 
recent report showed by immunofluoresence studies that indeed T AB2 in neuronal cells is 
localized in the nucleus and functions as a repressor protein of p50 NFKB-mediated gene 
expressions (Figure lB). The recent report of Tab2 deficient mice may support this model, 
as Tab2 deficient cells were found to normally activate NFrd3 promoter activity and JNK 
kinase activity upon IL-l stimulation36• Thus, TAB2 may not be required for the early steps 
ofiL-1 signaling. Alternatively, TAB2 may play a role proximal to the IL-l receptor as an 
adapter, but is functional redundant with the highly homologous TAB3 protein. 
TAB2: a role in apoptosis 
Concerning the hematopoietic system, the phenotype of the Tab2 deficient mice 
did reveal that TAB2 is required to prevent fetal liver apoptosis during mouse development 
and that TAKl and TABl phosphorylation (and likely activation) is dependent on TAB2 
expression36. Together with the studies from Baek et al., these studies provide important 
clues about the function ofTAB2, namely that TAB2 is involved in apoptosis regulation as 
well as NFKB activity regulations 36• In the studies presented here, we observed nuclear 
localization of TAB2 in hematopoietic and 3T3 fibroblast cells. However, low levels of 
TAB2 were also observed in the cytoplasm. This raises the possibility that (in some cell 
types) TAB2 might not only be modulating NFKB activity in the nucleus, but that TAB2 
also fulfils additional roles in the cytoplasm. In this regard it is interesting that TAB2 
interacts with TRAF6, another regulator ofiL-1 and TNFa signaling, but also an inducer of 
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apoptosis3.44. It has been suggested that the composition of these TRAF proteins in multi-
protein aggregates in the close proximity to their receptors determines cell fate, resulting 
either in cell viability or cell death3. Baud et al. showed that clustering of TRAF2 or 
TRAF6 proteins could induce NFKB and JNK activation resulting in subsequent target gene 
induction in the absence ofiL-1 or TNFa stimulation6. Therefore, one could speculate that 
the reported effect of NFKB and JNK activation upon overexpression ofT AB2 44.45 might 
be due to inappropriate cellular localization and/or enhanced binding of TAB2 to TRAF 
proteins resulting in clustering and thereby activating the signaling cascade in the absence 
of IL-l stimulation. However, this possibility remains speculative until the appropriate 
experiments are performed. 
B 
cytosol 
NFKB JNK 
Figure 1. Models for the role ofTAB2 in IL-l signaling 
(A) Model as proposed by Takaesu eta!. implicates TAB2 as an adapter protein in the proximal IL-
l signaling cascade 44. Binding of IL-l to the IL-l receptor results in recruitment of the adapter 
protein MyD88, the kinase IRAK and the adapter protein TRAF6. TRAF6 will bind to TAB2, and 
allows the TAKl-TABl complex to be brought in close proximity of the receptor. Activation of 
TAKl results in NFKB and JNK activation and further signaling. (B) Model as proposed by Baek et 
a!. for TAB2function5. Without IL-l stimulation, TAB2 is localized in the nucleus in a complex with 
NFKB subunits (p50) at the promoters of NFKB target genes. The presence of TAB2 mediates the 
repression of these NFKB target genes. Upon binding of IL-l to the IL-l receptor. MEKK is 
activated, translocates to the nucleus and phosphmylates TAB2. Subsequently, TAB2 is 
translocated from the nucleus to the cytoplasm, thereby relieving the repression of the NFKB target 
genes. Baek eta!. additionally suggested that TAB2 in the cytosol could function to activate NFKB 
and JNK signaling via the interaction with TAKl proximal of the IL-l receptor. 
Also, TAKI and TABl have been shown to induce apoptosis in vivo. Studies in 
Xenopus show that overexpression of TAKl and TABl results in apoptosis and lethality 
during development. Overexpression of the anti-apoptotic Bcl-2 gene was required in these 
studies to reveal that TAKl overexpression leads to the ventralization of the embryos at the 
expensive of neural tissue development39. Moreover, it was shown that TAKl and TABl 
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function downstream of the BMP receptor in Xenopus and are linked to the BMP receptor 
via XIAP50, which is known as an inhibitor of apoptosis. This raises the intriguing 
possibility that TAKl/TABl overexpression induces apoptosis by sequestering XIAP (or 
related lAP proteins). Thus, one could speculate that by regulating the availability and the 
local intracellular concentrations of TRAF (and lAP) proteins, the balance between cellular 
viability and apoptosis might be regulated by TAKl and TAB proteins. Therefore, it would 
be interesting to examine, in the mouse system, in more detail the intracellular localization 
of endogenous and overexpressed T AB2 full length and truncated proteins and to determine 
whether these proteins interact with known regulators of apoptosis. Such transgenic studies 
could reveal whether the level of T AB2 expression is important in regulating the balance 
between cell viability and apoptosis in a physiological context. 
In addition to acting directly on apoptosis regulators, TAB2 may regulate 
apoptosis and other cellular functions via the interaction with NFKB proteins to modulate 
NFKB activity. Several members of the NFKB family have been implicated as important 
regulators of cell viability and apoptosis12•23 • Interestingly, embryonic lethality has been 
observed in mice deficient for the NFKB member RelA or the NFKB regulator IKB kinase 2 
(Ikk-2) 7'26 . These mice die due to fetal liver apoptosis around El5 (RelA) or El2.5-E14 
(lkk-2), a similar phenotype observed for Tab2 deficient mice 36. Moreover, it was shown 
that NFKB members p65 and c-rel regulate gene expression of anti-apoptotic genes, 
including Bcl-2 and Bcl-xL.8•18• Bcl-xL deficient mice die around E13 due to fetal liver 
apoptosis 31 . Interestingly, the expression pattern of Bcl-xL and some NFKB members 
includes the fetal liver and adult hematopoietic tissues, and is similar to that ofT AB217•24. 
The proposed function by Baek et al. for T AB2 as a regulator of NFKB activity is 
so far consistent with reported studies that TAB2 is involved in apoptosis, which could be 
regulated via NFKB, as well as with the observations that TAB2 does not play a crucial role 
in proximal IL-l receptor signaling. However, as it was reported that the complex ofT AB2 
and NFKB at the promoters of certain target genes is disrupted upon IL-l stimulation, 
TAB2 can still be regarded as a regulator ofiL-1 signaling although at a different level in 
the signaling cascade than originally reported. 
Is T AB2 involved in other signaling pathway? 
Based on the phenotypes of the IL-l signaling component deficient mice in 
comparison with the Tab2 deficient mice, it is unlikely that the function of TAB2 is 
restricted to IL-l signaling. Several mouse models have been generated that lack expression 
of the ligand IL-l, the IL-l receptor or components of the IL-l signaling cascade, including 
MyD88 and IRAK-4 1.16.20•43 . In addition, also mice deficient for the closely related Il-18 
receptor have been generated 21 • These mice all display a similar phenotype. They do not 
show any developmental defects, are umesponsive to IL-l (or IL-18) stimulation and 
display defects within the immune system, including defects in B-cell activation and fever 
induction upon infection 1' 16'20'43'21 . In contrast, the Tab2 deficient mice display a rather 
severe phenotype, with embryonic lethality around El2.536• Moreover, approximately 90% 
of the heterozygous Tab2 deficient mice die within two weeks after birth, indicating that the 
dose ofTAB2 is also important 36• Thus, these dramatic phenotypic differences indicate that 
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the function of TAB2 is not solely restricted to IL-l signaling. Furthermore, by 
immunohistochemistry studies for TAB2 and IL-lRl in the midgestation mouse embryo we 
observed extensive, but not a complete, overlap in the expression of these proteins. 
Therefore, it seems likely that TAB2 fulfils a more general role in regulating some cellular 
processes. 
Apoptosis: a role in HSC development? 
Besides the studies on the expression of T AB2 and the role of IL-l on HSC 
regulation during mouse development, we also studied the effects of Bcl-2 overexpression 
on the hematopoietic compartment in the adult mouse and during development. Bcl-2 
protein family members clearly play an important role in the regulation of apoptosis2. As 
described in chapter 5, Bcl-2 overexpression was directed by the Ly6E (Sea-l) promoter in 
transgenic mice. As expected from overexpressing an anti-apoptosis regulator, we observed 
increased cell viability under stressful conditions in vivo, by total body irradiation studies, 
and in vitro by growth factor withdrawal in cell culture. However, also in steady-state 
conditions, without inducing cellular stress, we observed increased numbers of c-kit cells 
in the adult bone marrow. Moreover, upon transplantation we observed a higher HSC 
repopulation capacity in bone marrow cells of Bcl-2 overexpressing mice. Interestingly, 
also in the Ell AGM and liver we observed higher HSC repopulation capacity, suggesting 
that from the earliest developmental stages onwards HSCs might be normally prone to 
apoptosis. Whether this process of apoptosis already occurs in vivo during the development 
of the AGM or during the process of transplantation and/or homing to the bone marrow of 
these AGM HSCs is currently unclear. To determine whether apoptosis plays a role during 
the transplantation and/or homing process marked AGM HSCs (i.e. Ly6A-GFP derived 
HSCs) could be used for transplantation and thereafter the viability and homing efficiency 
of these cells could be determined. Taken together, further investigations are required to 
examine in more detail the expression and function of apoptosis regulators, including 
TAB2, within the hematopoietic compartment in the AGM and fetal liver. 
Conclusions 
The aim of the investigations presented here was to search for novel regulators of 
hematopoietic stem cells in the midgestation AGM region of the mouse embryo. By means 
of differential screening we found several differentially expressed genes in the AGM region 
at the time ofHSC emergence. One of these genes, the novel mouse gene Tab2, was shown 
to be expressed in a spatio-temporal manner consistent with known HSC activity. Although 
it has not been elucidated how TAB2 is involved in HSC regulation, we were able to reveal 
that the IL-l signaling pathway, in which TAB2 has been proposed to play a role, does 
affect the earliest definitive HSCs during mouse development. Moreover, we were able to 
reveal a possible role for apoptosis in these cells by means of Bcl-2 overexpression studies. 
Thus, while there are many questions that still need to be answered, these studies have led 
to increased insight into the numerous and highly controlled regulatory mechanisms that 
lead to the balanced emergence, expansion and maintenance of HSCs during mouse 
development. 
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Summary 
The hematopoietic system fulfills important roles for the viability of whole 
organisms from embryonic to adult stages oflife. For example, the erythroid branch of the 
hematopoietic hierarchy supplies oxygen to tissues and organs, while the lymphoid branch 
plays a crucial role protecting the organism against invading pathogens. These functions are 
carried out by the mature, differentiated cells of the hematopoietic system. Mature 
hematopoietic cells are produced through a complex differentiation hierarchy founded by 
hematopoietic stem cells (HSCs). During embryonic development HSCs are first generated 
in close association with one of the major blood vessels in the embryo, the dorsal aorta. 
Together with the aorta, the surrounding region, comprised of the primordial kidney and 
reproductive anlagen, is referred to as the aorta-gonad-mesonephros region or AGM. 
During mouse development, HSCs can be found from embryonic day 10.5 onwards in the 
AGM region and one day later in the fetal liver, where they remain until neonatal stages. 
Several regulators that play a role, in either the emergence and/or regulation ofHSCs in the 
embryo and the adult, have been identified over the years. Despite this knowledge and the 
fact that the insight in the regulatory processes are rapidly increasing, there are still gaps in 
the understanding of the molecular events leading to the emergence ofHSCs. 
To gain further insight into the genes that play a role in mouse HSCs and the cells 
that surround them in the AGM, we set out to identify genes that were differentially 
expressed (or in other words "turned on" or "turned off"), in the AGM region at the time of 
HSC emergence. By performing a screening for such genes, we identified several genes that 
were differentially expressed, among which were two novel mouse genes. These novel 
mouse genes were highly homologous to known human genes, suggesting they might have 
a similar function in human and mice. One of these genes, TAB2, had been suggested to 
play a role in interleukin-1 (IL-l) signaling. As TAB2 is a novel gene, little information is 
available about its expression pattern or its role in normal physiology. Therefore, we 
investigated the expression pattern of TAB2 in the adult mouse and during embryonic 
development. Besides expression in hematopoietic organs, TAB2 is also expressed in 
neural tissues, throughout embryonic and adult stages. Since others have shown that IL-l is 
a regulator of adult bone marrow HSCs, and T AB2 is thought to function in the IL-l 
signaling pathway, we examined whether IL-l also functions as a HSC regulator during 
development. Our studies show that IL-l is a potent HSC regulator in the AGM and fetal 
liver. In related studies to investigate the role of cell death in the regulation of HSCs in the 
adult and the embryo, we used a transgenic mouse model in which the cell survival gene 
Bcl-2 is overexpressed within HSCs. Our results indicate that indeed cell death and survival 
plays an important role in the hematopoietic system and particularly in HSCs throughout 
development. 
Altogether, these studies have resulted in novel insights into the regulation of 
HSCs in the midgestation mouse embryo. Both a novel gene, Tab2, and a known 
hematopoietic regulator, IL-l, have been implicated for the first time as possible regulators 
of HSCs in the AGM and fetal liver. TAB2, as a mediator of the pro-inflammatory 
regulator IL-l, is expressed in both neural and hematopoietic tissues. Therefore T AB2 is an 
interesting candidate for further studies concerning hematopoietic and neural regulation 
during embryonic development, adult tissue homeostasis and inflammation-mediated 
diseases. 
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Ret hematopoietische (b1oed) systeem vervu1t een aanta1 verschillende be1angrijke 
taken zowe1 gedurende de embryona1e ontwikke1ing a1s in vo1wassen dieren. Zo zorgen 
bijvoorbee1d de rode b1oedcellen ( erythrocyten) voor zuurstoftransport naar de 
verschillende organen en weefse1s, en de witte b1oedcellen (lymfocyten) spe1en een ro1 in 
het immuun systeem dat ons 1ichaam beschermt tegen allerlei ziekteverwekkers en 
lichaamsvreemde stoffen. Deze functies van het hematopoietische systeem worden 
uitgevoerd door rijpe/ gedifferentieerde bloedcellen, waarvan de meeste bloedceltypes een 
relatief korte levensduur hebben. Een continue aanmaak van deze cellen is dan ook 
noodzakelijk om het hematopoietische systeem in stand te houden. Nieuwe 
gedifferentieerde cellen worden gevormd via een complex netwerk van hematopoietische 
voorlopercellen die op hun beurt weer afstammen van de hematopoietische stamcellen. 
In de volwassen mens en muis bevinden de hematopoietische stamcellen zich in 
het beenmerg. Echter, tijdens de embryonale ontwikkeling van de mens en muis ontstaan 
deze hematopoietische stamcellen in de nabijheid van een van de grootste bloedvaten van 
het embryo, de dorsale aorta. In het gebied tussen de voor-en achterpoten van de muis 
wordt de dorsale aorta omringd door weefsels die later in de embryonale ontwikkeling de 
nier en de ges1achtsorganen gaan vormen. Deze regio wordt aangeduid als de aorta-gonade-
mesonephros regio ofwel AGM regio. Halverwege de ontwikkeling van de muis (tussen 
dag 10 en 11) ontstaan hematopoietische stamcellen in de AGM regio in de nabijheid van 
de dorsale aorta. Vlak na hun ontstaan, verlaten de hematopoietische stamcellen de AGM 
regio en kunnen ze gevonden worden in de foetale lever. De hematopoietische stamcellen 
blijven tot vlak voor de geboorte in de lever waama ze naar het beenmerg gaan om van 
hieruit de verschillende gedifferentieerde hematopoietische cellen te gaan produceren. 
Sinds lange tijd wordt er onderzoek gedaan om een beter inzicht te krijgen in het ontstaan 
en de regulatie van de hematopoietische stamcellen gedurende de embryonale 
ontwikkeling. Ondanks het feit dat een aantal belangrijke spelers in deze processen zijn 
gei:dentificeerd en gekarakteriseerd, is er nog geen volledig inzicht in de processen die zich 
afspelen in het embryo met betrekking tot het ontstaan en de regulatie van hematopoietische 
stamcellen. 
Om de inzichten in de regulatie en ontstaanswijze van hematopoietische 
stamcellen in de AGM regio te vergroten, hebben we onderzocht we1ke genen differentieel 
tot expressie komen ( ofwel welke genen "aangezet" en welke genen "uitgezet" worden) op 
het moment dat hematopoietische stamcellen ontstaan in de AGM regio. Zoals beschreven 
in hoofdstuk 2, hebben we een aanta1 genen gevonden die differentieel tot expressie komen, 
waaronder twee genen die in de muis nog niet eerder waren gei:dentificeerd. Deze twee 
genen waren echter in de mens al wel eerder beschreven en onderzoek wees uit dat deze 
genen tussen de mens en de muis nagenoeg identiek zijn. Dit zou erop kunnen duiden dat 
ook de functie van deze genen in de muis en mens vergelijkbaar is. 
Naar een van deze twee genen, name1ijk Tab2, is verder onderzoek gedaan. De 
eerste studie naar de functie van TAB2 is gepub1iceerd in 2000 door Takaesu en collega's. 
Deze studie suggereert dat TAB2 een rol speelt in de interleukine-1 (IL-l) 
signaleringsroute. IL-l is een cytokine dat een belangrijke rol speelt in de regulatie van 
ontstekingsreacties en waarvan bekend is dat het hematopoietische cellen, waaronder 
stamcellen, kan reguleren en activeren. Aangezien TAB2 een relatief nieuw gen is en er 
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daarom dus ook weinig over bekend is, hebben we eerst het expressie patroon in de 
volwassen muis en in het embryo onderzoeht, zoals besehreven in hoofdstuk 3. TAB2 komt 
tot expressie in versehillende hematopoietisehe organen, zoals eellen in het beenmerg, de 
milt en de thymus, maar ook in versehillende neurale weefsels, waaronder eellen in de 
hersenen en het ruggemerg. 
Naast het onderzoek naar het expressiepatroon van TAB2 hebben we ook getraeht 
om de funetie van TAB2 en IL-l te aehterhalen. In de volwassen mens en muis zijn al veel 
studies gedaan naar de rol die IL-l speelt in de regulatie van hematopoietisehe eellen. Er is 
eehter weinig bekend over de rol van IL-l tijdens de embryonale ontwikkeling. Aangezien 
TAB2 een rol speelt in de IL-l signaleringsroute, hebben wij onderzoeht of IL-l ook een 
rol speelt in de regulatie van hematopoietisehe eellen in muizenembryos. Zoals besehreven 
in hoofdstuk 4 laat ons onderzoek zien dat IL-l een regulator is van hematopoietisehe 
stameellen vanaf het moment dat deze eellen in het embryo ontstaan. Op dit moment is het 
nog niet helemaal duidelijk hoe IL-l zijn regulatoire funetie op hematopoietisehe 
stameellen uitoefent en tevens is het niet duidelijk welke rol TAB2 speelt in de 
signaleringsroute van IL-l. Verder onderzoek zal hierover uitsluitsel moeten geven. Op 
basis van bevindingen van anderen, zijn er enkele mogelijkheden voor de rol van IL-l in de 
regulatie van hematopoietisehe eellen. De meest waarsehijnlijke mogelijkheden zijn dat 
IL-l de migratie van hematopoietisehe stameellen van de AGM regio naar de foetale lever 
reguleert of dat IL-l een rol speelt in de instruetie van eellen tussen de keuze op leven en 
dood van deze eellen in het embryo. 
Om beter inzieht te krijgen in de rol die gereguleerde eeldood speelt in de 
ontwikkeling van het hematopoietisehe systeem, is er een muizenmodel gemaakt door 
middel van transgenese. De beslissing tussen leven en doodgaan van de eel wordt in 
belangrijke mate bepaald door de balans tussen het expressieniveau van een aantal genen, 
waarvan enkele eeldood bevorderen en andere genen juist de levensvatbaarheid van eellen 
vergroten. Door middel van signalen van buitenafwordt de eel beYnvloedt en zal de balans 
tussen deze genen gereguleerd worden. In het muizenmodel waarvan wij gebruik hebben 
gemaakt is de regulator Bcl-2 tot overexpressie gebraeht in het hematopoietisehe systeem. 
Anderen hadden al aangetoond dat hoge expressieniveaus van Bcl-2 de levensvatbaarheid 
van versehillende eeltypes kan vergroten. Uit onze studies, die besehreven zijn in hoofdstuk 
5, blijkt dat dit ook het geval is voor hematopoietisehe stameellen in het embryo. Tevens 
duiden de resultaten erop dat regulatie van leven en dood van hematopoietisehe stameellen 
in het embryo een belangrijke rol speelt in de normale ontwikkeling van het 
hematopoietisehe systeem. 
Samengevat hebben de studies die in dit proefsehrift besehreven staan nieuwe 
inziehten opgeleverd met betrekking tot de regulatie van hematopoietisehe stameellen 
gedurende de embryonale ontwikkeling van de muis. Dit is de eerste studie die de rol 
besehrijft van TAB2 en van IL-l in de regulatie van hematopoietisehe stameellen in de 
AGM regio en de foetale lever gedurende de embryonale ontwikkeling van de muis. Verder 
onderzoek naar T AB2 zal zowel in het hematopoietisehe als in het neurale systeem 
belangrijke inziehten opleveren met betrekking tot de embryonale ontwikkeling, 
homeostase in volwassenen en ontstekingsgerelateerde proeessen. 
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